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Abstract 
Oligodendrocytes are the myelinating cells of the central nervous system (CNS) and 
are implicated in the pathobiology of many CNS diseases including multiple sclerosis 
and schizophrenia. Oligodendrocyte precursor cells (OPCs) are capable of migrating 
long distances, but the mechanisms governing the migration of OPCs to their axonal 
destinations are not fully understood. We sought to understand the extrinsic and 
intrinsic factors that contribute to the migration of a subset of OPCs in the zebrafish 
hindbrain. We utilized the zebrafish transgenic tg(olig2:gfp) line to mark OPCs and 
characterise their normal migration patterns. These cells normally first migrate in a 
ventral direction, after which they migrate away from the midline dorsolaterally to 
populate the hindbrain. However, how these cells initiate migration in a ventral 
direction is not known. We have found that removing Hedgehog signalling at the 
onset of their migratory phase results in a failure of OPCs to migrate in their normal 
ventral fashion, while increasing Hedgehog signalling results in hypermigration of 
these cells. This suggests that Hedgehog might not just be important for OPC fate 
specification, via induction of transcription factors such as olig2, but may also be 
actively involved in the development of these cells post-specification. We propose 
that Sonic Hedgehog acts as a chemoattractant to drive the initial ventral migration 
of hindbrain OPCs and furthermore provide evidence that it may function at least in 
part by inducing disc1, a schizophrenia risk factor gene, which has known roles in 
neural crest and neuronal migration. With several studies supporting a role of DISC1 
in neuronal migration it has been hypothesised that DISC1 could also play a role in 
the process of myelination. White matter abnormalities are consistently reported in 
schizophrenia patients, and it is hypothesised that OPC migratory defects may cause 
these documented white matter abnormalities due to early genetic dysfunction. This 
thesis has provided evidence for a link between a well characterised schizophrenia 
risk factor gene, early OPC migration events and a fundamental signalling pathway.  
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 Introduction 
1.1 Oligodendrocytes 
 Function in the adult brain 
Oligodendrocytes are non-neuronal cells of the central nervous system (CNS); they 
are a member of the CNS glial family which also contains astrocytes, microglia and 
NG2 positive cells (Barres 2008, Nishiyama et al 2009) . The main function of 
mature oligodendrocytes is to myelinate the axons of neurons which facilitates 
saltatory nerve conduction, allowing for the rapid transduction of action potentials. 
Differentiated oligodendrocytes create a vast myelin sheath which wraps tightly 
around axons providing insulation, with a single oligodendrocyte having the 
capacity to myelinate several axons (Bunge 1968). There is also evidence which 
suggests that oligodendrocytes have additional roles to myelination, including 
providing trophic support and supplying energy to axons (Funfschilling et al 2012). 
Diseases of demyelination and subsequent white matter abnormalities can have 
devastating consequences on brain function. It is therefore critical to understand 
the molecular mechanisms underlying the development of myelinating 
oligodendrocytes from oligodendrocyte precursor cells (OPCs) in order to create 
successful intervention, treatment and recovery from white matter diseases. 
 White matter abnormalities in brain disorders 
1.1.2.1 Multiple Sclerosis 
Multiple sclerosis (MS) is a classic disease of demyelination, where severity varies 
between patients. It is an auto-immune disease of the central nervous system and 
involves stages of demyelination and then remyelination followed by recovery 
(Adams et al 1989, Prineas & Graham 1981). Although remyelination is able to 
occur in the early stages of the disease it is often incomplete. In later stages where 
chronic demyelination lesions are present, remyelination fails leading to irreparable 
damage to the brain (Chang et al 2002). Although several studies have shown that 
oligodendrocyte precursor cells can enter areas of demyelination and axonal 
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contact can occur, remyelination does not subsequently occur (Franklin & Ffrench-
Constant 2008). The molecular mechanisms underlying this deficiency in 
remyelination is not well understood. 
1.1.2.2 Schizophrenia 
Although Multiple Sclerosis is probably the most studied white matter disease of 
the central nervous system, in recent years there has been increasing evidence 
showing white matter abnormalities in patients with psychiatric disorders, for 
example in schizophrenia (SZ) (Takahashi et al 2011). The majority of myelination 
occurs after birth into early adulthood and it is at this stage that some psychiatric 
disorders are diagnosed, in particular schizophrenia. In patients with demyelinating 
diseases such as MS where there are lesions in the frontal lobe, schizophrenia- like 
symptoms also present in some individuals (Davis et al 2003).  Brain imaging 
techniques such as diffusor tensor imaging (DTI) have shown evidence of white 
matter integrity deficiencies in several brain regions including those dysfunctional 
in psychiatric disorders (Liddle 1996) (Foong et al 2000). Abnormalities in white 
matter of schizophrenia patients have also been described using Magnetic 
resonance imaging (MRI) (Flynn et al 2003). Studies analysing post-mortem brains 
of schizophrenia sufferers compared to healthy controls found differences in 
oligodendrocytes number and spacing suggesting that there is aberrant 
oligodendrocyte development in these patients (Hof et al 2003). Other evidence for 
white matter abnormalities includes expression differences in oligodendrocyte 
specific genes in schizophrenia patients. Genes associated with oligodendrocyte 
precursor cells, oligodendrocytes and myelin were seen to be reduced in 
schizophrenia patients, with these findings being replicated by several groups 
(Table 1) (Hakak et al 2001, Tkachev et al 2003). Another group analysed 
oligodendrocyte gene expression in sub-cortical regions and found that genes 
expressed in terminally differentiated oligodendrocytes were expressed at lower 
levels in sufferers compared to healthy controls (Barley et al 2009).  
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Gene Expression/Function Reference 
2’,3’-Cyclic nucleotide 3’ 
-phosphodiesterase (CNP) 
Has roles in process 
outgrowth  
(Flynn et al 2003) 
(Hakak et al 2001) 
Myelin association 
glycoprotein (MAG) 
Myelination process (Hakak et al 2001, 
Katsel et al 2005) 
Myelin basic protein 
(MBP) 
Major component of the 
myelin sheath 
(Tkachev et al 2003) 
Transferrin (TF) Transportation of iron 
ions, important for 
oligodendrocytes during 
myelination 
(Katsel et al 2005, 
Tkachev et al 2003) 
(Hakak et al 2001) 
 
Claudin 11 (CLDN11) Major component of 
myelin 
(Tkachev et al 2003) 
(Katsel et al 2005) 
Table 1: Oligodendrocyte genes showing lower expression in schizophrenia patients 
 
These observations from patient tissue were interesting since most psychiatric 
research has been predominantly focused on the neuronal aspect of the disease in 
the past. These insights into potential defects in oligodendrocyte development or 
maintenance have provided the research field with the opportunity to study how 
non-neuronal cell types contribute to these debilitating and complex brain 
disorders. However it must be appreciated that although these myelin related 
defects have been described in human patients it is still unknown whether these 
defects could be a secondary result of early neuronal defects, and should be a focus 
of future research as non-invasive imaging techniques improve. Tackling all aspects 
of disease progression is critical in the development of new treatments given the 
present clinical setting where many of the current treatments are inconsistent in 
their efficacy and unsuccessful for many sufferers (Insel 2010). Proper brain 
connectivity requires neuronal-glial interactions, and this further highlights the 
requirement for understanding their individual development but also in how 
neuron-glial interactions are established and how defects in either of these 
processes may contribute to disease (Maldonado & Angulo 2014). Although there is 
a huge body of evidence describing white matter and oligodendrocyte defects in 
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psychiatric disorders, there remains little mechanistic insight into when, where and 
how these white matter abnormalities arise; however some evidence which will be 
discussed below points to a dysfunction in OPC development in the early brain 
(Davis et al 2003).  
1.2 Schizophrenia 
 The symptoms of schizophrenia  
Schizophrenia currently affects 1% of the global population and is characterised by 
both positive (hallucinations) and negative (social withdrawal) symptoms. There is 
also a large degree of cognitive dysfunction which includes working memory and 
attention deficits. It is a debilitating, complex and costly disease. Schizophrenia is 
normally diagnosed during late adolescence. Current treatment success varies 
between patients with some sufferers failing to respond to any available treatment. 
Understanding the disease pathology and how it progresses could lead to improved 
treatments and ideally intervention methods which would halt disease progression 
or reduce the chance of it developing further (Insel 2010). 
 High heritability of Schizophrenia 
Psychiatric disorders such as schizophrenia are complicated diseases to study and 
model. Varying symptoms and severity between patients, differences in 
environmental factors and human specific behaviours create several limitations 
when trying to model mental illness in animals and understand the underlying 
mechanisms. However the discovery of a large genetic component in schizophrenia 
has opened up opportunities to study the disease through identification of genetic 
risk factors and pathways. The high heritability of the disease was recognized 
through family and twin studies (Sullivan et al 2003). A large study in Denmark 
looked at the incidence of schizophrenia in both the biological relatives and 
adoptive relatives of adoptees that suffered with schizophrenia (Kety 1987). 
Chronic schizophrenia was found to have significantly higher incidence in the 
biological relatives of those adoptees with schizophrenia compared to the control 
adoptive relatives. Another interesting study investigated the prevalence of the 
disease in monozygotic compared to dizygotic twins and found that monozygotic 
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twins had a higher concordance. However this was never 100% which showed that 
this disease has environmental factors to take into consideration and that risk 
factor genes are not completely causal (Cardno et al 1999).  These results were 
exciting, leading to a wide effort to decipher these risk factor genes, understand 
their function, and how they could contribute to brain disorders when 
compromised. Since the discovery of the first candidate risk factors genes, the field 
has since identified numerous risk factor genes for schizophrenia and other brain 
disorders in a variety of populations worldwide. Recent Genome Wide Association 
Studies (GWAS) have identified over a 100 credible risk loci, many of which were 
not previously reported and therefore the field of schizophrenia genetics is 
constantly evolving with new genes, biological pathways and interactions being 
implicated in mental illness through these large case studies, as genome techniques 
become more sophisticated (Schizophrenia Working Group of the Psychiatric 
Genomics 2014). Understanding the function of these genes in the healthy brain, 
and how they work in gene networks will help us to build knowledge around the 
pathophysiology of the disease. 
 The neurodevelopmental hypothesis of schizophrenia 
The underlying mechanisms of the disease are still largely unknown, however there 
have been several causal hypotheses suggested. One particular hypothesis however 
is now widely accepted and attempts to bring together genetic risk factors and 
dysfunction in early brain development.  The neurodevelopmental hypothesis was 
proposed after studies suggested that schizophrenia does not arise from a healthy 
brain i.e. abnormalities are present early on before diagnosis. A study which 
followed a cohort of individuals over 45 years found that those who later developed 
schizophrenia were delayed at several developmental milestones (Sorensen et al 
2010). Another observation is that schizophrenia is frequently diagnosed between 
18-25 years of age during the final stages of brain maturation. One particular area, 
the prefrontal cortex is the last to mature and is a region long implicated in mental 
illness (Paus et al 2008). Analysis of post-mortem brains from SZ patients revealed 
interesting findings such as reductions in neuronal numbers, mislocalisation of 
neurons and brain volume changes, suggesting deficiencies in neurodevelopment 
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(Akbarian et al 1993) (Altshuler et al 1987). More compelling evidence to 
strengthen this proposal is that a large majority of the risk factor genes identified to 
date have important known roles in neurodevelopment.  
Therefore the current neurodevelopmental hypothesis of Schizophrenia suggests 
that ‘Subtle abnormalities during brain development will later manifest to as an 
adult brain disorder due to early genetic dysfunction’. This hypothesis is now widely 
accepted in the field, although alternative hypotheses relating to synaptic 
dysfunction and altered neurotransmission remain popular, especially in relation to 
recent GWAS findings (Schizophrenia Working Group of the Psychiatric Genomics 
2014). 
 Risk factor genes and genetic overlap between 
psychiatric disorders 
Several genes have been identified from various genome studies in several 
populations, however no causal gene has been identified to date. Therefore 
schizophrenia is described as a polygenic disorder where several risk factor genes 
may need to have their function compromised in a variety of neurodevelopmental 
processes to later manifest as an adult brain disorder. It may be the case that 
individuals are genetically predisposed to schizophrenia and when exposed to 
particular environmental factors the disease is triggered in later life. Many genes 
have been suggested to confer risk to schizophrenia, although many since have 
failed to reach stringent genome wide significance but these genes have been key 
in identifying key biological pathways.  Interestingly, it has recently been 
demonstrated that there are varying degrees of genetic overlap between brain 
disorders including schizophrenia, bipolar disorder, depression and attention 
deficit/hyperactivity disorders through GWAS (Cross-Disorder Group of the 
Psychiatric Genomics et al 2013) (Ng et al 2009). Understanding this shared genetic 
risk between disorders may identify common pathways for therapeutic targets and 
could also lead to improved diagnostics in the future.  
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 Risk factor genes and white matter abnormalities  
One important question to address is which of the identified risk factor genes play a 
role in oligodendrocyte development and white matter maintenance, an area 
known to be perturbed in schizophrenia. Since white matter abnormalities have 
been well documented it is expected that a proportion of these genes will have a 
role in oligodendrocyte function and development. Do any of these risk factor 
genes have a direct role in white matter development, either at a later stage during 
myelination or at early stages during the development of OPCs? It is plausible that 
dysregulation of genes involved in OPC development contributes to schizophrenia, 
since this disease is proposed to be neurodevelopmental in origin and many of the 
genes implicated are involved in neurodevelopment. There have indeed been 
several genes involved in oligodendrocyte development and myelination associated 
with schizophrenia, including but not limited to: Neuregulin-1 (NRG1), ERBB4 (one 
of the receptors of NRG-1), Oligodendrocyte lineage transcription factor 2 (OLIG2), 
Myelin basic protein (MBP) and 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNP) 
(Georgieva et al 2006, Owen et al 2005, Stefansson et al 2002). A novel gene, 
Disrupted in Schizophrenia-1 (DISC1), originally established to have roles exclusively 
in neuron development has recently been suggested to have roles in 
oligodendrocyte development in both cell culture, mouse and zebrafish studies 
(Hattori et al 2014, Katsel et al 2011, Wood et al 2009). 
1.3 Disrupted in schizophrenia-1 (DISC1) 
 Discovery of DISC1 
In the last ten years research has focused on dissecting the roles of proteins which 
are encoded by risk factor genes in nervous system development, maturation and 
maintenance. DISC1 was one of the earliest schizophrenia susceptibility genes 
identified, with subsequent research building substantial evidence for roles in 
neuronal migration, neurite outgrowth and multiple cell signalling pathways. It has 
been widely referred to as one of the leading candidate risk factors conferring risk 
to schizophrenia, although recent GWAS have failed to report association with 
schizophrenia at genome wide significance level. However studies of DISC1 function 
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have still provided fundamental insights into SZ pathophysiology and 
neurodevelopmental processes in general (Ripke et al 2013). The DISC1 locus was 
initially described back in 1990, where a balanced t(1,11) chromosomal 
translocation in a Scottish family was seen to co-segregate with a high prevalence 
of mental illness, including SZ, bipolar disorder and major depression (St Clair et al 
1990). A high percentage of family members that carried the translocation suffered 
from mental illness, whereas those family members that were not carriers did not 
suffer any mental health issues. This suggested a direct causal link between the 
genes disrupted by this chromosomal translocation and mental illness. The 
chromosomal translocation caused a breakpoint in the DISC1 gene on chromosome 
1 which was discovered through positional cloning, and the function of this gene 
was unknown at the time (Millar et al 2000). Even though structural genetic 
variants such as these are rare, these types of mutations have been exceptionally 
useful in understanding mechanisms of disease (Porteous et al 2014). The DISC1 
gene was cloned over a decade ago now and has been extensively studied to reveal 
a novel protein harbouring numerous protein interacting partners with varied roles 
in neurodevelopment (Millar et al 2000, Semple et al 2001). Other studies showed 
positive associations between DISC1 and schizophrenia in different populations 
such as Finland, Iceland and Taiwan, although there were other studies which 
suggested a negative association (Chubb et al 2008, Ekelund et al 2001, Zhang et al 
2005). Furthermore, there is also evidence to suggest that DISC1 may also be a 
more general risk factor for mental illness including depression and autism (Chubb 
et al 2008). It is important to note that recent studies demonstrate that the DISC1 
locus does not reach genome wide significance for association to schizophrenia 
(Ripke et al 2013), however rare structural variants are not detected in GWAS and 
biological investigation of the DISC1 protein has provided extensive evidence for 
roles in neurodevelopment consistent with a role in mental illness.  
 DISC1 in the brain 
The human DISC1 gene spans 410 kb containing 13 exons, and encodes a full length 
854 amino acid protein with an N-terminal globular head domain containing 
putative nuclear localisation signals and a C-terminal domain with coiled-coiled 
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regions. A three-dimensional crystal structure of the DISC1 protein is yet to be 
elucidated (Chubb et al 2008). What is particularly interesting about this protein is 
that it is unique, it is unlike any other protein and there is limited homology 
between species, with the C-terminal domain showing higher conservation (Chubb 
et al 2008). DISC1 shows a diverse range of tissue and cellular expression patterns. 
It is expressed in the adult brain (predominantly in the hippocampus and frontal 
cortex) but it is also expressed in the heart, kidney and liver, and has been reported 
to be localised to several cellular compartments including mitochondrial, nuclear, 
cytoplasmic and centrosomal locations (Figure 1-1). 
 
Figure 1-1: DISC1 biology 
The DISC1 protein has a C-terminal domain made up of coiled-coil domains which harbors 
the majority of binding sites for its interacting partners. The protein has been suggested to 
occupy a variety of cellular localizations. Mutation of DISC1 affects a variety of brain 
functions and is implicated in several psychiatric disorders. (Adapted from (Porteous et al 
2011) license number: 3457600782345) 
 
There are several isoforms of DISC1 identified in humans suggesting a variety of 
biological functions. To date there are 22 predicted DISC1 isoforms listed on 
Ensembl 
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(http://www.ensembl.org/Homo_sapiens/Transcript/ProteinSummary?db=core;g=
ENSG00000162946;r=1:231626815-232041272;t=ENST00000439617). In mouse, 
different isoforms have been shown to be developmentally regulated, with 
expression peaking at stages of neurogenesis and neuronal migration during 
embryonic development, and later at the onset of puberty during final brain 
maturation (Schurov et al 2004). There are now several mouse models based on 
DISC1, but it must be stressed that many aspects of mental illness such as 
hallucinations are specific to humans. Therefore the disease can never be fully 
recapitulated in animal model systems. However mouse models have been shown 
by many to display characteristics comparable to those seen in schizophrenia 
patients including behavioural, anatomical and cognitive changes. For example a 
study screened for Disc1 mutations in a library of N-ethyl-N-nitrosourea (ENU)-
treated mice and identified two missense mutations; Q31L and L100P. These 
mutant mice were characterised and both showed a reduced brain volume 
compared to wild-type controls, with the volume decrease being most prominent in 
the cerebellum, cortex and thalamus. Although both mutations were associated 
with brain volume decrease, one mutant (L100P) showed behavioural changes 
reported to be similar to those in schizophrenia, whereas the other mutant (Q31L) 
displayed behavioural changes more akin to depression (Clapcote et al 2007). 
Another study using in utero gene transfer caused knock down of Disc1 expression 
in the prefrontal cortex of mouse embryos. During adulthood these mice elicited 
schizophrenia-like behaviours due to circuitry abnormalities caused by aberrant 
neurodevelopment including abnormalities in dopaminergic maturation (Niwa et al 
2010). 
Much of what is known about the function of DISC1 in neurodevelopment has come 
from yeast two hybrid (Y2H) studies that have implicated DISC1 in several aspects 
of neurodevelopment (Figure 1-1). Several of the protein binding sites for these 
functions have been shown to be present in the C-terminal end of the protein, 
which is lost in the original Scottish family (Porteous et al 2011).  
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 Interacting partners implicated in neuronal migration  
To date, several interacting partners of DISC1 have been identified through yeast 
and mammalian two hybrid experiments (Camargo et al 2007). A large proportion 
of these were cytoskeletal proteins with roles in neuronal migration and neurite 
outgrowth for example NDEL1, LIS1 and FEZ1. LIS1 is a critical protein for neuronal 
migration; mutations in the gene encoding it cause lissencephaly, a condition that 
results from severe neuronal migration defects. NDEL1 (also referred to as NUDEL) 
was originally characterised through its interaction with LIS1 and dynein and has 
been shown to be a cytoskeletal protein important for coupling the centrosome to 
the nucleus (nucleokinesis) during cell migration (Niethammer et al 2000). The 
complex formed between DISC1 and NDEL1 is developmentally regulated in the 
mouse brain with a peak at E17 and during early postnatal development. 
Interestingly relative protein co-localisation between LIS1, NDEL1 and DISC1 was 
observed in the developing mouse cerebral cortex and hippocampus (Brandon et al 
2004). DISC1 was also shown to localise to the centrosome, through co-localisation 
with Ƴ-tubulin, which suggested that interactions with proteins such as NDEL1 could 
be required for its centrosomal recruitment (Morris et al 2003). It has been 
subsequently shown from these initial studies that DISC1 forms complexes with 
NDEL1 and through this complex can also interact with LIS1 and that it also has 
important roles in neuronal migration (Figure 1-2A). Another study identified a 
decrease in NDEL1, LIS1 and FEZ1 in the hippocampus of individuals with 
schizophrenia during post-mortem brain analysis (Lipska et al 2006). FEZ1 is a 
protein that is important for axon outgrowth, another process relying heavily on 
the cytoskeleton, and has similarly been shown to interact with DISC1 through Y2H 
experiments. DISC1 has also been shown to interact with microtubules and 
microtubule-associated proteins, namely MAP1A and MIPT3 (Morris et al 2003). 
These interactions with centrosomal and microtubule-associated proteins have led 
to the proposal that DISC1 could have functions in creating stable protein networks 
important for neuronal migration during brain development. In mutation cases 
where the domains harbouring the major binding sites are affected, such as in the 
original chromosomal translocation identified in the Scottish family, this could 
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result in destabilisation of protein complexes and aberrant migration during 
development (Millar et al 2000). 
 
Figure 1-2: The DISC1 protein at the centrosome and primary cilia 
The DISC1 protein has been reported to localize to the centrosome and interact with 
centrosomal proteins implicated in neuronal migration (A). The DISC1 protein has also been 
reported to localize to the basal body of primary cilia where it interacts with other basal 
body proteins(B). Taken from  (Wang & Brandon 2011) License number: 3458260976001.  
 
Several studies have since supported a role for DISC1 in neuronal migration, key 
studies will be discussed here. RNA interference based knockdown of Disc1 in the 
embryonic mouse brain via in utero electroporation resulted in neuronal migration 
delays. At E18.5 there was a significant increase in the distance between the 
centrosome and the nucleus which does suggest there is mis-positioning of the 
centrosome in the absence of DISC1, thereby presenting a possible role for DISC1 in 
centrosomal/nuclear positioning (Kamiya et al 2005). The same group later showed 
an interaction between PCM1, BBS4 and DISC1. Pericentriolar material 1 (PCM1) 
has itself been proposed as a genetic risk factor for schizophrenia (Blouin et al 
1998), whereas BBS4 is mutated in Bardet-Biedl syndrome, a ciliopathy where 
patients display neuropsychiatric symptoms. DISC1 and BBS4 were shown to recruit 
PCM1 to the centrosome through complex formation. Disruption of this complex 
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caused defects in neuronal migration (Kamiya et al 2008). An interaction between 
DISC1 and amyloid precursor protein (APP), a protein central to the pathogenesis of 
Alzheimer’s disease, has been reported to be involved in cortical precursor 
neuronal migration. Overexpression of DISC1 could rescue an APP knockdown 
migration defect phenotype in vivo, while APP knockdown in vitro caused a 
redistribution of DISC1 (Young-Pearse et al 2010). A more recent study 
demonstrated a role for Disc1 in cortical interneuron migration. Suppression of 
Disc1 resulted in delayed cortical interneuron migration and additionally these cells 
showed abnormal morphology with longer branches indicative of reduced 
nucleokinesis and less branching suggesting cells were unable to sense their 
external environment (Steinecke et al 2012).  
Taken together these studies have provided a substantial body of evidence that 
DISC1 is important for neuronal migration in brain development. Mutations in 
DISC1 could therefore contribute to schizophrenia pathology via migratory defects 
which cause mis-positioning of neurons and lead to brain connectivity 
abnormalities. 
 Primary cilia and DISC1 
Primary cilia are finger-like projections of the plasma membrane and are present on 
most cell types in the body including neuronal cells. Their function has been 
repeatedly shown to be critical for cellular development and homeostasis with 
many human disorders resulting from mutations in genes important for primary 
and motile ciliogenesis (Goetz & Anderson 2010). A feature of some ciliopathies is 
brain deformities which suggest that cilia have important roles in 
neurodevelopment (Lee & Gleeson 2011). Cilia are now appreciated as signalling 
hubs of the cell, important for transducing a wide variety of signalling pathways 
including the SHH signalling pathway. Interestingly, there has been a handful of 
studies linking DISC1 to primary cilia both directly using immunofluorescence and 
through known interacting partners of DISC1 including TRAF3IP1 (also known as 
MIP-T3) (Figure 1-2B). DISC1-GFP was shown to localise to the basal body of cilia 
when transfected into cultured NIH3T3 cells. Furthermore, knockdown of DISC1 
through siRNA reduced primary cilia number suggesting that DISC1 could have 
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functions in regulating the formation of cilia (Marley & von Zastrow 2010). Another 
study showed that mice mutated in Traf3ip1, which encodes a DISC1-interacting 
partner, were devoid of cilia and had disrupted SHH signalling. Homozygous mutant 
embryos had neural patterning defects, confirming the requirement for functional 
cilia and SHH signalling in dorso- ventral neural tube development (Berbari et al 
2011). Although DISC1 has not as yet been shown to localise to neuronal cilia this 
data is still very interesting. Recent studies have shown primary cilia to have a role 
in directing migration of interneurons. Migrating interneurons were found to 
display primary cilia expressing receptors for guidance cues including ErbB4, 
Robo1/2 and CXCR4/7 (Higginbotham et al 2012). Another paper showed that 
primary cilia on neurons undergoing migration were located to the leading process. 
The authors also discovered that chemical inhibition of SHH signalling caused 
altered leading process dynamics which suggests that during migration primary cilia 
could be transducing SHH which drives migration of neurons in the required 
direction (Baudoin et al 2012). 
One could therefore hypothesise that DISC1 functions through or responds to 
signals transduced by primary cilia during migration of CNS cell types. Positional 
cues provided by the external environment are sensed by primary cilia, then in turn 
cytoskeletal proteins enriched in the basal body or cilia axoneme respond to these 
signals and function to drive migration accordingly. 
 Evidence for a role of DISC1 in OL development 
Although the majority of studies about DISC1 biology and function are focused on 
its role in neuronal development and maintenance there have been recent studies 
which have also linked DISC1 to oligodendrocyte development. However further 
investigation is required to understand the role of DISC1 in this process. A study 
utilising a mouse model expressing an inducible human mutant dominant negative 
form of DISC1 exclusively in the forebrain analysed for oligodendrocyte gene 
expression changes. It was found that the human mutant DISC1 caused significant 
changes in the expression of oligodendrocyte related genes in mice, including Olig2, 
Sox10, Mag, Plp, Pdgfra, Cnp1 and Qki all of which were up-regulated (Katsel et al 
2011). Furthermore, this study found increased expression of Nrg-1 and its 
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receptors. NRG-1 signalling is important in oligodendrocyte development and there 
is also evidence suggesting it to be a genetic risk factor for schizophrenia (Vartanian 
et al 1999) (Li et al 2006). This suggests that DISC1 could regulate or work in 
conjunction with NRG1 during oligodendrocyte development. Another study 
showed that in Nrg1 knockout mice, Disc1 expression was reduced during 
neurodevelopment. The study also showed that DISC1 was expressed in a variety of 
brain cell types including neurons, astrocytes, oligodendrocytes and microglia in 
vitro (Seshadri et al 2010). Expression in oligodendrocytes was restricted to cell 
bodies and expression in OPCs was not addressed. Cells were co-stained with an 
anti-DISC1 mExon3 antibody and cell specific antibodies, however the specificity of 
the anti-DISC1 mExon3 has not been extensively scrutinised. 
A recent in vitro study using primary rat oligodendrocyte precursor cells suggested 
that DISC1 was a negative regulator of oligodendrocyte differentiation, with 
knockdown via RNA interference resulting in a higher percentage of mature 
oligodendrocytes. When overexpressed, DISC1 caused an increase in the number of 
progenitors. It was also suggested that Sox10 and Nkx2.2 had functions in 
oligodendrocyte development downstream of DISC1 since their expression was 
decreased when DISC1 was overexpressed, and increased upon DISC1 knockdown. 
The study did not give an indication as to an effect of OPC migration when DISC1 
expression was altered (Hattori et al 2014). 
The same group recently identified a role for a DISC1 interaction partner in 
regulating oligodendrocyte differentiation. DISC1-binding zinc finger protein (DBZ) 
was shown to be specifically expressed in the CNS, including the oligodendrocyte 
lineage. DBZ knockout mice had an increased number of immature 
oligodendrocytes suggesting that it acts in oligodendrocyte differentiation (Shimizu 
et al 2014). When compared to DISC1 which was suggested by the previous study to 
promote the oligodendrocyte precursor cell state, it could perhaps be hypothesised 
that DBZ binds to DISC1 during later stages of oligodendrocyte differentiation and 
inhibits its progenitor promoting function. However this has not been shown and is 
merely speculative. 
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Furthermore, a CNS exon array carried out in neurons, astrocytes, OPCs and 
oligodendrocytes showed DISC1 to be most highly expressed in OPCs, further 
encouraging a fundamental role for DISC1 in OPCs (Cahoy et al 2008). 
1.4 Oligodendrocyte development 
 Specification of oligodendrocyte precursor cells 
Oligodendrocyte precursor cells are produced from the same pool of progenitors 
that first produce motor neurons (pMN) in the ventral neural tube (Pringle et al 
1996). A discrete population of OPCs is specified in the ventral neural tube and this 
initial specification is governed by opposing extracellular signals. Sonic hedgehog 
(SHH), a protein secreted by the notochord, which sits below the neural tube, and 
then floor plate of the ventral neural tube, is crucial for orchestrating the early 
patterning of the dorso-ventral CNS. The opposing signal is bone morphogenic 
protein (BMP), which acts dorsally, and works to repress the long range SHH signal 
thereby setting up a morphogen gradient of SHH (Mehler et al 1997). Another 
dorsal signal which acts to repress SHH is Wnt/beta-catenin (Robertson et al 2004). 
SHH specifies discrete sections of the D/V neural tube through regulation of 
transcription factors to create different progenitor regions. Ablation of ventral SHH 
results in a failure to produce oligodendrocytes (Orentas et al 1999). OPCs are born 
in one of these discrete progenitor regions and then subsequently migrate to their 
axonal destinations creating a widespread distribution of oligodendrocytes 
throughout the nervous system. This is not the only population of oligodendrocyte 
precursor cells in the developing CNS, it should be noted that there is another 
population which is specified by a SHH-independent pathway in the dorsal 
telencephalon (Cai et al 2005, Fogarty et al 2005) 
 Early gene expression in OPC specification 
The basic helix-loop-helix transcription factors OLIG1 and OLIG2 act downstream of 
SHH signalling to specify the pMN domain which gives rise to first MNs and then 
OLs (Lu et al 2000, Takebayashi et al 2000, Zhou et al 2000). OLIG2 is critical for the 
development of these cells (Zhou & Anderson 2002) which then subsequently 
express NKX2.2 once specification of motor neurons is complete. Olig2 knockout 
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mice fail to give rise to oligodendrocytes in the majority of the CNS (Zhou & 
Anderson 2002), however studies have suggested that Nkx2.2 expression is not 
critical for early specification of OPCs but involved in their maturation during 
differentiation (Qi et al 2001). Another transcription factor reported to have a 
required role in OPC specification is Ascl1/mash1. Mice lacking Ascl1 have 
drastically reduced numbers of OPCs early on but these are recovered at later 
stages (Sugimori et al 2008). Studies in the zebrafish have identified a role for Delta-
Notch signalling in maintaining some olig2+ precursors once pMNs are specified 
(Park & Appel 2003). Early specification of OPCs is also dependent on the growth 
factor neuregulin-1 (NRG1). In spinal cord explants lacking Nrg1, oligodendrocytes 
fail to develop (Vartanian et al 1999). NRG1 also acts a chemoattractant during OPC 
migration. 
 Proliferation of OPCs 
Once the initial specification of OPCs has been established through expression of 
the transcription factors described above, OPCs undergo proliferation both before 
and after migration. These waves of proliferation are dependent on various growth 
factors which also act to promote the survival of OPCs. Platelet derived growth 
factor A (PDGF-A) is an important growth factor for oligodendrocyte proliferation. 
Loss of PDGF-A in a knock out mouse leads to a decrease in OPC numbers and 
hypomyelination (Fruttiger et al 1999), whereas overexpression of this growth 
factor increases OPC number (Calver et al 1998). Other growth factors such as bFGF 
(McKinnon et al 1991)and CXCL2 are also involved in OPC proliferation and 
development (Robinson et al 1998).  
 Migration of OPCs to their axonal targets 
Once OPCs have proliferated they need to exit their defined progenitor domains 
and migrate to populate the CNS, which requires a wide variety of external factors 
to create defined maps for OPCs to respond and migrate in the specified direction. 
The capacity of OPCs to migrate long distances has been known for some time from 
initial studies using the optic nerve  (Small et al 1987) (Ono et al 1997). Growth 
factors such as PDGF-AA and FGF-2 are responsible for directing OPCs to 
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destinations far away from their birth place by inducing cell motility, but also by 
acting as chemoattractants (Bribian et al 2006). Other chemoattractants include 
netrin-1 and semaphorins 3A and 3F (Spassky et al 2002). SHH has also been 
proposed to act as a chemoattractant in the optic nerve (Merchan et al 2007). 
Chemorepellents are also required during migration to ensure OPCs do not travel 
past their destinations and these include chemokine (C-X-C motif) ligand 1 (CXCL1) 
and some members of the semaphorin family (Tsai et al 2002). Communication with 
ECM proteins fine-tunes the direction of OPC migration. Adhesion molecules have 
the ability to control the speed and direction by which OPCs migrate and these are 
present of the surfaces on surrounding cells, including axons and astrocytes (de 
Castro & Bribian 2005). Some of these adhesion molecules are also thought to act 
as stop signals for migrating OPCs, which will therefore act as a cue to OPCs that 
they have reached their desired axonal destination. OPCs also repel each other 
using contact inhibition, thus distributing themselves more uniformly with no two 
cells being too close together. All these factors help migrating OPCs to 
communicate with and respond correctly to their external environment. 
As discussed earlier, migration defects in neuronal cells have been commonly 
described in schizophrenia patients with many of the risk factor genes identified 
having functional roles in the cytoskeleton and neuronal migration. At this point it 
can be proposed that an area of oligodendrocyte biology that may be defective in 
SZ brains is OPC migration. If OPCs lack the ability to migrate at full capacity it 
would mean that at least a proportion of those destined for areas far away from the 
birth place my never reach their correct axons leading to defective myelination of 
those neurons. This could subsequently result in brain connectivity alterations, 
potentially leading to cognitive defects and psychosis. 
 Transition from OPC state to differentiated 
oligodendrocytes 
After proliferation and migration, OPCs will start to up-regulate genes required for 
their terminal differentiation. It is at this point that cells will start to lose their 
capacity for migration/proliferation and undergo drastic morphological changes. 
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Early OPCs have a bipolar simple morphology (Figure 1-3A) but as development 
progresses and the cells start to differentiate they become more complex and 
extend long fine processes characteristic of pre-myelinating oligodendrocytes 
(Figure 1-3C). 
  
Figure 1-3: Morphologies of oligodendrocytes during development 
During early development oligodendrocyte precursor cells have a simple bipolar 
morphology (A). During migration OPCs extend long processes into the surrounding 
environment (B). Once at their destination, differentiated oligodendrocytes extend fine 
processes to wrap and myelinate axons (C). OPCs are shown from the zebrafish 
tg(olig2:gfp) line 
 
There are two opposing actions occurring during early differentiation; factors that 
promote differentiation and factors that function to inhibit differentiation. Those 
factors that act to inhibit the differentiation of OPCs include G protein-coupled 
receptor 17 (GPR17) (Chen et al 2009), members of the Notch signalling pathway 
(Kondo & Raff 2000, Wang et al 1998) and Leucine-rich repeat and immunoglobulin 
domain-containing-1 (LINGO1). Insulin-like growth factor 1 (IGF-1) is a promoter of 
OL differentiation; in mice lacking Igf-1 there is a decrease in myelin and mature 
OLs (Ye et al 2002). There are also a number of transcription factors which are 
expressed during differentiation. As mentioned previously Mash1/Ascl1 and Nkx2.2 
also have roles in OL differentiation (Sugimori et al 2008) (Qi et al 2001). OLIG2 is 
expressed throughout OPC development and has also been suggested to have a 
role in OPC differentiation. One recent study showed that it is responsible for 
recruiting BRG-1, a chromatin-remodelling enzyme, to key gene regulatory 
elements during differentiation (Yu et al 2013). 
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 Myelination 
The final stage of OL development is the myelination of axons in the CNS and it has 
been recently demonstrated that OLs have only a short window of time in which to 
make contact and myelinate axons (Czopka et al 2013). A number of studies have 
identified signalling systems that assist OLs in sensing their axonal environments, 
allowing for process extension and subsequent myelination. Although OLIG1 is well 
known as an OL lineage specification transcription factor, its role in myelination was 
not shown until later. In Olig1 knock out mice, although OPCs form there is a failure 
in myelination although the underlying mechanism has not yet been elucidated (Xin 
et al 2005). In order to myelinate axons, oligodendrocytes are required to 
synthesise specific proteins including Proteolipid Protein (PLP) and Myelin Basic 
Protein (MBP) (Campagnoni 1988). As previously discussed, in humans the majority 
of myelination occurs post-natally up until early adulthood. The majority of studies 
have used the murine model to investigate oligodendrocyte development, however 
other models systems including the zebrafish has also provided valuable 
information. 
1.5 The zebrafish (Danio rerio) as a model system of 
myelination  
 Advantages of the zebrafish 
The zebrafish embryo offers many advantages making it an excellent model system 
to study vertebrate development, but it has also found favour in modelling human 
diseases. The zebrafish genome has approximately 70% of human genes, making it 
a valuable genetic tool in understanding human genetic function in development, 
maintenance and disease (Howe et al 2013). Fish are relatively inexpensive to 
maintain compared to mice and rats. They also have a short generation time, 
produce 100-200 embryos per clutch and are externally fertilised. Being externally 
fertilised means that they can be easily manipulated at early stages of 
development. Another advantage is that their embryos are also transparent during 
early development, allowing for easier visualisation of dynamic processes such as 
cell migration. There are many transgenic lines available in which different cell 
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types of the brain are labelled via expression of fluorescent proteins including the 
tg(olig2:gfp) line which was used during this project for analysing OPCs (Park et al 
2002). This simple visualisation of OPCs means that we could more efficiently 
analyse OPC migration in a temporal manner.  
 Myelination studies in the zebrafish 
Although the majority of oligodendrocyte and myelination studies discussed above 
were based on mouse/rat and cell culture studies, more recently the zebrafish has 
been exploited as a model system for studying many aspects of Schwann cell and 
oligodendrocyte myelination. However this discussion will describe zebrafish 
oligodendrocyte myelination studies only (Levavasseur et al 1998) (Brosamle & 
Halpern 2002, Park et al 2002). Since fish have a greater capacity to regenerate the 
CNS, understanding their genetic and developmental differences is of great interest 
(Stuermer et al 1992). One of the first studies to address myelination in the 
zebrafish was by Halpern et al, whereby the orthologues of key myelin genes were 
investigated in zebrafish larvae and myelination was characterised using in situ 
hybridisation and electron microscopy. Expression of plp, mbp and p0 was observed 
in the zebrafish embryo as early as 2 dpf, and in larvae myelinated axons were 
detected at 7 dpf, making them a rapid tool for understanding myelination with 
conservation of critical myelin genes (Brosamle & Halpern 2002). Similarly other 
groups have identified the zebrafish as a useful model system and have further 
investigated the development and genetics of OPC myelination during CNS 
development. One such study focused on dissecting the genes required for 
zebrafish myelination using ENU mutagenesis and described a number of mutations 
affecting mbp expression, and therefore myelination, in the CNS, PNS (Peripheral 
nervous system) or both. Three mutations were found to affect CNS myelination 
and were named molst20, st47 and st51. These mutants had altered shh and/or olig2 
expression abnormalities, suggesting that they interfered with early stages of 
oligodendrocyte development, most likely during OPC specification. A further three 
mutations were found to affect both CNS and PNS myelination, showing genetic 
overlap between Schwann cell and oligodendrocyte myelination as with higher 
vertebrate systems (Pogoda et al 2006). Other groups focused on using in vivo live 
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imaging of transgenic zebrafish lines specifically marking oligodendrocytes to 
observe their migration, distribution and axonal contact behaviours. Using the 
tg(nkx2.2:megfp) and tg(olig2:gfp) lines, live embryos were mounted and 
oligodendrocytes imaged over various time periods where they showed dynamic 
behaviours. Oligodendrocytes were observed extending filopodium-like processes 
with continuous extension and retraction into the surrounding environment before 
settling into their final location, and the migratory path and final position seemed 
to rely on contact between OPCs. Interestingly, when OPCs were ablated, 
neighbouring OPCs moved into the ablated area to allow for evenly dispersed 
oligodendrocytes and the authors suggest that this retraction and extension of 
processes acts as a surveillance mechanisms to ensure a uniformly distributed 
population of oligodendrocytes prior to axonal wrapping (Kirby et al 2006). In mice 
and human systems, OPCs can replace ablated areas showing evolutionary 
similarities, and suggesting that OPCs may compete for space.  
Oligodendrocytes that associate with large axons are limited in how many axons 
they can myelinate. If they associate with small axons, they capable of myelinating 
several axons but how this relationship is established is unknown. Whether axons 
play a role in governing how many axons an oligodendrocyte can myelinate was 
addressed using the zebrafish. In the zebrafish, the first axon to be myelinated is 
the Mauthner axon which is very large in size. Addition of more Mauthner axons 
can regulate myelination; oligodendrocytes that would normally only myelinate a 
single Mauthner axon in this case could myelinate a larger number and this was not 
at the expense of other axons. This suggested that axons can regulate 
oligodendrocyte myelination (Almeida et al 2011). Several other studies have 
sought to investigate the role of single genes in aspects of zebrafish myelination 
including kif1b and tuba8l3a (puma) which were shown to have roles in mRNA 
localisation of mbp and lingo-1, which was identified as a negative regulator of 
oligodendrocyte differentiation (Lyons et al 2009) (Larson et al 2010) (Yin & Hu 
2014). Another study showed additional roles in for sox10, not only to promote 
myelin gene expression but also in the survival of oligodendrocytes prior to axonal 
wrapping (Takada et al 2010). 
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A very recent genetic screen identified a mutation in the hmgcs1 gene in the 
zebrafish, which caused aberrations in OPC migration whereby cells migrated past 
their axon targets and therefore failed to myelinate. These OPCs also failed to 
express any myelin genes. This gene has roles in the cholesterol biosynthetic 
pathway which also synthesises isoprenoids and it is known that myelin requires 
high levels of cholesterol. This data showed that cholesterol biosynthetic pathway 
products had roles in OPC migration and the expression of myelin genes which was 
a novel observation (Mathews et al 2014). 
 Using the zebrafish as a model system for 
schizophrenia 
Although the zebrafish is a very powerful developmental biology tool it is unable to 
recapitulate certain behaviours that are characteristic of psychiatric disorders. 
Mouse models with behavioural changes of relevance to schizophrenia have also 
been developed, but even these higher vertebrate models possess limitations since 
many of the symptoms in schizophrenia (such as hallucinations) are self-reported 
and assumed to be human specific (Pletnikov et al 2008) (Hikida et al 2007). 
Nonetheless, zebrafish are still a powerful system for investigating the underlying 
genetics and molecular mechanisms controlling neurodevelopmental processes 
since their nervous system is less complex than that of higher vertebrates but share 
many common features and signalling pathways. 
  Zebrafish disc1 
As previously mentioned, there is high genetic similarity between the zebrafish 
genome and the human genome. The DISC1 gene is conserved between species, 
although there is no reported homolog in Drosophila (D.melanogaster) and worms 
(C.elegans), which suggests that its functional roles may lie exclusively in complex 
brain development such as myelination (Chubb et al 2008). There have been three 
different transcripts of zebrafish disc1 identified thus far; all three transcripts 
maintain the same protein coding length, only differing in their untranslated 
regions (UTR). Since there have been several human isoforms identified it is 
plausible that more zebrafish disc1 isoforms are present and this requires further 
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investigation. With regards to sequence conservation with human DISC1, the C-
terminal end is more highly conserved compared to the N-terminal end which is 
poorly conserved. The C-terminal end is 35% identical to the human protein and 
shares 57% similarity. As with the C-terminal portion of the human DISC1 gene it is 
predicted to form multiple coiled-coil domains. Its location within the genome also 
shows similarity to human DISC1, with the genes TSNAX and EGLN1 and their fish 
orthologues being positioned directly upstream to DISC1 in both humans and 
zebrafish (Wood et al 2009). When semi-quantitative RT-PCR of disc1 was used to 
investigate disc1 expression throughout development, it was found to be 
dynamically regulated (Drerup et al 2009). Expression was high at 3 hours post-
fertilisation, this suggests that there is maternal disc1 mRNA that is deposited 
during early development. Expression was subsequently down-regulated between 
12 and 48 hpf, after which disc1 started to be expressed again from 48 hpf and 
subsequently increased. At 120 hpf, expression of disc1 was still present. Since 
there was no expression identified using this method between 12-48 hpf during 
which time the body axis is established and the nervous system specified, it 
suggests that disc1 does not have early roles but functions later during nervous 
system development (Drerup et al 2009). However expression of the disc1 mRNA 
transcript was detected through in situ hybridisation at 8 somites, 16 somites and 
24 hpf. Since the expression pattern at these early times points appeared specific it 
would suggest that the RT-PCR results are inaccurate. These results do suggest that 
disc1 is maternally expressed during early development and shows specific 
expression in different tissue regions during the developmental process. 
 Zebrafish disc1 in brain development  
To date there has been only a handful of studies investigating the role of disc1 in 
zebrafish development, and those studies that have been performed suggest 
important roles for disc1 in the development of a variety of cell types as 
summarised in the table below. 
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Publication disc1 function identified 
(Drerup et al 2009) Role in cranial neural crest development through suppression 
of the transcription factors sox10 and foxd3 
(De Rienzo et al 2011) Role of disc1 in brain development through regulation of the β-
catenin-mediated Wnt pathway 
(Wood et al 2009) Role of disc1 in the development of hindbrain OPCs. 
Table 2: Studies identifying roles for disc1 in zebrafish development 
 
A role for disc1 in cranial neural crest (CNC) development has been characterised in 
the zebrafish through morpholino knockdown analysis of disc1 in developing 
embryos. Cranial neural crest cells, like oligodendrocyte precursor cells, have the 
capacity to migrate long distances from their origin. CNC cells give rise to numerous 
tissues including pigment cells, the peripheral nervous system (PNS) and jaw 
cartilage. The migration direction and final location is important for their 
subsequent differentiation into the correct cell type through exposure to the 
appropriate signals. It was found that a loss of the Disc1 protein in developing 
embryos resulted in aberrant directional migration of CNC cells however their 
motility was not affected. It was also observed that in disc1 morphants, the 
expression of sox10 and foxd3 was increased and these transcription factors have 
known roles in CNC cell migration and differentiation. The authors suggested that 
disc1 is responsible for sox10 and foxd3 repression in CNC cells. Another hypothesis 
could be that CNC cells lose their ability to respond to positional information and 
therefore migrate in aberrant directions due to loss of disc1. It is interesting that 
CNC cells were reported to not have altered motility, as it might be expected that 
upon knockdown of a cytoskeletal scaffold protein with known roles in neuronal 
migration, the cells would have altered motility however only the direction of 
migration in this case was compromised. The same group also reported lower jaw 
cartilage defects in disc1 morphants (Drerup et al 2009). CNC cells give rise to the 
jaw cartilage and this is therefore consistent with aberrant CNC migration.  
Another group analysed the zebrafish disc1fh291 mutant identified through a TILLING 
screen. This mutation leads to a premature stop codon in exon 2 and therefore is 
predicted to give rise to a prematurely terminated protein product. Although 
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heterozygotes developed normally, homozygotes presented with brain 
abnormalities at 24 hpf including small ventricles. Mutants also presented with a 
bent tail. This was phenocopied in disc1 morphant embryos, and the phenotype 
could be rescued with injection of human Disc1 RNA. The authors suggest that 
zebrafish disc1 functions through β-catenin-mediated Wnt signalling (De Rienzo et 
al 2011).  This group did not describe any lower jaw cartilage cranio-facial defects 
that have been recognised by two other groups working with disc1 morphants, 
suggesting inconsistencies between studies (Drerup et al 2009, Wood et al 2009).  
Finally, a role for disc1 in zebrafish OPC development was described in a study 
performed in our group at the University of Sheffield, where the author suggested 
that disc1 could have active roles in OPC migration (Wood et al 2009). Using in situ 
hybridisation, the expression pattern of disc1 during development was analysed. 
Expression at 24 hpf was observed in presumptive neural crest and the otic vesicles 
and whereas at 50 hpf, expression was found in the developing lower jaw cartilage, 
otic vesicles and in a strip of midline expression in the hindbrain. This defined strip 
of expression was very similar to the expression of olig2 which was intriguing, as it 
suggested a potential link between disc1 and oligodendrocyte development (Figure 
1-4).  
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Figure 1-4: Overlapping expression patterns of disc1 and olig2 in the midline of the 
zebrafish hindbrain 
The expression pattern of disc1 mRNA (A) in the midline of the zebrafish hindbrain was 
similar to the expression pattern of olig2, a genetic marker of the oligodendrocyte lineage 
(B) which suggested that disc1 may have a role in oligodendrocyte development. (Wood et 
al 2009) 
 
To determine whether disc1 functions during OPC development, two morpholinos 
(MO) were designed, a translation blocking and a splice blocking morpholino which 
were injected into embryos at the one cell stage. Embryos were then allowed to 
develop until 50 hpf (during the time where disc1 was normally expressed) and 
compared against control morpholino-injected embryos. In control embryos, OPCs 
in the hindbrain had migrated away from their birthplace in rhombomeres 5 and 6 
both along the anterior-posterior axis and laterally to populate the hindbrain. 
However in disc1 morphants, OPCs were specified but remained restricted to their 
birthplace and failed to expand to populate the hindbrain (Figure 1-5 A and B). This 
suggested that disc1 was not required for the initial specification of OPCs but has 
functions in later stages of development, perhaps a direct role in migration. 
Cartilage analysis using Alcian blue staining showed lower jaw defects similar to 
those documented by Drerup et al (Figure 1-5 E and F). 
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Figure 1-5: OPC development and lower cartilage defects in disc1 morphants 
In control embryos, olig2+ positive OPCs migrate from rhombomeres 5 and 6 into the 
surrounding hindbrain (A). When disc1 was knocked down using morpholino injections, 
OPCs were restricted to their birthplace and failed to migrate into the surrounding 
hindbrain (arrow in B). The disc1 morphants also displayed lower jaw cartilage defects, 
although the ethmoid plate and the trabeculae developed normally but were smaller 
(compare arrows in C with D). The meckels and ceratohyal cartilage were abnormal and 
other branchial cartilages were absent (Compare E with F). (Wood et al 2009) 
 
 
 At 5 dpf, disc1 morphants were analysed for genetic markers of differentiated 
oligodendrocytes and it was observed that expression of OL markers was lost in the 
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morphants compared to control-injected embryos (Figure 1-6). If OPCs were unable 
to reach their axonal targets within the hindbrain, then the cells might not be 
exposed to appropriate signals to initiate differentiation. Whether and how disc1 
contributes to the migration of OPCs was not formally addressed however it could 
be hypothesised that it works as a cytoskeletal scaffold protein, required to create 
cytoskeletal protein complexes to drive the physical movement of cells from their 
birthplace into the surrounding environment.  
 
Figure 1-6: Expression analysis for plp1b and mbp show a loss of differentiated 
oligodendrocytes in disc1 morphants. 
At 5 dpf, control embryos shows expression of mbp and plp1b, which are markers of 
oligodendrocyte differentiation and myelination (A and C). In disc1 morphants there was no 
expression of these genes suggesting a loss of differentiated oligodendrocytes in the 
hindbrain (B and D). (Wood et al 2009) 
 
Zebrafish oligodendrocyte hindbrain development has not been well characterised 
in comparison to zebrafish spinal cord OPC development and so these findings also 
presented an opportunity to characterise the mechanisms involved in hindbrain 
OPC development and migration. A handful of studies has investigated the 
development of this subset of cells but further work was required to identify 
30 
 
similarities and differences between the development of hindbrain OPCs compared 
with spinal cord OPCs. Further investigation was also required to address 
evolutionary differences in OPC development between zebrafish and higher 
vertebrates. 
 OPC development in the zebrafish hindbrain 
A study characterising the development of olig2-positive cells in the hindbrain was 
published soon after our group published evidence of a role for disc1 in OPC 
hindbrain development (Zannino & Appel 2009). The transcription factor olig2 is 
not only a marker of the oligodendrocyte lineage in the zebrafish spinal cord, but 
also of motor neurons in a common pool of precursors identified as pMN 
(Takebayashi et al 2000) (Lu et al 2002). This common pool of olig2 expressing 
pMNs first gives rise to motor neurons after which oligodendrocytes are specified. 
In the hindbrain, both motor neurons and OPCs are specified in rhombomeres 
suggesting that they could arise from a common pool of olig2-positive precursor 
cells as in the spinal cord. The study aimed to address whether olig2-positive 
progenitors in rhombomeres 5 and 6 are a common pool for motor neurons and 
oligodendrocytes. The group showed that it was the case and these olig2-positive 
cells give rise to abducens motor neurons and some hindbrain OPCs (Zannino & 
Appel 2009). Furthermore this study demonstrated that the OPCs specified in this 
region actively migrate away from the birthplace using live imaging techniques. 
Morphologically, motor neurons and oligodendrocytes can be readily distinguished 
therefore OPCs can be exclusively analysed using the tg(olig2:gfp) line. OPCs 
undergoing migration contain a cell body with a single or two processes (Figure 1-7 
yellow arrows). Whereas abducens motor neurons extend long thin axonal 
processes anteriorly on either side of the midline (Figure 1-7 blue arrow). Cells 
remaining in r5 and r6 will contain the cell bodies of abducens motor neurons, 
neuroepithelial cells and OPCs that have not started to migrate (Figure 1-7).   
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Figure 1-7: The tg(olig2:gfp) line expresses GFP in many cell types of the hindbrain. 
A population of cerebellar neurons is labelled with GFP (red arrows). The abducens motor 
neurons (blue arrows) are also labelled with GFP and extend long processes anteriorly. 
OPCs (yellow arrows) also express GFP and have a bipolar morphology during early 
migration ( yellow arrow in A) and then extend fine process indicative of differentiation and 
myelination events (yellow arrow in B). 
 
 
Another group recently studied the role of FGF signalling on OPC development in 
the zebrafish hindbrain and their data suggests that FGF signalling works in 
conjunction with Shh signalling to control olig2 expression. Upon chemical 
inhibition of FGF signalling using SU5402 at 20 hpf before normal specification of 
the cell type, olig2 expression was lost in the hindbrain but normally expressed in 
the spinal cord and midbrain. Similarly sox10 expression was also reduced in the 
hindbrain. The authors found no increase in apoptotic cells in the hindbrain of 
SU5402 treated embryos which suggested that inhibiting FGF signalling does not 
cause cell death but specifically causes a loss of olig2 expression and it is likely that 
cells remain in their progenitor state (Esain et al 2010). The study also showed that 
in the Shh signalling pathway mutant smoothened, sox10 and olig2 expression was 
lost as expected but FGF signalling was unaffected. This provided evidence of an 
independent role for FGF-signalling in the control of olig2 expression. Although 
these studies have provided valuable information regarding the development of 
OPCs and other cells in the hindbrain further work is necessary to complete the 
characterisation of hindbrain OPCs. 
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1.6 Hypothesis 
Given the established roles of DISC1 in neuronal migration in rodents, it was an 
interesting observation that in the zebrafish CNS, disc1 appears to be 
predominately expressed in oligodendrocyte precursors. Although there has been a 
recent publication suggesting a direct link between Disc1 and oligodendrocyte 
differentiation in the mouse, its role in oligodendrocyte development has not been 
explored in depth (Katsel et al 2011). The zebrafish provides another system in 
which disc1 function in non-neuronal brain development can be studied. 
Investigating how disc1 functions in normal OPC development could potentially 
provide fundamental insight into the oligodendrocyte and white matter 
abnormalities that have been well documented in schizophrenia and therefore 
further investigation is warranted. Furthermore, the development of hindbrain 
OPCs in the zebrafish has not been thoroughly investigated, so addressing the 
mechanisms controlling their general development in more detail may also provide 
useful contributions to the field of neurobiology. 
The starting hypothesis for this project was: 
‘The schizophrenia risk factor, disc1, drives OPC migration in the hindbrain of the 
zebrafish embryo, through regulating cytoskeletal complexes’ 
1.7 Project objectives 
This project aimed to characterise general OPC development in the hindbrain over 
an extended time course, specifically focusing on initial process extension and 
migration direction. The second aim was to confirm disc1 expression in OPCs and 
attempt to elucidate its cellular localisation in OPCs to investigate protein 
recruitment during migration and to develop a candidate list of interacting partners 
also involved in OPC migration through similar cellular localisations. Finally we 
sought to identify novel signalling pathways with roles in OPC development using a 
medium-throughput in vivo drug screen.  
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 Material and Methods 
2.1 Zebrafish husbandry  
 Zebrafish line maintenance  
The LWT, AB and Nacre wild-type zebrafish strains were raised and maintained at 
the Bateson Centre, BMS aquaria, University of Sheffield and the Institute of 
Molecular and Cell Biology IMCB in an AVA approved zebrafish aquarium, 
Singapore. 
The Tg(olig2:gfp) transgenic line (Shin et al 2003),  ptch1/ptch2 (Koudijs et al 2008), 
iguanats294e (Brand et al 1996) and smub641 (Varga et al 2001) mutant zebrafish lines 
were maintained at the Bateson Centre, BMS aquaria, University of Sheffield and 
the Institute of Molecular and Cell Biology, Singapore. 
The Tg(shha:gfp) transgenic line (Ertzer et al 2007) was maintained at the Institute 
of Molecular and Cell Biology, Singapore. 
Adult Zebrafish were maintained on a 14 hour light/10 hour dark cycle according to 
standard protocols at 28 °C and were mated using spawning tanks and through pair 
mating in individual cross tanks (Nüsslein-Volhard & Dahm 2002).  
 Embryo harvesting 
Eggs were collected using a plastic tea strainer and transferred to 90mm petri 
dishes (Sterilin, Newport, UK) in batches of 50 and allowed to develop to the 
desired developmental stage using standard staging protocols (Kimmel et al 1995). 
Embryos were raised at 28°C in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM 
CaCl 2, 0.33 mM MgSO4 , 0.0001% methylene blue). 
2.2 General Molecular Cloning  
 Polymerase chain reaction (PCR) 
2.2.1.1 Standard PCR 
Each 20 µl PCR reaction contained 10ng of template DNA, 1 µl of Advantage 2 
polymerase mix (Clontech), 2 µl 10X buffer, 10pmol/µl of each forward (FWD) and 
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reverse (RVS) primer and 0.2 mM dNTP mix. Reaction mixtures were kept on ice 
until they were placed in a thermal cycler (Bio-Rad, DNA Engine Peltier Thermal 
Cycler). The cycling reaction was performed with the following conditions:  
template denaturation 95°C for 1 minute followed by 27-30 amplification cycles at 
95°C for 30 seconds, 53-61°C for 30 seconds (dependent on primer annealing 
temperature) and then 68°C for 1 minute per 1 kb of product. Finally, reactions 
were incubated at 68°C for 10 minutes for proof-reading, after which samples were 
kept at 4°C. 
2.2.1.2 PCR for cloning 
Each 50 µl reaction contained 50-100ng plasmid DNA or 1 µl of a cDNA synthesis 
reaction, 1 µl of expand high fidelity enzyme mix (Roche), 5 µl of 10X expand high 
fidelity buffer containing 15 mM MgCl2, 10 pmol/µl of each FWD and RVS primer 
and 0.2mM dNTP mix. The cycling reaction was performed with the following 
conditions: 94°C for 2 minutes followed by 30 cycles of 94°C for 30 seconds, 53-
61°C for 30 seconds (dependent on primer annealing temperature) and then 72°C 
for 1 minute per 1kb of product. Finally the reactions were incubated at 72°C for 10 
minutes, after which samples were held at 4°C. 
 Purification of PCR products 
PCR-amplified DNA was purified using the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s protocol. DNA was eluted in 30 -50 µl nuclease free 
sterile water. 
 Gel extraction 
DNA fragments were electrophoresed in a 1% agarose gel and subsequently 
extracted using the QIAquick Gel Extraction Kit (Qiagen) according the 
manufacturer’s protocol. DNA was eluted in 30-50 µl nuclease free sterile water. 
 Restriction endonuclease digestion 
Restriction endonuclease reactions were performed in 20–50 µl volumes using 1 
unit of the appropriate restriction enzyme for every 1 µg of DNA using the required 
buffer in sterile water. The reaction was incubated at the temperature specified by 
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the manufacturer (New England Biolab) for 2-4 hours. DNA was then purified using 
the PCR purification or gel extraction protocols outlined previously (Section 2.2.2 
and 2.2.3). 
 Cloning 
2.2.5.1 Standard cloning 
DNA was amplified through PCR using modified primers containing the required 
endonuclease restriction sites, then the product was purified and digested using the 
appropriate restriction enzymes. At the same time approximately 50 ng of the 
required vector was also digested with the same restriction endonucleases. Both 
the vector and PCR product were gel extracted and purified. The vector was then 
treated with Antarctic Phosphatase (New England Biolabs) to prevent 
recircularisation. A ligation reaction was then set up containing approximately a 3:1 
molar ratio of PCR product to vector in a final volume of 10µl containing T4 DNA 
ligase and ligase buffer (Roche). The ligation reaction was left for 1 hour at room 
temperate and then 1-2µl was transformed into chemically competent E.coli (see 
section 2.2.6). The next day, single colonies were prepped, grown in liquid culture 
and plasmid DNA purified using the QIAprep Spin Miniprep Kit (Qiagen). To screen 
for positive inserts plasmid DNA was digested with the same restriction 
endonucleases as with the ligation reaction, and fragments were then 
electrophoresed and examined for 2 bands containing the correct sized vector and 
insert bands.  
2.2.5.2 TOPO cloning 
DNA was amplified by PCR (section 2.2.1.2) and purified (section 2.2.2), Taq 
polymerase leaves terminal deoxyadenosine (A) overhangs on the 3’ end of the PCR 
product which is utilised by the TOPO® TA Cloning® system (Life Technologies). PCR 
products were gel extracted and a ligation reaction set up containing 0.5-4 µl of PCR 
product, 1 µl of pCR™II-TOPO® vector or pCR™2.1-TOPO® vector, 1 µl of salt 
solution made up to 6 µl with nuclease free water. The reaction was left at room 
temperature for 15 minutes and then kept on ice prior to bacterial transformation. 
1-2 µl of the reaction was transformed into E.coli which was spread on LB-agar 
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plates containing the relevant antibiotic for selection that had previously been 
spread with 50µl X-gal for blue white colony screening. White colonies were 
selected and screened for positive inserts as outlined in the previous section 
(2.2.5.1). 
 Transformation of competent cells 
For each single transformation, 1 vial containing 50-100 µl of chemically competent 
cells E.coli DH5α was used. The cells were placed on ice to thaw, after which 10-20 
ng of DNA was added and mixed gently with the cells which were then kept on ice 
for 30 minutes. The cells were then heat-shocked at 42.2°C for 1 minute and 
returned to ice for 10 minutes. After that 250 µl of LB media (without antibiotic) 
was added and the cells were placed in a 37°C shaking incubator for 1 hour. 50-100 
µl of culture was then spread on a pre-warmed agar plate containing the required 
antibiotic. Plates were then incubated overnight at 37°C. The next day individual 
colonies were picked and grown in LB media containing the required antibiotic 
overnight in a 37°C shaking incubator. The next day, plasmid DNA was isolated 
using the QIAprep Spin Miniprep Kit or the QIAGEN Plasmid Midi Kit (Qiagen) and 
eluted in 50-500µl nuclease-free sterile water. 
 RNA extraction 
2.2.7.1 Trizol method 
500 µl of Trizol reagent (Life Technologies) was added to 30 dechorionated embryos 
and the embryos were lysed by passing through a hypodermic needle to disrupt the 
tissue. A further 500 µl of Trizol was then added followed by incubation for 5 
minutes at room temperature. After this, 200 µl of chloroform was added, and the 
tube was shaken vigorously for 15 seconds and then incubated for 3 minutes at 
room temperature. Subsequently the tube was centrifuged at 12,000g at 4°C for 15 
minutes; the upper aqueous phase was transferred to a fresh tube and the RNA was 
precipitated by mixing with 500 µl of isopropyl alcohol. The sample was incubated 
for 10 minutes at room temperature and then centrifuged at 12,000g for 10 
minutes at 4°C to pellet the RNA. The RNA pellet was then washed with 1ml of cold 
75% ethanol. The pellet was air-dried and dissolved in 20 µl of DEPC-treated water. 
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2.2.7.2 RNA extraction using the RNeasy Mini Kit 
As an alternative to the Trizol RNA extraction protocol, RNA was extracted using the 
Qiagen RNeasy Mini Kit according to the manufacture’s protocol.  
 First strand cDNA synthesis 
2-3µg of RNA was added to a 10µl reaction containing 0.05ng of oligo(dT)20 and 
10ng of dNTP mix. The reaction was mixed and incubated for 5 minutes at 65°C, 
after which it was cooled on ice for 1 minute. The following was then added to the 
reaction: 2 µl of 0.1M DDT, 2 µl 10x reverse transcriptase reaction buffer, 40 units 
of RNaseOUT and 200 units of Superscript III reverse transcriptase (Life 
Technologies, Invitrogen), then the samples were mixed by pipetting and incubated 
for 60 minutes at 50°C. The reaction was then terminated at 85°C for 5 minutes, 
after which 1 µl RNaseH was added and incubated for 20 minutes at 37°C to destroy 
the RNA. The cDNA samples were then stored at -20°C. 
  Quantitative Polymerase Chain Reaction (qPCR) 
12.5 ng of cDNA was added to a 10 µl reaction containing 0.5 µl of 20X PrimeTime 
Assay (Integrate DNA technologies (IDT)) primers, 5µl of 2X Brilliant III ultra-fast 
qPCR master mix (Aligent) and 3.5µl of nuclease free water in 96 well plates. 
Quantitative PCR was performed using the BioRad C1000 touch thermal cycler 
CFX96 Real time system. Prime time Mini qPCR assay primers were designed using 
the IDT real time PCR tool and did not require prior optimisation 
(http://eu.idtdna.com/Scitools/Applications/RealTimePCR/). All reactions were 
denatured at 95°C for 3 minutes followed by 40 cycles of 95°C for 10 seconds, 60°C 
for 30 seconds. Data was exported and analysed on the Bio-Rad CFX Manager, after 
which data were exported onto Microsoft Excel and processed.  
 Digoxigenin- labelled RNA probe synthesis 
Digoxigenin (DIG)-labelled anti-sense RNA probes were generated through in vitro 
transcription. At least 1 µg of linearized plasmid DNA was required as the template 
in a 20µl reaction which also contained 2 µl 10X DIG labelling mix,  2 µl 10X reaction 
buffer, 1 µl of RNasin (RNase Inhibitor) and 2 µl of RNA polymerase (T7,T3 or SP6) 
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in nuclease free water. The reaction was then incubated for a minimum of 2 hours 
at 37°C, then 1 µl of RNase free DNase was added and returned to 37°C for 15 
minutes to destroy the template DNA.  One microliter of 0.5M EDTA (pH8.0) was 
added and mixed gently to stop the reaction, then 2.5 µl 4M LiCl and 75µl of cold 
EtOH followed by gentle mixing. This solution was kept at -20°C overnight to 
precipitate the RNA. The next day the tube was centrifuged at 12,000 rpm for 30 
minutes at 4°C, the supernatant was carefully discarded and the pellet was washed 
in 1ml of 70% EtOH and centrifuged again for 10 minutes at 12,000 rpm at 4°C. The 
supernatant was carefully removed to leave the RNA pellet which was air dried and 
dissolved in 20 µl DEPC-treated water. DIG-labelled RNA probes were stored at -
80°C in aqueous solution or at -20°C if diluted in hybridisation A solution. 
2.3 Microinjection 
For microinjection, adult pairs were set up using barriers in a pair mating tank. The 
barriers kept the females and males apart thereby controlling when they mated. 
This meant that fresh 1 cell stage embryos could be obtained throughout the 
duration of microinjection allowing for maximum numbers of embryos to be 
injected. Glass capillaries (Harvard apparatus, GC120T-10) were individually placed 
in a flaming/Brown p-97 micropipette puller which used a heated filament to pull a 
single glass capillary into two microinjection needles. The needle was filled with the 
appropriate solution using Eppendorf microloader pipette tips, and the needle end 
was blunted using sharp forceps. The microinjector was calibrated using a graticule, 
after which embryos were harvested and brushed individually in wells of a 1.5% 
agarose mould. Embryos were aligned to have the cell away from the injection 
manipulator so that the needle entered the embryo through the yolk and injected 
into the cell to minimise damage. Embryos were injected in rows of 25 and batches 
of 100 in the first 30 minutes of development, after which they were placed in fresh 
egg water and left to develop at 28°C. Un-injected embryos were kept as controls 
for survival and fresh embryos were collected for each injection round. 
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 Morpholino antisense oligonucleotides 
Morpholinos were designed and manufactured by Gene Tools, LLC (Philomath, OR, 
USA). They were provided in lyophilised form and resuspended with sterile water 
into a 1mM stock solution (except for p53 MO which was prepared as a 2mM 
stock). Sequences were as follows: 
disc1aug: 5’-CCTGACCATTCCTGCGAACATCATG-3’ 
olig2aug: 5’-CGTTCAGTGCGCTCTCAGCTTCTCG-3’ 
p53MO: 5’-GCGCCATTGCTTTGCAAGAATTG-3’ 
CoMO (human beta globin):  5’-CCTCTTACCTCAGTTACAATTTATA 3’ 
 Capped mRNA 
Capped mRNA was synthesised using mMESSAGE mMACHINE® kit (Ambion) 
according to the manufacturer’s instructions and was injected at a concentration of 
25-100 ng/µl in DEPC-treated water. 
 Plasmid DNA 
Plasmid DNA containing I-SceI sites was linearized in a 5 µl reaction containing 750 
ng of DNA, 0.5 µl of I-SceI buffer and 0.5 µl of I-SceI enzyme. The reaction was 
incubated for 30 minutes at room temperature before being injected at a 
concentration of 25-50 ng/µl. 
 TALEN mRNA and donor DNA 
TALEN mRNA and donor DNA was co-injected into embryos. TALEN mRNA was 
injected at a concentration of 150 ng/µl (per each arm) and while linearized donor 
DNA was injected at 50 ng/µl.  
2.4 TALEN-based genome editing 
 TALEN arm synthesis 
TALEN left and right arm plasmids were designed and synthesised by ZGENEBIO, 
Taiwan. The disc1 gene was targeted around the TGA STOP codon at the 3’ end of 
the gene. A 16bp TALEN left arm was synthesised on the 5’ side of the TGA stop in 
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exon 14 and a 17bp TALEN right arm was synthesised on the 3’ side of the TGA stop 
in the 3’ UTR. The spacer sequence of 16bp between the two arms was the target 
region where double strand breaks (DSB) should be induced (Figure 2-1). 
 
Figure 2-1: Sequence of the TALEN targeting site in the 3’ disc1 gene 
The TALEN target site is situated in the 3’ end of the gene, the spacer sequence 
contains the stop codon of the disc1 gene (shown in the red box). Repeat variable 
diresidues (RVD) are responsible for the recognition of a specific nucleotide. 
 
The TALEN arm plasmids were sent spotted on filter paper and were retransformed 
into E.coli and propagated on LB-kanamycin plates (Figure 2-2). 
 
Figure 2-2: TALEN arm vector map information 
 
 Donor DNA synthesis 
The donor DNA was designed and synthesised by ZGENEBIO, Taiwan. Left and right 
500bp homology arms were designed around a mCherry and poly A tail sequence 
(Figure 2-3). Donor DNA was sent on filter paper and retransformed on an ampicillin 
plate. DNA was linearized with EcoR1 and BamHI for 2 hours, then gel extracted and 
purified using a QIAquick Gel Extraction Kit (Qiagen). 
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Figure 2-3: Donor DNA vector map information 
The donor DNA vector contained a mCherry sequence with a polyA tail. On either side of 
the fluorescent sequence was the left and right 500 bp disc1 homology arms (labelled as L 
arm and R arm). 
 
 TALEN mRNA synthesis 
The left and right TALEN arms were linearized using Not1 (section 2.2.4) and 
purified (section 2.2.2). This linearized purified DNA, was used as a template for an 
in vitro transcription reaction (section 2.3.2) using SP6 polymerase. Capped mRNA 
was synthesised using the mMESSAGE mMACHINE® kit (Ambion) according to the 
manufacturers protocol. Aliquots were stored at -80°C. 
 
 Screening for DSBs 
Wildtype AB embryos were injected with the left and right TALEN mRNAs at a range 
of concentrations and DNA was extracted from batches of 30 pooled embryos 
harvested between 24-48 hpf using 20 0µl of DNA extraction buffer. A 453 bp 
region surrounding the STOP codon of disc1 was amplified. 10 µl of the PCR product 
was added to a 20 µl reaction containing 1 µl of T7 endonuclease and 2 µl 10X NEB2 
buffer (New England Biolabs) which was then incubated at 37°C for 1 hour. Samples 
were electrophoresed on a 3% agarose/TBE gel; if samples had 2 products, the 
same genomic DNA was re-amplified using PCR and cloned using the TOPO® TA 
Cloning® system (Life Technologies). The TOPO reaction was transformed into E.coli 
and positive white colonies selected for sequencing. Sequences were aligned with 
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the wild type disc1 sequence 
(http://www.ensembl.org/Danio_rerio/Gene/Summary?db=core;g=ENSDARG00000
021895;r=13:50035365-50123165) using FinchTV (Geospiza) and DNASTAR-
lasergene SeqMan Pro to analyse the rate of INDELs induced by the TALEN mRNA.   
2.5 Antibody development 
Zebrafish Disc1 monoclonal antibodies were developed by Abmart using their SEAL 
technology against the peptide EDNLPVQSRD (residues 119-128). In total 6 different 
antibodies were developed against the same peptide. Ascites fluid was provided in 
lyophilised form and was resuspended in 50% glycerol and stored at -20°C. 
Antibody reference name Concentration (mg/ml) Volume (ul) 
2D24 36.5 100 
2I13 15.6 500 
6D7 19.8 500 
6G10 26.4 500 
7A10 18.0 100 
7F14 20.8 500 
 Table 3: Antibodies developed against zebrafish disc1 
 
Antibodies were tested by western blot and immunofluorescence analysis using 
various concentrations and conditions to analyse the efficiency of the antibodies to 
detect endogenous and over-expressed Disc1. 
2.6 Cryostat sectioning 
Embryos were first fixed in 4% PFA overnight at 4°C and then mounted in a 1.5% 
low melting point (LMP) agarose and 5% sucrose solution. Once the agarose had 
set, embryos in agarose were placed in a 30% sucrose solution overnight at 4°C. 
Samples were then frozen in optimal cutting temperature (OCT) compound (Agar 
Scientific) and then sectioned on a cryostat taking 20 to 40 µM sections. The 
sections were then baked onto slides for 2 hours at 37°C and stored at -20°C. 
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2.7 5-bromo-2-deoxyuridine (BrdU) pulse labelling 
Embryos were transferred from 5, 10 and 15% DMSO in E3 medium before being 
incubated for 20 minute on ice in E3 medium containing 2 mg/ml BrdU in 15% 
DMSO. Embryos were then returned to E3 medium for 20 minutes after which 
embryos were fixed in 4% PFA overnight at 4°C. To detect BrdU incorporation 
embryos were dehydrated in 100% MeOH and were stored at -20°C for at least 1 
hour. Embryos were then rehydrated through a PBS/MeOH series after which they 
were washed in PBS twice for 5 minutes. Embryos were then permeabilised in 10 
µg/ml Proteinase K for a period of time dependent on their development stage (24 
hpf for 10 minutes, 36 hpf for 15 minutes, 48 hpf for 20 minutes). Embryos were 
rinsed in glycine (2 mg/ml in PBS) twice and were then washed in PBS for 5X5 
minutes. The embryos were then re-fixed in 4% PFA for 20 minutes, then washed 
for 5X 5 minutes in water and were then incubated in 2N HCL made from 
concentrated HCL for 1 hour. Embryos were then washed for 6X15 minutes PBXT 
and were then blocked in 10% normal goat serum (NGS) for 1 hour. Embryos were 
then incubated in 1:200 primary BrdU antibody (Sigma) in 5% NGS in PBXT 
overnight and the following day were washed for 6-15 minutes in PBXT before 
being incubated overnight in secondary antibody in 2% NGS in PBXT. The next day 
embryos were washed for 6X15 minutes in PBXT before being re-fixed in 4% PFA 
prior to dissection and imaging (Lyons et al 2005). 
2.8 In situ hybridisation 
 Whole mount chromogenic in situ hybridisation 
Embryos were fixed overnight at 4 °C in 4% PFA and then washed in PBST for 3x 10 
minutes before being transferred into 100% Methanol (MeOH). Embryos were then 
stored overnight at -20°C but can be stored in 100% MeOH at -20 °C indefinitely 
until use. Embryos were rehydrated in 50% MeOH in PBS which was followed by 5X 
5 minute washes in PBST. Embryos were then permeabilised in 10 µg/ml proteinase 
K for a period of time dependent on their developmental stage (<15 somites for 1-2 
minutes, 15-25 somites for 5 minutes, 24 hpf for 10 minutes, 36 hpf for 15 minutes, 
48 hpf for 20 minutes and 72 hours for 40 minutes). Embryos were then re-fixed in 
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4 % PFA for 20 minutes followed by 5X 5 minute washes with PBST. Embryos were 
then rinsed in pre-heated hybridisation buffer at 70°C and then placed in fresh 
hybridisation buffer at 70°C for >3 hours. Embryos were then hybridised overnight 
at 70°C in the appropriate DIG labelled RNA probe. Embryos were washed at 70°C in 
50:50 hybridisation solution: 2XSSC for 20 minutes, 2XSSC for 20 minutes, followed 
by 2X 60 minute washes in 0.2XSSC. Embryos were then washed at room 
temperature (RT) for 10 minutes in 50:50 0.2XSSC: PBT followed by a 10 minute 
wash in PBT. Embryos were blocked in PBT for 3 hours at RT and then incubated 
overnight at 4°C in 1:2000 anti-DIG alkaline phosphatase (Roche). The following day 
embryos were washed for 6X 20 minutes in PBST and then equilibrated in AP 
staining buffer without NBT/BCIP for 3x 15 minutes. Embryos were then stained in 
the dark in AP staining buffer containing 3.5 µl/ml BCIP and 4.5 µl/ml NBT until 
stained to the desired level of intensity and were then rinsed in AP staining buffer 
lacking NBT/BCIP before being washed in PBST for 3X 5 minutes. Embryos were 
then fixed in 4% PFA overnight at 4°C before being transferred through a 
glycerol/PBS series and stored in 80% glycerol/20% PBS. Mutant and sibling 
embryos were treated the same during in situ hybridisation and stained in staining 
buffer for the same length of time. 
  TSA fluorescent in situ hybridisation 
Fluorescent in situ hybridisation was carried out using the Tyramide Signal 
Amplification (TSA™) system from Perkin Elmer. Day 1 of in situ hybridisation was 
performed as previously described (section 2.8.1). One day 2, the 2XSSC washes 
were also the same, however after these washes embryos were placed in 50:50 
2XSSC: PBST for 10 minutes and afterwards for 10 minutes in PBT. Embryos were 
then blocked for 3 hours at RT in Maleate buffer blocking reagent before being 
incubated in 1:500 anti-DIG POD (Roche) overnight at 4°C. The next day, embryos 
were rinsed in PBST and then washed for 6X 15 minutes in PBST. Embryos were 
then equilibrated in TNT for 3X 5 minutes. Embryos were then stained with 1:200 
TSA™ DNP (HRP) in amplification diluent for 1 hour. The reaction was stopped by 
washing the embryos 3x 10 minutes in TNT. Embryos were then blocked in Maleate 
buffer blocking reagent for 3 hours after which they were incubated in anti-DNP 
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POD at 1:1000 (Perkin Elmer) overnight at 4°C. Embryos were then rinsed in PBST 
and then washed for 6X 15 minutes in PBST. Embryos were equilibrated in TNT for 
3X 5 minutes before being incubated in 1:200 TSA™ Plus Cyanine 3 in amplification 
dilutant. The reaction was stopped by washing embryos in TNT for 3X 5 minute. 
Embryos were then washed for 4X 15 minutes in PBST and then transferred into 4% 
PFA for 30 minutes. Finally, embryos were washed in PBST for 5x5 minutes after 
which embryos were ran through a glycerol series and stored in 80% glycerol/20% 
PBS. 
 Antibody staining after in situ hybridisation 
The in situ hybridisation stain was developed as normal and then embryos were 
washed in PBST and fixed for 20 minutes in 4% PFA at RT. Embryos were then 
washed for 5x5 minutes in PBST and then incubated in PBDT blocking solution for 1 
hour at RT, followed by incubation overnight at 4°C in primary antibody diluted in 
PBDT. The following day, embryos were washed for 4X 30 minutes in PBDT followed 
by incubation in the secondary antibody for 2 hours at RT. Embryos were washed 
for 6X 15 minutes in PBDT, then ran through a glycerol series before being stored in 
80% glycerol in PBS. 
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 In situ Hybridisation RNA probes 
Probe name Gene RE/polymerase Reference 
disc1 Disrupted in 
schizophrenia-1 
Spe1/T7 Wood et al 2009 
olig2 Oligodendrocyte 
transcription factor-2 
Sma1/T7 IMAGE: BC06559 
sox10 SRY-box 10 Sal1/T7 IMAGE:7168235 
(Dutton et al 2001) 
nrg-1 Neuregulin-1 Ecor1/T7 IMAGE: 8339257 
hhip Hedgehog interacting 
protein  
Not1/T7 (Koudijs et al 2005) 
fabp7a Brain fatty acid binding 
protein 
Not1/SP6 This thesis 
pafah1b1b 
(previous name 
Lis1a) 
platelet-activating factor 
acetylhydrolase, isoform 
Ib, alpha subunit b 
Not1/SP6 This thesis 
pafah1b1a 
(previous name 
lis1b) 
platelet-activating factor 
acetylhydrolase, isoform 
Ib, alpha subunit a 
Not1/SP6 This thesis 
ndel1a nudE nuclear 
distribution gene E 
homolog like 1 (A. 
nidulans) A 
Not1/SP6 This thesis 
ndel1b nudE nuclear 
distribution gene E 
homolog like 1 (A. 
nidulans) B 
Not1/SP6 This thesis 
Table 4: Riboprobes used for in situ hybridisation 
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2.9 Immunohistochemistry 
 Whole mount Immunohistochemistry  
Embryos were fixed for 2 hours at RT, then washed for 5X 5 minutes in PBXT. 
(Alternatively, embryos were fixed for either 2 hours or overnight at 4°C, washed 
for 5x 5 minutes in PBS and stored in 100% MeOH at least overnight at -20°C. 
Embryos were then rehydrated in serial dilutions of MeOH in PBS (75%, 50% and 
25% MeOH) and washed 5x 5 minutes in PBXT). Embryos over 2 dpf then 
underwent acetone cracking. Embryos were placed in 100% acetone and incubated 
at -20°C for 20-30 minutes dependent on their developmental stage, after which 
they were washed 5X 5 minutes in PBXT and then blocked in PBDT blocking solution 
for >1 hour at RT. Embryos were then incubated overnight at 4°C in primary 
antibody diluted in PBDT, followed by 4X 30 minute washes the next day. Embryos 
were then incubated in secondary antibody diluted in PBDT for 2 hours at RT or 
overnight at 4°C. Embryos were washed for 4X 30 minutes in PBDT and transferred 
into 80% glycerol/20% PBS. 
 Immunohistochemistry on sections 
Slides were defrosted at RT for >30 minutes after which sections on the slide were 
circled with a PAP pen (Abcam) and allowed to dry for >30 minutes. Sections were 
rinsed twice in PBDT and then washed for 3X 5 minutes in PBDT. Slides were 
blocked for 1 hour at RT in PBDT blocking buffer after which 500 µl of primary 
antibody diluted in PBDT was pipetted onto each slide and incubated for 1-2 hours 
in a humidified chamber at RT. Slides were then washed for 5x 5 minutes in PBDT 
and then 500 µl of secondary antibody diluted in PBDT was pipetted onto each slide 
which was then incubated for 1 hour at RT in a humidified chamber in the dark. 
Slides were washed for 5X 5 minutes in PBDT in the dark, after which 2 drops of 
Vectashield (Vector Laboratories) were added to each slide prior to being covered 
with a coverslip. Each coverslip was held in place by clear nail polish that was 
applied around the edges. 
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 Primary Antibodies 
Epitope/antibody Staining dilution Supplier/reference 
Rabbit Arl13b 1:500 (Duldulao et al 2009) 
Mouse mCherry 1:500 Living Colours 
Rabbit GFP 1:1000 Torrey Pines 
Mouse acetylated tubulin 1:500 Sigma 
Mouse gamma tubulin 1:500 Sigma 
Mouse zrf-1 1:1000 ZIRC 
Mouse BrdU 1:200 Sigma 
Table 5: Primary antibody information used in immunohistochemistry 
 
 Secondary Antibodies 
Alexa fluor Secondary 
antibody 
Concentration Supplier/reference 
Alexa fluor 488 donkey 
anti-rabbit 
1:500 Abcam 
Alexa fluor 488 donkey 
anti-mouse 
1:500 Abcam 
Alexa fluor 555 donkey 
anti-rabbit 
1:500 Abcam 
Alexa fluor 555 donkey 
anti-mouse 
1:500 Abcam 
Table 6: Secondary antibody information used in immunohistochemistry 
 
2.10  Mounting and imaging 
Embryos stored in 80% glycerol/20% PBS were transferred into a cavity dish and 
dissected under a Leica dissecting microscope using fine needles. Windows were 
created in electrical tape stuck on microscope slides, where a central square was 
cut and the specimen placed in the centre in 80% glycerol/20% PBS for light 
microscopy or Vectashield for fluorescence imaging. The number of layers of 
electrical tape used was dependent on the thickness of the specimen to be imaged. 
A coverslip was placed over the embryo prior to imaging. 
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For light microscopy, images were obtained using a Leica DM2500 compound 
microscope fitted with a Leica DFC-420C digital camera, or a Carl Zeiss AXIO Zeiss 
Imager M2 and AXIO Vision 4.7.2 software. An Olympus FV-1000 confocal 
microscope was used to capture confocal images utilising the Olympus FluoView 
FV-1000 ASW 1.6 software. Images were then compiled into composite figures 
using ImageJ (National institutes of Health) and Adobe Photoshop CS6.0 software. 
2.11  Cyclopamine treatments 
Dechorionated embryos were treated in E3 containing the appropriate 
concentration of cyclopamine (20, 40 or 60 µM) diluted from a stock concentration 
of 20 mM in DMSO (LC Laboratories). Embryos were treated from 34 hpf or 38 hpf 
and kept in cyclopamine solution until the desired time point. Embryos were then 
fixed in 4% PFA. 
2.12  Bead implantation assay 
 Shh protein preparation 
Recombinant mouse Sonic Hedgehog (Shh) N-terminus (R&D systems) was 
reconstituted to 25 µg/ml in 0.1% BSA in PBS, 20 µl aliquots were prepared and 
stored at -80°C. 
 Bead preparation 
CM Affi-Gel® Blue Gel agarose beads (Bio-Rad) were washed in PBS and the smallest 
beads collected for implantation. Ten agarose beads were placed in a petri dish lid 
after which excess PBS was removed and beads were soaked in 15 µl of 25 µg/ml 
recombinant mouse Shh N-terminus overnight at 4°C. 
 Implantation 
Tg(olig2:gfp) embryos at 34 hpf were dechorionated and then anaesthetized with 
tricaine. Embryos were placed on 1.5% LMP-agarose and a small incision was made 
into the dorsal hindbrain using minute pins (Fine Science Tools). The minute pin was 
used to pick up a single agarose bead and the bead was inserted into the hindbrain 
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where the incision was made. Embryos were then placed in fresh egg water, left to 
develop until 50 hpf and were fixed in 4% PFA. 
2.13  Drug screening assay 
 Control drug assay 
Embryos were exposed at different developmental stages to positive control 
compounds EGFR-inhibitor I and EGFR-inhibitor II (Calbiochem) the former of which 
has been previously shown to affect OPC development (Wood et al 2009). Embryos 
were harvested and allowed to develop up to 26, 28, 30 or 32 hpf before being 
exposed to either 50 µM EGFR-inhibitor I or EGFR-inhibitor II separately in 1% 
DMSO in 5 ml of E3 medium. Embryos were incubated at 28°C and fixed in fish fix at 
50 hpf.  
 Embryo and plate preparation 
Nacre wild-type embryos were treated with 10 mg/ml of Pronase (Sigma) at 24 hpf 
for 15 minutes at 28°C to remove their chorions, and transferred into fresh E3 
medium. The embryos were left to recover for an hour and were then transferred 
into 96 well mesh bottom plates, with 3 embryos per well. The embryos were then 
put into E3 medium containing the chemical compounds (in DMSO) at 28 hpf and 
kept overnight in a 28⁰C incubator. At 50/51 hpf the embryos were fixed in Fish Fix 
(25 ml per plate) overnight at 4⁰C. The next day the embryos were bleached (30 ml 
per plate) for 20 minutes to remove pigment in the eyes and head and were then 
transferred into 50:50 PBS: MeOH before being stored in 100% MeOH at -20⁰C. 
Dependent on the yield of embryos, approximately 2 to 4 plates were screened 
each week. 
 Spectrum library drug preparation 
The drug screen utilised the Spectrum library (Microsource delivery system), copy 
plate number 6, which contained a collection of 2000 compounds at 2.5 mM. The 
drug plates were in a 96 well format; 247.5 µl of E3 Medium (lacking methylene 
blue) and 2.5 µl of compound were added to each well, to give a final test 
concentration of 25 µM. Rows 1 and 12 contained control samples and rows 2-11 
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contained test compounds from the Spectrum library 2. The mesh bottom plates 
containing the embryos were placed into the plastic bottom plates holding the 
compound and E3 solution, thereby exposing the embryos to the drugs. A total of 
25 plates were used in the primary drug screen (Figure 2-4). 
 
Figure 2-4: Set up of screening plate 
Rows 1 and 12 contained controls, blue well represent the DMSO controls. The red well 
contained F8148.5 mutants which act as a positive control for decreased migration. The 
yellow and green EGFR=-inhibitor I and II which also act as a positive control for decreased 
migration. Rows 2-11 contained the spectrum library compounds (25 µM of the compound 
in each well). A total of 25 plates were used to test the entire spectrum library all of which 
were prepared the exact same.  
 
 Automated in situ hybridisation staining 
Embryos were kept in the mesh bottom plates throughout the in situ hybridisation 
staining process (see chapter 2.6.1). All solutions were made up manually but the 
washes were carried out using the Biolane robot using a standard in situ 
hybridisation protocol. Four 96 well plates could be processed at one time using the 
Biolane robot. All washes and blocking was performed in the Biolane robot, 
however the incubation in the DIG-olig2 riboprobe diluted in hybridisation A 
solution and staining in AP buffer containing NCIP/BCIP was done manually. Once 
the desired level of staining had been reached embryos were fixed in fish fix and 
stored at 4⁰C. The embryos were transferred to 80% glycerol/20% PBS prior to 
imaging. 
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Figure 2-5: Biolane Robot for automated an olig2 in situ hybridisation  
The Biolane robot was used during the drug screen to analyse for OPC migration defects. 
The Biolane robot could stain 4 plates at a time (two plates on the left hand side with the 
blue tubes and two plates on the right hand side with the red tubes). Solutions were made 
up manually and attached to the Biolane robot which was programmed to carry out the 
automated in situ hybridization over 3 days. 
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2.14  Solutions and buffers 
 General buffers and solutions 
E3 medium 15 mM NaCl, 0.5 mM Kcl, 1 mM CaCl₂, I 
mM MgSO₄, 1.5mM KH₂PO₄, 0.05 mM 
NA2HPO4, 0.7 mM NaHCO₃ and 
0.0001% Methylene Blue per litre 
Fish Fix 0.1 M Phosphate buffer, 0.12 mM 
CaCL2, 4% sucrose (w/v), 4% 
paraformaldehyde (PFA) powder (w/v) 
Phosphate Buffered Saline (PBS) 1 PBS tablet in 200 mls H2O (137 mM 
NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄, 
1.47 mM KH₂PO₄, final pH 7.4) 
Bleaching Solution  3% H₂O₂, 0.5% KOH in PBS 
Diethylpyrocarbonate (DEPC) treated 
water 
 0.1% DEPC (1 ml in 1l H20) incubated 
at 37°C overnight then autoclaved 15 
minutes at 121⁰C 
PBST PBS with 0.1% Tween20 (v/v) 
DNA extraction buffer 10mM Tris pH 8, 2mM EDTA, 0.2% 
Triton X-100, 200µg/ml Proteinase K 
Table 7: Recipe information for general buffers and solutions 
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 Buffers for in situ hybridisation 
Hybridisation A Solution  50% formamide, 5XSSC, 500 µg/ml 
tRNA, 50 µg/ml Heparin, 0.1% 
tween20, pH 6.0 with 1 M Citric Acid 
(0.46 ml per 50 ml) 
tRNA and Heparin omitted in hybB 
solution 
PBT PBST, 2%sheep serum, 0.2% BSA 
AP Staining Buffer 100mM Tris-HCL pH 9.5, 50mM MgCl2, 
100mM NaCl, 0.1% Tween20 (v/v) 
AP Staining solution 100mM Tris-HCL pH 9.5, 50mM MgCl2, 
100mM NaCl, 0.1% Tween20 (v/v), 4.5 
ul/ml NBT, 3.5ul/ml BCIP 
Table 8: Recipe information for in situ hybridisation buffers 
 
 Buffers for TSA fluorescent in situ hybridisation 
Maleate Buffer (MB) 150mM maleic acid, 100mM NaCl,  pH 
7.5. Stored at 4°C 
Maleate buffer blocking reagent 2% blocking reagent (Roche) in 1xMB 
TNT 100mM Tris pH7.5, 150mM NaCl, 
0.05% Tween20 
Table 9: Recipe information for TSA fluorescent in situ hybridisation buffers  
 
 
 Buffers for Immunohistochemistry  
PBXT PBS plus 0.1% Triton X-100 
PBDT PBS, 1% DMSO, 1% BSA, 0.5% Triton-X 
100 
Blocking solution PBDT + 2% Sheep serum 
Table 10: Recipe information for immunohistochemistry buffers 
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2.15  Primers 
Primers were designed using Primer3 v0.4.0 (http://bioinfo.ut.ee/primer3-0.4.0/) 
 Primers to screen for TALEN induced mutations 
 Primer Name Primer sequence Primer 
detail 
FWD.disc1.DSB.exon14 GGGGAAAAACATATTCAGGGTGGTCTAAT 453bp 
region 
around 
disc1 stop 
codon 
RVS.disc1.DBS.3’UTR GCAGCTTCACTTGTGCGCATCA 
Table 11: Primer sequences used in TALEN induced mutation screening 
 
 Primers to screen for homologous recombination 
events 
Primer Name Primer sequence Primer detail 
FWDdisc1.intron14.F2 GACGGTTCCACCAGCTGATTCTCTTC 
 
FWD primer in 
intron 14 of 
disc1, upstream 
of left homology 
arm. 
1238bp region 
RVSmcherryR2 CTCCATGTGCACCTTGAAGCGC 
Table 12: Primer sequences for homologous recombination screening  
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 Primers for cDNA templates for in situ hybridisation 
probes 
Primer name Primer sequence 
FWD.ndel1a GCTCAATATTGTGGGCGATT 
RVS.ndel1a TGACCAAAACCAGTGTTCCA 
FWD.fabp7a GATGCATTTTGTGCCACTTG 
RVS.fabp7a ACAAAGGCAGGCCTCAATAA 
FWD.lis1a ACGAGCTAAACCGAGCGATA 
RVS.lis1a AGGTGTTGTGAAGGGTCCTG 
Table 13: Primer sequences for cDNA amplification 
 
 Prime Time Mini qPCR Assay primers for qPCR (IDT) 
Primers were designed using IDT real time PCR tool 
Probe sequence: 5’/56-FAM/CGTTTCGCT/ZEN/CTCGCTGACCTTCT/3IABkFQ/-3’ 
Primer name Primer sequence 
FOR.Disc1 CGAGTGCTGAGTTTGTCCATC 
REV.Disc1 ATTTCCTGATACGGCTGTGAG 
FOR. Ef1a GGCTGGTGTTGGTGAATTTG 
REV.Ef1a TTCTTGGCTATAATTGGGCTCC 
Table 14: Primer sequences for qPCR 
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 Oligodendrocyte precursor cell 
migration and proliferation analysis in 
the hindbrain of the zebrafish embryo 
Understanding the external signalling pathways which initiate migration of 
oligodendrocyte precursor cells (OPCs), and the downstream targets of these 
signalling pathways will provide valuable information regarding OPC hindbrain 
development. 
3.1 Time course of OPC development in the zebrafish hindbrain 
To better characterise OPC development in the early zebrafish hindbrain, OPCs 
were analysed using a genetic marker of their lineage concentrating on proliferation 
and migration events which occurred between developmental stages 24 hours post 
fertilisation (hpf) and 3 days post fertilisation (dpf). 
 Time course of OPC development in the zebrafish 
hindbrain using in situ hybridisation 
Using in situ hybridisation to detect expression of the transcription factor olig2, a 
well-established genetic marker of the oligodendrocyte lineage, the expression 
pattern of this gene was analysed over a developmental time course to determine 
how OPCs populated the hindbrain. Of particular interest was: I) when and where 
were olig2-positive cells first specified in the hindbrain; II) when did olig2-positive 
cells first undergo proliferation prior to migration; III) when did olig2-positive cells 
start to migrate away from their birthplace; IV)  in which direction did olig2-positive 
cells first migrate and what were their subsequent directions of migration; V) when 
did cells complete migration and what was the final pattern of olig2-positive cell 
expression, and finally; VI) when did olig2 positive cells start to change their shape 
from simple to more complex morphology to indicate the beginning of 
differentiation events. 
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A DIG-labelled anti-sense olig2 riboprobe was transcribed and used to detect olig2 
mRNA expression using chromogenic detection methods in AB strain wild-type 
embryos. The transcription factor olig2, also marks neuroepithelium, motor 
neurons and OPCs and therefore we also relied on morphological changes to 
determine their cellular specification. These embryos were fixed at 24 hpf, 30 hpf, 
36 hpf, 48 hpf, 54 hpf and 72 hpf for analysis over two days of development. 
Embryos were mounted so as to view both dorsal and lateral orientations which 
were compared to determine early events in OPC development in the hindbrain. 
Dorsal views of the zebrafish embryo head showed that olig2-positive cells were 
first specified at 24 hpf in distinct patches of cells in rhombomeres 5 and 6 with 
expression of olig2 in these areas increasing at 30 hpf suggesting that a round of 
cellulae proliferation had occurred (Figure 3-1 comparing panels A to B). At 36 hpf 
olig2-positive cells were present in three distinct patches of expression in 
rhombomeres 5, 6 and 7 (Figure 3-1 C). By 48 hpf olig2-positive cells had 
delaminated away from r5/6 and expanded along the anterior-posterior axis and 
subsequently started to migrate laterally away from the midline (Figure 3-1 D). At 
54 hpf OPCs had migrated long distances away from the midline to populate the 
majority of the hindbrain, at this point they showed a uniform distribution on either 
side of midline (Figure 3-1 E). This uniform distribution was very consistent between 
wild type embryos suggesting that migration is a highly regulated process. Finally at 
72hpf OPCs had reached their destination within the hindbrain and olig2 expression 
seemed to have been down-regulated (Figure 3-1 F). At this point it would be 
expected that OPCs will have begun pre-differentiation, and morphological changes 
will have started to occur as OPCs seek axonal targets. 
Lateral views of olig2 positive cell development showed similar changes in olig2-
positive cell expression as with the dorsal views, however this orientation showed 
more clearly how OPCs moved in a ventral direction (Figure 3-2 comparing panels C 
to D). OPCs always migrated from the midline in a ventral direction and did not 
display any movement upwards from the midline into dorsal territories (Figure 3-2 
D-E).  
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 Time course of OPC development utilizing the 
tg(olig2:gfp) line 
Although the olig2 expression analysis using in situ hybridisation was informative as 
to the development of OPCs in the hindbrain, no conclusions could be drawn as to 
the direction that OPCs first extend their processes and therefore their initial path 
of early migration. This was important to address, as deciphering where processes 
were first extending would provide essential information as to the location of early 
extracellular signalling, such as a chemoattractant required to initiate migration.  It 
also failed to address any morphological changes over development as staining for 
cytoplasmic mRNA is insufficient for labelling the fine processes extended by OPCs. 
This analysis of process extension was achieved using the tg(olig2:gfp) line (Figure 
3-3). This transgenic reporter line, uses olig2 regulatory elements to drive the 
expression of green fluorescent protein (GFP) so that development of the OPC 
lineage can be tracked using GFP expression as a read out (Shin et al 2003). As 
discussed in section 1.5.6, this transgenic marker also labels cerebellar neurons, the 
pMN domain and neuroepithelial cells which have been marked with arrows in 
(Figure 1-7) and only morphologically distinguishable olig2-positive OPCs were 
included in the analysis studies. Embryos were fixed at the same time points as with 
the previous time course and immunofluorescence staining using an anti-GFP 
antibody was performed to enhance the GFP signal. Embryos were mounted 
dorsally to view the process extension pattern of GFP-positive cells throughout the 
whole hindbrain. Transverse sections were taken through the hindbrain to visualise 
how OPCs extended processes along the dorso-ventral axis. These two views of OPC 
development provided a clear picture of process extension patterns both at initial 
stages of migration and during migration. Dorsal images showed the same pattern 
of expression as with the olig2 in situ hybridisation analysis but the images provided 
more detailed information regarding cell morphology changes throughout this 
developmental time period. Early on during specification and migration during 24-
48hpf developmental stages, GFP-olig2 positive cells were of relatively simple 
morphology at 24-36 hpf in r5/6 and were a combination of neuroepithelium, early 
motor neurons and early OPCs (Figure 3-3 A-C). After 36 hpf GFP-olig2 positive cells 
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that had delaminated from their birthplace and started migration way from the 
midline had morphological characteristics of early OPCs.  They were bipolar and 
extended few processes during this migratory phase (Figure 3-3 C-E).  At 72hpf 
OPCs cells extended from the midline were likely to have reached their axonal 
targets and more substantial morphological changes in OPCs were observed; OPCs 
changed from a simple bipolar morphology to cells extending multiple fine 
processes indicative of early differentiation events (Figure 3-3 F red arrow). This line 
also allowed for the visualisation of single cells which meant that migration analysis 
could be performed on dorsal sections. Those olig2 positive cells in the hindbrain 
that had migrated away from r5/6 were counted during the different 
developmental stages. At 24 hpf and 30 hpf there were no GFP olig2-positive cells 
that had extended away from r5/6, however at 36 hpf there was some cellular 
migration along the posterior midline (4±3, n=10). By 48 hpf there were several 
cells that had migrated away from r5/6 along the midline and out laterally (52±7, 
n=10) suggesting extensive migration between these time points. It is also likely 
that proliferation of the pMN domain in r5/6 has occurred, however due to the high 
density of cells in r5/6 this could not be accurately quantified. At 54 hpf there had 
been more lateral movement of GFP olig2-positive cells (120±20, n=10) and finally 
at 72 hpf cells were uniformly distributed and populated the entire ventral 
hindbrain (150±20, n=10). As migration progressed, the cell counts suggested that 
proliferation had taken place within r5/6 during these developmental stages 
allowing for close and uniform distribution of OPCs in the ventral hindbrain. 
Transverse sections showed that OPCs initially extended processes in a ventral 
direction rather than a dorsal direction during early migration, which suggested 
that there may be a chemoattractant located in a lower ventral position to newly 
specified OPCs in the midline. Furthermore OPCs were restricted to the ventral 
portion of the hindbrain and this can be observed in transverse sections (Figure 3-4) 
but also lateral sections where it can be clearly seen that the dorsal area of the 
hindbrain are devoid of OPCs (Figure 3-2). It was hypothesised that OPCs responded 
to this ventral chemoattractant(s) and initially migrated in this direction before 
migrating laterally to populate the lower hindbrain (Figure 3-4). It is reasonable to 
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assume that a ventral chemoattractant exists since hindbrain OPCs are restricted to 
the ventral region during development.  
This early analysis of olig2-positive OPC development addressed several points; I) 
olig2 positive OPCs were first specified at 24 hpf in rhombomeres 5 and 6 of the 
hindbrain, at this point OPCs were indistinguishable from neuroepithelium and 
pMN cells which are also marked by olig2 and present in r5/6; II) olig2-postive cells 
underwent presumptive early rounds of proliferation up until 36 hpf; III) OPCs that 
had delaminated from r5/6 extended ventral processes during very early migration; 
IV) then olig2-positive OPCs migrated along the anterior-posterior axis before 
migrating into the lateral domains of the hindbrain; V) by 3 dpf olig2-positive OPC 
cells had migrated to populate the ventral half of the hindbrain and started to 
undergo morphological changes, extending several fine processes thereby revealing 
differentiation events. OPCs first extended processes ventrally and remained 
ventral during migration which led to the proposal that a ventral chemoattractant is 
required during the early stages of the initiation of migration, and perhaps during 
later stages as well to ensure that OPCs remain restricted to the ventral hindbrain. 
The aim of this analysis was to observe early OPC development with particular 
focus on early migration events. One question that arose from this analysis was: 
what extracellular signal in the ventral portion of the hindbrain, was controlling the 
initial ventral process extension?  
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3.2 Expression of sox10 in migrating olig2-positive cells 
identifies bona fide oligodendrocyte precursor cells 
Before identifying the extracellular signalling pathways that initiate migration it was 
important to confirm that the olig2-positive cells that were migrating away from 
the birthplace were OPCs since olig2 also marks neuroepithelial cells and pMNs in 
rhombomeres 5 and 6 (Zannino & Appel 2009). To confirm this, fluorescent in situ 
hybridisation in tg(olig2:gfp) embryos was performed using a sox10 riboprobe  
during the migratory phase (50 hpf) and at 72 hpf when OPCs had populated the 
ventral hindbrain. The sox10 transcription factor is a specific marker of OPCs and 
oligodendrocytes in the CNS, however it is also expressed in neural crest and otic 
cells (Kuhlbrodt et al 1998) (Stolt et al 2002). A combination of olig2 and sox10 
expression however in a single cell marks OPCs. Expression of sox10 was confirmed 
in migrating GFP olig2-positive cells at 50 hpf (Figure 3-5 E and F) and at 72 hpf 
when GFP olig2-positive cells had populated the hindbrain (Figure 3-6 E and F). 
These stained embryos showed that the previous analysis of GFP positive cell 
specification and migration in the hindbrain was labelling OPCs and investigation of 
extracellular signals directing olig2/sox10 positive cell migration could now 
confidently be pursued.  
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Figure 3-5: The expression pattern of sox10 overlaps with migrating GFP olig2-positive 
cells in the hindbrain of 50 hpf tg(olig2:gfp) embryos. 
sox10 expression was seen to overlap with expression of GFP olig2-postive cells in the 
hindbrain confirming their identity as OPCs in dorsal sections (A, C and E). In transverse 
sections through rhombomeres 5 and 6 (A, B and F), not all GFP olig2-positive cells were 
labelled with sox10 in the midline suggesting these are neuroepithelial or abducens motor 
neurons (F). Scale bar 100 µM. 
 
68 
 
 
Figure 3-6: The expression pattern of sox10 in the hindbrain overlaps with GFP olig2-
postive cells that have populated the hindbrain by 72 hpf in tg(olig2:gfp) embryos. 
The expression pattern of GFP olig2 positive cells overlapped with sox10 mRNA in OPCs 
that had populated the hindbrain in dorsal sections (A,C and E), however some GFP olig2 
positive cells in the midline in a transverse section of rhombomere 5 showed top midline 
cells did not express sox10, these cell types were likely to be the abducens motor neurons 
(B, D and F). Scale bar 100 µM. 
 
 
 
 
 
 
69 
 
3.3 Identifying the extracellular ventral chemoattractant 
Sonic Hedgehog (Shh) 
Early OPCs in the zebrafish hindbrain always initially extended processes and 
migrated in a ventral manner, no dorsal process extension was ever observed 
during early migration which suggested that there is a ventral chemoattractant 
signalling beneath OPCs to encourage their downward movement (Figure 3-7).  
 Analysis of Shh signalling during early OPC migration 
There are already known signalling pathways (Section 1.4 for details) required for 
proper OPC development in mouse and other animal systems which provided a 
candidate list of potential chemoattractants controlling early ventral OPC migration. 
The candidate chemoattractant signal was hypothesised to have a ventral neural 
tube location and one particular signalling pathway with already known roles in 
OPC development is the Hedgehog (Hh) pathway. The hedgehog pathway is a 
conserved signalling pathway, however there are some differences between the 
mammalian Hh pathway and zebrafish Hh pathway. There are three known classes 
of Hh genes in vertebrates named; Sonic (SHH), Indian (IHH) and Desert hedgehog 
(DHH). Most vertebrates have one member of each gene however in zebrafish 
there are 5 hedgehog genes identified thus far. Zebrafish have two sonic hedgehog 
genes, shh and twhh (also referred to as shhb) (Ekker et al 1995, Krauss et al 1993). 
Zebrafish also have two Indian hedgehog genes ihha and ihhb, finally there is one 
desert hedgehog gene (dhh) (Avaron et al 2006, Currie & Ingham 1996). Although 
the roles of Shh in zebrafish oligodendrocyte development has been most 
extensively studied, there have also been documented roles for ihhb in neural tube 
oligodendrocyte specification independent from shh (Chung et al 2013). In 
mammals the Hh ligand binds to the Ptc receptor, which in the absence of a Hh 
ligand acts to repress the smoothened receptor (Smo), causing the release of Smo 
from Ptc. The smoothened receptor then accumulates on primary cilia and causes a 
downstream signaling pathway and a transcriptional response by Gli proteins. 
Zebrafish possess only one smo gene however there are two ptch genes; ptch1 and 
ptch2 (Koudijs et al 2008). The Shh signalling pathway is fundamental in patterning 
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the dorso-ventral axis of the neural tube through creation of a morphogen gradient 
which starts in the notochord and floor plate (Section 1.4.1), and although shh 
signalling has been suggested to have roles in OPC migration in the optic nerve, its 
role in the migration of hindbrain OPCs in the zebrafish has not been explored. 
Therefore a potential role for shh in hindbrain OPC migration was investigated 
further. 
 
 
Figure 3-7: OPCs extending processes in a ventral direction only 
A transverse section taken through the hindbrain at 50 hpf during active migration showed 
OPCs exclusively extending initial ventral processes. Processes started to move laterally 
after initial ventral migration to populate the ventral hindbrain. No dorsal process 
extension was ever observed during initial migration which proposed a potential ventral 
chemoattractant is required for directing this downward movement. Red arrows 
demonstrate the direction of initial extension of OPC processes during early migration. 
 
Utilizing the Tg(shha:gfp) line, a reporter line which produces GFP expression under 
the control of shha regulatory elements, the expression of GFP during the migratory 
phase of OPC development, was determined. Expression of GFP was still robust 
during later stages of development with its expression as expected in the very 
lower ventral hindbrain. This transgenic line suggested that Shh signalling might still 
be active at 50hpf (during migration) and at 72 hpf (end of main migratory phase) 
providing evidence for a potential additional migratory role in OPC development 
(Figure 3-8). To confirm that GFP was truly marking expression of shha during these 
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later stages since GFP has a long half-life, expression analysis of shha and shhb 
mRNA using in situ hybridization studies was investigated in the literature. 
Expression of both paralogs were seen to be expressed in the midline of the 
hindbrain at these later stages (Ertzer et al 2007) (Ekker et al 1995) (Thisse et al 
2004). 
 
 
 
Figure 3-8: Shh signalling in the tg(shha:gfp) zebrafish line  
 In the zebrafish hindbrain, expression of GFP is maintained at 50 hpf (A and B), well after 
the initial specification of OPCs has occurred. Expression of GFP is maintained throughout 
migration and is still present at 72 hpf (C and D). Panels A and C show dorsal sections and 
panels B and D show transverse sections. Scale bar 100 µM 
 
When expression of GFP in tg(olig2:gfp) embryos and GFP in tg(shha:gfp) embryos 
was compared side by side in transverse sections, it revealed that a strip of shha 
promoter activity sat directly below the GFP expressing OPCs. Expression did not 
seem to overlap in the midline and birthplace of OPCs but there was apparent 
overlap of expression in the migratory zone which suggested that Shh could be an 
active chemoattractant and did not act to repel OPCs (Figure 3-9). 
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Figure 3-9: Comparison of Tg(shha:gfp) and Tg(olig2:gfp) expression in transverse 
sections through the zebrafish hindbrain at 50hpf 
GFP expressing OPCs extended processes ventrally (B) towards GFP-positive Shh expressing 
cells (A) which appear to be located just below the OPC birthplace in the midline. The nuclei 
of cells is stained with DAPI (blue). Scale bar 50 µM 
 
 Responding to Shh through primary cilia 
If Shh signals to OPCs to direct their migration then these OPCs need to have the 
ability to respond to this signalling pathway. It is well known that primary cilia play 
a crucial role in transducing the Hh signal in many cell types, which allows cells to 
respond to their external environment. If Hh is important for initiating ventral 
migration of OPCs, then it might be expected that they express primary cilia prior to 
migration and during migration to transduce the signal and respond accordingly. 
Responding accordingly would involve up-regulating the expression of cytoskeletal 
proteins required to physically move the cell in the appropriate direction. Primary 
and motile cilia are conventionally labelled using primary antibodies against 
acetylated tubulin, which labels the axoneme of cilia, however acetylated tubulin 
also labels neurons. Therefore another antibody which exclusively labels cilia was 
required when analysing cilia in the CNS. An alternative antibody against ADP-
ribosylation factor-like protein 13B (Arl13b), which is a component of cilia and is 
required for their formation, was used to address potential OPC primary cilia (Zhang 
et al 2013). Arl13b staining in transverse sections showed cilia on OPCs in the 
ventricular zone which could be a combination of motile and primary cilia (Figure 
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3-10 A red arrow) but also showed primary cilia on OPCs away from the ventricular 
zone (Figure 3-10 A white arrow). Primary cilia could be labelled at 36hpf prior to 
onset of the main migratory phase but were not detected on migrating OPCs at 
50hpf in both manually taken larger transverse sections and in thin cryostat 
sections (Figure 3-10 B). This may have been because during migration primary cilia 
may have to be constantly disassembled and reassembled (Baudoin et al 2012) so it 
may have been a case that the imaged sections did not capture primary cilia during 
such a highly dynamic process, but that they are present transiently.  
 
Figure 3-10: Primary cilia on OPCs in transverse sections through the hindbrain in 
tg(olig2:gfp) embryos. 
At 36hpf OPCs had primary cilia, as shown by Arl13b staining, prior to migration onset (A). 
At 50hpf during the main phase of migration, although primary cilia were readily observed 
in the notochord, no primary cilia were detected on migrating OPCs. Staining of primary 
cilia in red, staining of GFP olig2+ cells in green and the nuclei of cells are stained with DAPI 
(blue). Red arrow labels cilia in the ventricular zone which could be a combination of 
primary and motile cilia. White arrow indicates a primary cilium on a pre-migratory OPC. 
Scale bar 20 µM 
 
Analysis of Hh signalling provided evidence that it could be a ventral 
chemoattractant for OPCs. The tg(shha:gfp) line suggested that shha is expressed 
ventral to the birth place of OPCs and might be directly involved in the OPC 
migratory pathway, since there was apparent overlap with the region of GFP-
positive OPC expression. Analysis of Arl13b protein expression showed that OPCs 
have primary cilia prior to migration and these primary cilia could be responsible for 
transducing the Shh signal thereby allowing cells to respond and migrate in the 
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required direction. No primary cilia were detected at 50 hpf during the main period 
of migration although this could have been because primary cilia go through 
assembly rounds which meant that they were harder to capture in fixed specimens. 
It could also be that during these stages, Shh signalling occurs in a primary cilia 
independent process. 
3.4 Analysis of OPC development defects in stable Hh 
pathway mutant zebrafish lines. 
The next question to answer was how OPC development was affected in Hh 
pathway stable mutant zebrafish lines, in particular focusing on deficiencies in 
migration direction and capacity. There were several mutant lines available in both 
zebrafish facilities in which Hh signalling is affected. Mutants either had a loss of 
function mutation which resulted in a gain of Hh signalling or loss of function 
mutation which resulted in a loss of Hh signalling through the embryo (Table 15). 
OPCs were labelled using in situ hybridisation with a DIG-labelled anti-sense olig2 
riboprobe in Hh signalling mutants at 50 hpf or 72 hpf and these experiments 
indicated various OPC development and migration defects. 
Zebrafish mutant line Mutation/phenotype Reference 
ptch1;ptch2 Loss of function 
Mutation in the ptch1 and 
ptch2 receptors leads to 
constitutively active Hh 
signalling in cells 
(Koudijs et al 2008) 
smob641 Loss of function 
Mutation in the smoothened 
receptor leads to a loss of Hh 
signal transduction 
(Varga et al 2001) 
iguana ts294e Mutation in a ciliary protein 
resulting in a secondary loss 
of function in Hh signalling 
(Brand et al 1996) 
Table 15: Stable Hh signalling mutant lines used in olig2 expression analysis 
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 Gain of function mutant analysis 
The ptch1(+/-)/ptch2(+/-) double mutant line was in-crossed to produce ptch1(-/-
)/ptch2(-/-) homozygous mutants (which will be referred to as ptch1;ptch2 mutants 
from now on) and siblings which were fixed and analysed for OPC migration defects 
at 50 hpf and 72 hpf. These ptch1;ptch2 mutant embryos have constitutively active 
Hh signalling and therefore leading to increased Hh signalling throughout the 
embryo. When olig2 expression was scrutinised in these mutants and compared 
against siblings there were clear changes in olig2 expression. Positive cells for olig2 
which had extended above the midline into dorsal domains were counted in lateral 
sections. In wildtype siblings no cells were observed above the midline at 50 hpf (0, 
n=5), however in the ptch1;ptch2 mutants several cells were observed above the 
midline with large variations between individual embryos (18±10, n=5). As 
discussed earlier, OPC migration is highly regulated and OPCs always formed a 
uniform distribution pattern which is consistent between wild type embryos. 
However it was observed in the ptch1;ptch2 mutants that the expression of olig2 
differed substantially between individual mutants (Figure 3-11B-F). This suggested 
that a defined gradient of Shh is required to create the ideal chemoattractant 
environment and excessive transduction of the signal can skew the migratory map 
that caused it to be deregulated and aberrant cellular migration to occur in these 
mutants.  
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Figure 3-11: olig2 positive cell expression pattern in ptch1;ptch2 mutants at 50 hpf 
The olig2 positive cell expression pattern in wild type embryos is a midline strip of cells 
with expression extending ventrally (A) and this is consistent between individuals. No 
expression of olig2 is seen in the dorsal hindbrain. In ptch1;ptch2 mutants however the 
expression pattern of these cells is altered, the defined midline strip of cells is lost with 
cells entering the dorsal part of the hindbrain in some cases (C). The expression pattern is 
also highly varied between individual mutant embryos. Scale bar 100 µM 
 
 
Furthermore the normal ventral pattern of olig2 was disordered with expression in 
both ventral and dorsal parts of the hindbrain (compare Figure 3-12 B to D). This 
demonstrates that constitutive activation of Hh signalling results in abnormal OPC 
migration. One interpretation of this result is that this type of mutation meant that 
cells could not determine the location of the signal, although the actual Hh protein 
remains unaffected and the distribution is unaltered, cells do not interpret this 
signal properly. Therefore cells continually respond to the signal and do not 
interpret the signal as ventral leading to a loss of positional information.  
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Figure 3-12: Expression of olig2 positive cells in ptch1;ptch2 mutant and sibling embryos 
hindbrains at 72 hpf 
At 72hpf the uniform expression pattern of olig2 in siblings (A) is lost in ptch1;ptch2 
mutants (C). In transverse sections of the hindbrain, olig2 expression is mainly restricted to 
the ventral portion of the hindbrain in siblings (B), whereas in ptch1;ptch2 mutants 
extensive expression of olig2 is seen in the dorsal hindbrain (D). Images in A and C are 
dorsal views, B and D are transverse sections. Scale bar 100 µM 
 
 Loss of function mutant analysis 
An incross of Smob641 (+/-) carriers gave homozygous mutants which were analysed 
for the expression of olig2-positive cells and compared with siblings at 50 hpf. No 
olig2 positive cells were identified in smob641 homozygous mutants which was 
expected since Shh is critical in the initial specification of OPCs and is required to 
turn on olig2 expression (Figure 3-13 B). Similarly in iguanats294e mutants, in the 
majority of embryos there was no olig2 expression, because of the secondary Shh 
signalling defect, however in some embryos only a small number of OPCs were 
specified (Figure 3-13 C). These loss of function mutants were therefore unsuitable 
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to analyse Shh function during later stages of OPC development due to the early 
specification defect. 
 
Figure 3-13: Expression of olig2 positive cells in smob641 and iguanats294e hindbrain 
embryos at 50 hpf. 
At 50 hpf OPCs have been specified and are actively migrating (A), in smob641 mutants 
although cerebellar neurons are specified (red arrow), hindbrain OPCs are not specified due 
to complete loss of Shh signalling (B). In iguanats294e mutants a small number of OPCs are 
specified but fail to migrate from the midline (C). Scale bar 100 µM 
 
Analysis of ptch1;ptch2 mutants, which possess constitutively active Hh signalling, 
showed evidence for disordered OPC migration where cells failed to form a uniform 
expression pattern. OPCs also migrated out of the ventral region where they are 
normally restricted to into the dorsal hindbrain, suggesting that Hh was unable to 
be sensed as a ventral source which led to misdirected migration. 
Loss of function mutants failed to specify OPCs since Hh signalling is critical for their 
early development and therefore these were an unsuitable model to analyse how 
migration is affected upon removal of Hh signalling. An assay which caused a 
temporal loss of Hh prior to migration and after specification was therefore 
required to decipher how loss of Hh affects OPC migration. 
3.5 An assay to analyse temporal loss of Hh signalling on OPC 
migration post-specification 
To determine whether Hh could be contributing to OPC development after their 
initial specification, it was necessary to disrupt Hh signaling in a temporal manner. 
This was achieved using cyclopamine (cyc), a widely ultilized and well characterised 
chemical inhibitor of Shh signalling, through blocking the receptor pathway (Chen 
et al 2002). The data obtained thus far has led to the hypothesis that Shh acts as a 
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ventral external cue providing positional information to OPCs and, upon removal of 
this signal or the ability to respond to it, OPCs would either fail to migrate away 
from their birthplace or show an abnormal migratory pattern.  
 Cyclopamine treatment affects OPC migration in the 
hindbrain 
When 40 µM cyclopamine was applied to tg(olig2:gfp) embryos (n=20) at 34 hpf 
and fixed specimens analysed at either 50 hpf (n=10) or 3 dpf (n=10) there 
appeared to be clear defects in proliferation and migration of OPCs in cyclopamine 
treated embryos. The overall morphology of the embryos was unaffected with no 
overt signs of toxicity. OPCs failed to migrate fully both along the anterior-posterior 
axis and laterally to uniformly populate the hindbrain (Figure 3-14). In contrast, the 
development of GFP-positive cerebellar neurons and the abducens motor neurons 
was normal which suggests that the development of these cell types are Hh-
independent or other pathways could compensate for the loss of Hh signalling 
(Figure 3-14 B arrows). This suggested that Shh may function as a chemoattractant 
actively involved in the initial migration of OPCs to their axonal destinations. 
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Figure 3-14: tg(olig2:gfp) embryos treated with cyclopamine from 34 hpf then fixed at 50 
hpf and 3 dpf 
OPCs failed to migrate fully to uniformly populate the hindbrain in cyclopamine treated 
embryos (C and D) compared with controls embryos (A and B). The development of olig2-
positive cerebellar neurons (red arrows) and the abducens motor neurons (blue arrows) 
was normal. At 3 dpf OPCs that had migrated were disordered and lacked even dispersal in 
the hindbrain (compare D with B). 10 embryos per treatment group were used. Scale bar 
100 µM 
 
 Cyclopamine treatment affects migration and 
proliferation of OPCs in a dose-dependent manner 
Varying concentrations of cyclopamine (20, 40 and 60 µM) were applied to embryos 
which resulted in migration defects varying in severity (Figure 3-15) with the least 
amount of OPCs migrating away from r5/6 in the 60 µM treatment group (Figure 
3-15 G-H). Quantification of the number of cells that had migrated away from r5/r6 
in treated zebrafish (n=5 per treatment group) showed that the number of OPCs 
that had migrated away from their birthplace reduced dramatically with increasing 
cyclopamine concentration (Figure 3-16). Individual OPCs that had migrated away 
from r5/6 were counted in a z-stack projection of the whole zebrafish hindbrain 
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(Figure 3-15 C, depicted by red box). It is important to note that although there is a 
migration defect there also seemed to be a proliferation defect. 
Individual OPCs were readily identified and quantified but the number of OPCs that 
remained in their birthplace in r5/6 could not be counted since there was a high 
density of cells in this region. Therefore it was difficult to conclude from these 
experiments that the observed phenotype was strictly a migration defect, it could 
be the case that there was deficiency in proliferation which resulted in secondary 
decrease in migration. Applying cyclopamine at 40hpf when OPCs have started the 
main period of migration did also affect the number of OPCs migrating away from 
r5/6 but to a lesser extent. Applying cyclopamine at this late stage however will 
most likely have resulted in residual Shh signal still being maintained during the 
early migration phase which provided OPCs.  
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Figure 3-15: The effect of different cyclopamine concentrations on OPC migration in the 
hindbrain 
Treatment of cyclopamine at differing concentrations resulted in differing severities of OPC 
migration defects. The lowest treatment of 20 µM resulted in a less dramatic migration 
defect then in a higher treatment group of 40 µM (compare C and E), increasing the 
concentration of cyclopamine higher to 60 µM reduced the number of OPCs migrating 
away from the midline even more (compare G to E). 5 embryos were used per treatment 
group. Scale bar 100 µM. 
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Figure 3-16: Quantification of OPCs that migrated away from r5/6 in the presence of a 
range of cyclopamine concentrations 
Quantification of OPC numbers that had migrated away from r5/6 during migration stages 
shows that in cyclopamine treated fish there was a considerable decrease in cells 
compared to untreated fish (A). After migration there was a small number of OPCs 
populating the hindbrain in cyclopamine treated fish compared to controls (B). Each 
treatment group n=5. 
 
 
A temporal loss of Shh signalling prior to the main phase of migration, but after the 
initial specification of the cell type had occurred, resulted in an apparent migration 
defect but these experiments also suggested that there was a proliferation defect. 
Although quantification of OPCs that had left their birthplace in r5/6 was 
determined, OPCs that remained in r5/6 could not be counted individually due to 
the high density of cells, which were tightly packed in the birthplace that also 
contained other cell types (Figure 3-16). This meant that it could not be definitively 
concluded whether this phenotype is a specific migration defect or a combination 
of migration and proliferation defects. It is known in other animal systems that Hh 
is a promoter of proliferation and also cell survival so it is reasonable to hypothesise 
that removing Hh signalling at later stages of development could affect proliferation 
and OPC cell numbers. However in the zebrafish, Zannino et al produced time lapse 
movies of OPCs migrating in the hindbrain and it would seem that little division of 
cells occurred whilst cells were migrating (Zannino & Appel 2009). To determine 
whether there was a loss of hindbrain OPC proliferation in cyclopamine treated 
embryos, embryos were pulse labelled with 5-Bromo-2-deoxyuridine (BrdU) at 50 
hpf after overnight exposure to cyclopamine from 36 hpf. BrdU is incorporated into 
newly synthesised DNA and therefore detects proliferating cells. However although 
several attempts were made to BrdU label embryos, no specific BrdU labelling could 
be detected. Detection of BrdU requires a harsh acid treatment which can cause 
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some experimental difficulties and be inconsistent so that could be one of the 
reasons for the failure in BrdU staining. Since embryos were treated with BrdU at 
50 hpf it could also have be that the embryos were too old, with thick skin which 
could have made it more difficult for the BrdU to penetrate the embryos. Embryos 
were then pulse labelled with BrdU at an earlier time point of 36 hpf to investigate 
whether age was the limiting factor. In this experiment cyclopamine was applied at 
32 hpf, however again although some staining could be seen in the ventricular zone 
of the hindbrain (Figure 3-17 A and B arrow), no single cells could be resolved and 
accurate counts could therefore not be taken. Furthermore OPCs were treated with 
cyclopamine for a reduced time compared to the overnight treatment in previous 
experiments and therefore the compound may have not had a long enough 
exposure time to exert its effect on OPCs. Future attempts could utilize 5-Ethynyl-
2´-deoxyuridine (EdU) which does not require the acid treatment and could provide 
more reliable results. It was of importance to find evidence for a direct role of Shh 
in OPC migration since no definitive answer could be concluded from BrdU 
proliferation analysis.  
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Figure 3-17: BrdU analysis of hindbrain OPCs in cyclopamine treated embryos at 36 hpf 
Tg(olig2:gfp) embryos were treated with cyclopamine at 32 hpf for four hours, then at 36 
hpf embryos were were pulse labelled with BrdU to analyse any proliferative defects. 
Staining with mouse anti-BrdU antibody showed some BrdU incorporation in the 
ventricular zone (arrow A and B) which did overlap with some GFP-positive staining (E and 
F) however single cell incorporation could not be distinguished. Scale bar 100 µM 
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3.6 Introducing a dorsal source of Shh into the zebrafish 
hindbrain 
To investigate whether Hh signalling has the potential to direct OPC process 
extension and migration, an assay was developed whereby a secondary source of 
Shh was introduced in the dorsal region of the hindbrain, which would compete 
with the endogenous ventral source. It was reasoned that if OPCs extended their 
processes up dorsally toward the secondary source of Shh it would suggest that Shh 
is sufficient to direct OPC migration, and could be responsible for the initial ventral 
process extension observed in tg(olig2:gfp) embryos. 
 Introducing a secondary dorsal source of Shh caused 
OPCs to alter process extension direction 
To provide more direct evidence for an effect of Shh signalling on OPC migration, a 
dorsal source of mouse N-terminal Shh protein was injected into the dorsal 
hindbrain at 36 hpf. However this protein was prone to dispersal and it was difficult 
to ensure that the protein would remain in a fixed dorsal position. To overcome this 
problem a CM Affi-Gel® Blue Gel agarose bead soaked in mouse N-terminal Shh 
protein was introduced, which resulted in a more reliable fixed dorsal source of 
protein. A single agarose bead was inserted into the hindbrain of each individual 
embryo (n=5). Positioning the bead in the exact place was critical. If the bead was 
too far from midline OPCs they would be unable to detect and transduce the signal, 
if they were placed too close to the OPCs then too high a concentration may have 
acted as a stop signal to cells. It was found that beads that were positioned in the 
correct place (Figure 3-18) were able to induce the OPCs in the immediate vicinity 
to extend processes dorsally in contact with the beads (Figure 3-18B). This dorsal 
process extension was not observed in embryos implanted with control beads 
soaked in buffer alone. Attempts were made to label any primary cilia located on 
these extension processes through labelling with anti-Arl13b however the antibody 
failed to detect any primary cilia throughout the entire hindbrain brain which 
suggested an issue with the protocol or the antibody. Several attempts to increase 
permeability did not resolve the issue and since the antibody had been kept at 4°C 
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for two years it could have been denatured over time and lost its binding affinity. 
The antibody was not commercially available and a fresh aliquot was not available 
prior to submission of this thesis but will be a focus of future investigations. 
 
Figure 3-18: The effect of a dorsal Shh-impregnated bead on OPC migration 
To directly assess the effect of Shh on OPC migration, agarose beads soaked in Shh protein 
were implanted dorsally in the hindbrain at 34 hpf, prior to the main wave of OPC 
migration. Analysis took place at 50 hpf during the active migration wave when processes 
were being extended into the surrounding environment.  OPCs could be seen extending 
process dorsally towards the Shh-impregnated beads (B) whereas in control embryos, 
processes only extended in their normal ventral and lateral directions (A). N=5. Scale bar 50 
µM 
 
3.7 Discussion  
This data supports a role for Hh in OPC migration although further analysis is 
required to separate the migratory phenotype from the proliferation defects 
observed after temporal loss of Hh. Increased responsiveness of OPCs to Hh 
signalling in the ptch1;ptch2 mutants resulted in aberrant migration with cells 
entering dorsal regions of hindbrain (Figure 3-12). This suggests that a particular 
level of Hh signalling and responsiveness is required to ensure that cells are 
provided with and able to respond appropriately to ventral directional information. 
If OPCs were unable to perceive and transduce the signal as exclusively ventrally 
then they might be expected to migrate in different directions as they would have 
lost this positional information. Results to support this were observed in the 
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ptch1;ptch2 mutants (see section 3.4.1). Introducing a dorsal source of Shh caused 
some OPCs in the immediate vicinity of the extraneous dorsal Shh signal, to extend 
processes in a dorsal upward direction (Figure 3-18). Evidence does need to be 
provided that this dorsal extension is a primary consequence of the Shh source and 
not due to the release of other growth factors in response to Shh or cell injury.  
As discussed in (section 1.5.6), a study was published implicating FGF signaling in 
OPC hindbrain development, whereby upon chemical knockdown of FGF signaling, 
olig2 cells were not specified. To investigate whether FGF signaling has subsequent 
roles in OPC migration, tg(olig2:gfp) embryos were treated post specification with 
20 µM SU5402 (following the protocol in original publication (Esain et al 2010)). 
Embryos were kept overnight and were then fixed at 50 hpf and analysed. This dose 
was very toxic to embryos, with a high proportion of death and necrosis. It was 
concluded that overnight exposure with this concentration was too high and the 
concentration was tested at 10 µM and 5 µM, however although embryo death was 
reduced they were still showing signs of toxicity when analysed morphologically. 
Unlike treatment with cyclopamine where embryos did not display toxicity signs, 
prolonged exposure to SU5402 showed too much necrosis and analysis for a role in 
olig2-positive cell migration could not be determined. In conclusion, the results 
present in this chapter suggested that Hh is one of the external signalling cues that 
promote proliferation and the early ventral migration of newly specified OPCs in 
the embryonic zebrafish hindbrain. 
This project also aimed to address the question: What are the potential 
downstream target genes of these signalling pathways which lead the physical 
movement of OPCs in the required direction? 
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 disc1 as a potential 
downstream target of Hh signalling in 
OPC development 
 
4.1 disc1 is expressed in migrating OPCs in the zebrafish 
hindbrain 
Previous work has shown that morpholino knock down of disc1 in the zebrafish, a 
gene implicated in neural crest and neuronal migration (Drerup et al 2009), resulted 
in defects in proliferation and migration of OPCs in the hindbrain (Wood et al 2009). 
OPCs remained restricted to their birthplace in rhombomeres 5 and 6 and did not 
migrate to populate the hindbrain. Subsequently there was a loss of differentiated 
OPCs in the hindbrain at 5 dpf. Functional analysis in other systems has provided 
compelling evidence for DISC1 as a cytoskeletal hub protein with a large number of 
protein binding partners (Camargo et al 2007). The majority of these interacting 
proteins are components of the cytoskeleton. This led to the hypothesis that in the 
zebrafish hindbrain, Disc1 could be contributing to OPC migration, through 
recruitment of cytoskeletal proteins and formation of relevant complexes to cause 
the physical movement of cells in a ventral direction in response to extracellular 
signals including Shh.  
 Analysing expression of disc1 in the zebrafish 
hindbrain 
Previous worked suggested that disc1 was expressed in a similar region to olig2 
positive cells using in situ hybridisation comparison during migration however it 
was not confirmed in same specimen double staining methods (Wood et al 2009). 
Since there were no antibodies available for Disc1 that were cross-reactive with the 
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zebrafish protein, a TSA fluorescent in situ mRNA stain was performed with 
immunofluorescence staining for GFP in the tg(olig2:gfp) line to look for co-
localisation of disc1 mRNA with GFP. Indeed disc1 was confirmed to be expressed in 
GFP positive OPCs at 50 hpf (Figure 4-2 A-C). Midline expression of disc1 was 
observed in migrating OPCs but not r5/6 where the OPCs were stationary (Figure 
4-1 C). These patches of cells in r5/6 also contained abducens motor neurons which 
suggested that disc1 was expressed in migrating OPCs in the midline of the 
hindbrain (Figure 4-1 C arrow). It should be noted that TSA methods of fluorescent 
in situ hybridisation, although powerful in detecting low abundance mRNA there is 
also a degree of background staining which can be visualised in some of these 
images. 
 
Figure 4-1: Expression of disc1 in migrating OPCs 
Expression of disc1 appears higher in migrating OPCs along the anterior-posterior axis than 
in GFP positive cells in r5/6 which contain stationary OPCs and abducens motor neurons. All 
images are dorsal with anterior to the left and posterior to the right. Scale bar 20 µM 
 
An interesting observation during disc1 expression of analysis was the discovery of 
two lateral patches of disc1 expression in the superficial dorsal regions (Figure 4-2 A 
arrow) along with expression of disc1 in migrating OPCs. Transverse sectioning 
showed that these lateral patches of expression were very superficial in the 
hindbrain and did not extend down into the hindbrain (Figure 4-3 A arrow). 
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Figure 4-2: Expression of disc1 in superficial dorsal regions of the hindbrain in 50 hpf 
embryos 
Expression of disc1 was observed in two lateral strips on either side of the midline in 
superficial dorsal sections (white arrow in A) which sat more medially to the lateral GFP 
positive strips which did not overlap suggesting that they are labelling different cell 
populations (B and C). Scale bar: 100 µM 
 
 
 
Figure 4-3: Expression of disc1 in a transverse section through the hindbrain of 50 hpf 
embryos 
Expression of disc1 in transverse sections shows expression in the developing otic vesicle 
and a strip of expression down the midline (A) which overlaps with GFP expression in 
tg(olig2:gfp) embryos (C). Lateral patches of expression in the superficial dorsal hindbrain 
might correspond to radial glia cells (white arrow in A). All images are transverse, dorsal at 
the top and ventral at the bottom. Scale bar 50 µM 
 
The superficial lateral stripes of disc1 expression was an interesting observation in 
light of a paper which showed that another gene, brain fatty acid binding protein 
(fabp7a) had a very similar expression pattern (Esain et al 2010). This gene is known 
to be expressed in radial glia, neuronal precursors of the brain and when expression 
of this gene was investigated by fluorescent in situ hybridisation then it was 
apparent that disc1 shows a very similar pattern of expression to fabp7a in the 
hindbrain (Figure 4-4 compare A to B). Radial glia were originally named due their 
appearance and function in new born neuronal migration. Radial glia act as a 
platform for neurons migrating away from their birthplace due to their long radial 
processes, but more recently they have been identified as key progenitor cells of 
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the developing CNS which can give rise to neurons, astrocytes and also 
oligodendrocytes (Sild & Ruthazer 2011).  
 
Figure 4-4: Comparison of disc1 and fabp7a expression in the superficial dorsal hindbrain 
at 50 hpf 
Expression of disc1 was observed in lateral strips on either side of midline in the dorsal 
hindbrain (A) showed a similar expression pattern to fabp7a, which is a genetic expression 
marker for radial glia (B). Scale bar 100 µM 
 
This similarity in expression suggests that disc1 could also have a role in the 
development of this neuronal cell type which would correlate well with the known 
roles for DISC1 in human and mouse neural cell development.  Extensive 
investigation into the role of disc1 in radial glia development was beyond the scope 
of this project however some speculations were made as to function of disc1 in the 
development of these fabp7a-positive cells. Antibody staining of Zrf-1 which labels 
glial fibrillary acidic protein (GFAP), another marker of radial glia shows expression 
of long radial glial fibres throughout the hindbrain with extensive expression in the 
most ventral part of the hindbrain (Figure 4-5). Expression of fabp7a mRNA also 
showed some expression in radial fibres which co-localised with Zrf-1 in superficial 
lateral patches (Figure 4-5 C arrow). Comparison of Zrf-1 expression in tg(olig2:gfp) 
embryos showed migrating OPCs sitting dorsal to Zrf-1 expression, with radial glia 
extending fibres on either side of the midline. The data suggests that disc1 
expression and its potential function in radial glia is likely to be independent to its 
roles in OPC migration. The expression of disc1 in radial glial cells could identify a 
function for the cytoskeletal protein in radial fibre extension during the 
development of radial glia used by migrating new born neurons. Alternatively it 
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could be expressed in radial glia cells in the context of neuronal or astroglial 
progenitors. Further experiments and investigations would be required to identify 
the function of disc1 in radial glia which could be an interesting avenue for future 
projects. 
  
Figure 4-5: Expression of Zrf-1 shows extension of radial glia processes throughout the 
hindbrain in transverse sections in 50 hpf embryos. 
Expression of Zrf-1 and fabp7a mRNA show radial glia fibres (C arrow). Expression of Zrf-1 
sits ventral to olig2 positive cells and extends process on either side of the midline (F 
arrow). Scale bar 50 µM 
 
Expression of disc1 was also observed in 72 hpf embryos in OPCs during the later 
stages of the main migratory period and the onset of differentiation (Figure 4-6). 
This suggests a possible role for disc1 at later stages of development as well as 
during migration, furthermore roles for disc1 in oligodendrocyte differentiation 
have recently been postulated (Hattori et al 2014). 
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Figure 4-6: shows disc1 expression in olig2 positive cells in 72 hpf embryos 
Expression of disc1 remained at 72 hpf in olig2-positive cells during the final OPC migratory 
stage and beginnings of differentiation (A-C shows whole zebrafish hindbrain scale bar 75 
µM). A zoomed in image of OPCs in the midline (D-F) shows co-localization of disc1 in GFP 
cells. A zoomed image of migrating OPCs shows disc1 co-localization in GFP cells (G-I). D-I 
scale bar 10 µM 
 
 olig2 morphants display a loss of disc1 midline 
expression 
To confirm the fluorescent in situ hybridisation data which suggests that disc1 is 
expressed in olig2-positive cells, olig2 was knocked down using a previously 
described translation blocking morpholino to determine whether midline disc1 
expression is affected upon removal of this cell type (Park et al 2002). If olig2 
expression is lost then OPCs are not specified (Zhou & Anderson 2002). It would 
therefore be expected that disc1 OPC expression would be lost in olig2 morphants, 
which indeed was the case. Embryos were injected with two doses of morpholino, 
an intermediate concentration and a higher concentration. Although disc1 
expression was maintained in the developing otic vesicle, the lower jaw and 
presumptive radial glia, disc1 was lost in the midline in 1pmol of olig2 MO injected 
embryos and reduced in a lower dose of 0.6pmol (Figure 4-7). This result 
demonstrates that disc1 is expressed in olig2-positive midline cells since upon loss 
of olig2 which results in a loss of OPCs, disc1 is no longer expressed. 
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Figure 4-7: shows disc1 expression in olig2 morphants 
Knock down of olig2 through a translation blocking morpholino resulted in reduced disc1 
expression (A) or a complete loss of disc1 expression with a higher dose of morpholino (B) 
in the midline of the hindbrain. Expression of disc1 was maintained in the otic vesicle, 
lower jaw and presumptive radial glia. Red arrow in B shows loss of GFP-olig2 expression. 
Scale bar 50 µM. 
 
 
4.2 Analysis of disc1 expression in shh pathway mutant lines 
To determine whether disc1 is a downstream target of Shh signalling, in situ 
hybridisation was performed in smob641 (-/-), iguanats294e (-/-), ptch1;ptch2(-/-) mutants 
to analyse expression changes of disc1 in response to defective Shh signalling.  
 Expression of disc1 around the midline is altered in 
Shh pathway mutant embryos 
As expected disc1 expression was lost in iguana ts294e (-/-) (Figure 4-8 B arrow) and 
smob641 (-/-) (Figure 4-9 B arrow) mutants compared to sibling controls at 50 hpf, 
since the inhibition of Hh signalling in these mutants leads to an OPC specification 
defect. Mutant embryos were considerably smaller then wildtype siblings which 
reflect how fundamental Hh signalling is in early embryo development and a loss of 
global Hh signalling results in decreased survival and proliferation of a wide range 
of cell types (Chen et al 2001). 
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Figure 4-8: Comparison of midline disc1 expression between sibling and iguanats294e(-/-) 
embryos at 50 hpf. 
Expression of disc1 was lost in the midline in iguanats294e (-/-) mutants (black arrow in B) but 
expression was maintained in the developing ear but was reduced. Images show transverse 
sections. 50 µM 
 
 
 
Figure 4-9: Comparison of midline disc1 expression between sibling and smob641(-/-) 
embryos at 50 hpf. 
Expression of disc1 is lost in the midline of smob641(-/-) mutants (black arrow in B) compared 
to sibling disc1 expression. All images are transverse sections. 50 µM 
 
Interestingly in ptch1;ptch2  mutant embryos disc1 expression was increased 
around the midline compared to sibling embryos at 50 hpf (Figure 4-10), which 
could have been a result of seemingly excessive migration of olig2-positive cells in 
these mutants (Figure 3-12). The expression of disc1 was altered from a thin strip of 
expression in the midline which would normally create a diamond shape of 
expression in the ventral portion of the hindbrain (Figure 4-10B), to expanded 
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expression on either side of the midline in dorsal views (Figure 4-10 compare A and 
C).  
 
Figure 4-10: Comparison of disc1 expression in ptch1;ptch2 mutants and sibling controls 
at 50 hpf 
Expression of disc1 was increased in ptch1;ptch2 mutants in the hindbrain midline (arrow in 
C). A and C are dorsal views, B and D are transverse views. Expression in otic vesicles also 
show increased expression in ptch1;ptch2 mutants (C). Scale bar 100 µM 
 
Altered expression of disc1 mRNA in the different Hh pathway mutant embryos 
suggests that it may be a downstream target of Hh signalling. In ptch1;ptch2 mutant 
embryos, disc1 expression was considerably increased around the midline, 
suggesting that increased Hh signalling transduction due to ptch loss of function 
resulted in disc1 up-regulation. This subsequently could have contributed to the 
excessive migration witnessed in these mutants (Figure 3-12), with cells migrating 
out of their normal restricted ventral region into dorsal areas of the hindbrain. Of 
course it is important to acknowledge here that these mutant embryos have grossly 
altered morphology due to a severe patterning phenotype. Expression of disc1 was 
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completely lost in the midline in the loss of function Shh mutants since OPCs failed 
to be specified.  
4.3 Quantification of disc1 expression in hedgehog signallling 
mutants 
To provide further evidence for regulation of disc1 expression by Shh we sought to 
quantify disc1 expression in the mutant lines using quantitative PCR to verify the in 
situ hybridisation data. The Shh smob641 and ptch1;ptch2 mutants and siblings 
(which were a combination of single homozygote mutants, various combinations of 
homozygotes and heterozygotes and wild type embryos) were collected at 50 hpf 
and cDNA was synthesised from RNA extracted from pools of 20 embryos. QPCR 
expression data was collected and compared against a reference housekeeping 
gene, elongation factor 1-alpha (ef1a) (Livak & Schmittgen 2001) (Tang et al 2007). 
Expression of disc1 was compared between smob641 mutants and their siblings, and 
as expected there was a loss of disc1 expression in the homozygous mutants 
compared to their sibling counterparts. In fact there was complete loss of disc1 
expression in smob641 mutants compared to siblings i.e. expression didn’t pass the 
threshold suggesting there was no gene product (Figure 4-11 A). Expression of disc1 
was then compared between ptch1; ptch2 mutants and their siblings. Surprisingly, 
there was slightly lower expression of disc1 in ptch1;ptch2 mutants compared to 
ptch1;ptch2 siblings which was inconsistent with the in situ hybridisation data 
which suggested increased expression of disc1 in the midline (Figure 4-11 B). These 
sibling pools will have contained a combination of ptch1 (-/-) homozygotes, ptch2 (-/-) 
homozygotes, ptch1 (-/-); ptch2 (+/-) and ptch2 (-/-); ptch1 (+/-) embryos along with wild 
type siblings and these combinations of patched mutants could have contained 
increased disc1 expression which may have masked any increases in disc1 
expression in the double mutants. The double mutants were very morphologically 
abnormal and smaller in size and therefore could be lacking cell populations that 
normally express disc1 which may also have skewed the results. Comparing the 
expression levels of disc1 between the two pools of siblings, revealed that the 
ptch1;ptch2 siblings had higher expression then the smob641 siblings (Figure 4-11 C). 
When disc1 expression in ptch1;ptch2 mutants was compared against smob641 
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siblings there was increased expression in the double mutants as originally 
expected, thereby suggesting that the ptch1;ptch2 sibling pools contained an 
accumulation of increased disc1 expression from the combination of heterozygotes 
and single homozygotes (Figure 4-11 D). This could therefore suggest that disc1 is 
upregulated in response to increased Shh signalling but this data is a very 
preliminary finding. One biological set of 20 embryos was used for each group and 
these were subjected to 3 technical replicates. Further biological replicates are 
required to confirm these findings and to assess inconsistences between pools of 
embryos. Individually pooling ptch1;ptch2 in-crosses based on genotype would be 
ideal but difficult, since genotyping of each embryo would be required. Analysing 
the expression pattern of disc1 using in situ hybridisation in the different single 
patched homozygous and heterozygous combinations could be used to confirm 
increased disc1 expansion in the midline compared to wild type siblings. 
 
Figure 4-11: Quantification of disc1 expression in Hh signalling stable mutant lines 
Expression of disc1 was quantified using qPCR in Shh signaling stable mutants and were 
compared against disc1 expression levels in their sibling counterparts. Expression of disc1 
failed to reach the threshold in smob641 mutants suggesting no gene product compared to 
sibling control smob641 embryos (A). Expression of disc1 in ptch1;ptch2 double mutants 
compared to ptch1;ptch2 siblings showed very similar expression levels (B). When the 
siblings from both sets were compared it was shown that disc1 was expressed at three 
times higher levels in the ptch1;ptch2 siblings compared to the smob641 siblings (C). Finally 
when the expression of ptch1;ptch2 mutants was compared against expression in the 
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smob641 siblings, the mutants displayed 2.4X higher expression of disc1 (D). Error bars show 
SEM. 
 
4.4 Loss of disc1 expression in cyclopamine treated embryos 
As discussed before, the Hh loss of function mutant zebrafish lines were not 
appropriate to investigate the effect of Hh loss on later stages of OPC development 
since OPCs are not specified in these mutants. Similarly, they were unsuitable to 
determine the effect of loss of Hh signalling on disc1 expression in OPCs. However 
cyclopamine treatment allowed temporal removal of Hh signalling thereby enabling 
OPCs to be specified as normal in the embryo prior to loss of Hh signalling.  
 Expression of disc1 in the midline is lost in 
cyclopamine treated embryos 
 Cyclopamine (40 µM) was applied to tg(olig2:gfp) embryos (n=10)  prior to the 
main period of OPC migration as with previous experiments and the embryos fixed 
at 50 hpf. Embryos were then analysed for disc1 mRNA expression using in situ 
hybridisation. These experiments revealed a clear loss of disc1 in the midline of 
cyclopamine treated embryos as well as the previously described apparent 
reduction in migration of OPCs from the midline (Figure 4-12 Compare D to C). 
Expression of disc1 was however maintained around the otic vesicle and developing 
jaw. 
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Figure 4-12: shows disc1 expression in the midline of cyclopamine treated embryos 
Cyclopamine was applied at 34 hpf prior to migration and fixed at 50 hpf, treated embryos 
(n=10) had a loss of disc1 expression (D arrow) compared to untreated embryos (C). Panel B 
shows a loss of GFP positive cell migration as a result of temporal Hh signalling loss. All 
images are transverse sections. Scale bar 50 µM 
 
These experiments suggest that disc1 could be a downstream target of Hh 
signalling, however it whether it is secondary to altered olig2 expression is not 
known. These data suggests that Hh signalling ventrally during OPC development 
could be involved in migration since migration does seem to affect during altered 
signalling. Whether this is a direct result of proliferation defects is still to be 
elucidated, and will be of focus for future experiments. It can be hypothesised that 
if Hh signalling is required for OPC migration it could be through regulation of Disc1 
protein and other cytoskeletal proteins, however this is merely speculative. 
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 Investigating the cellular 
localisation of Disc1 in OPCs 
5.1 Introduction 
Yeast two hybrid studies have suggested that the DISC1 protein acts as a scaffold 
with the capacity to bind several proteins (Section 1.3). Many of these multiple 
binding partners are cytoskeletal proteins and provided the possibility that DISC1 
brings proteins together to create cytoskeletal complexes required for processes 
such as cell migration. As discussed previously, DISC1 has roles in neuronal 
migration involving such protein complexes so it seemed reasonable to hypothesize 
that the zebrafish Disc1 protein could contribute to OPC migration through similar 
protein interactions.  
5.2 Investigating potential Disc1 OPC protein interactors 
To try and identify the relevant protein binding partners of Disc1 which could be 
involved in OPC migration, fluorescent in situ hybridisation of cytoskeletal partners 
with already established functions with DISC1 in neuronal migration were 
performed in tg(olig2:gfp) embryos. Two proteins known to bind DISC1 and form 
complexes in cell culture and mouse systems are LIS1 and NDEL1, so expression of 
their zebrafish orthologues were initially investigated in hindbrain OPCs during the 
main migration phase (Morris et al 2003) (Kamiya et al 2005). 
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Figure 5-1: Expression pattern lis1a and ndel1a in 50 hpf tg(olig2:gfp) embryos 
Fluorescent in situ hybridization of ndel1a, shows weak expression in the brain that does 
not overlap with GFP olig2-positive cells (A-C). Expression of lis1a shows stronger brain 
expression surrounding GFP olig2-positive cells but there is no overlap (D-F). All images are 
anterior to left and posterior to the right. All images are dorsal views. Scale bar 30 µM 
 
No expression of either ndel1a or lis1a was observed in OPCs (Figure 5-1), 
suggesting that their function in cell migration with DISC1 may be specific for 
neuronal migration in other systems and not important in zebrafish OPCs, at least 
during this stage of development. The expression patterns of ndel1b and lis1b did 
not show expression in OPCs either (data not shown). Although this data suggests 
that these particular proteins are not involved in OPC migration it cannot be 
completely ruled out. These proteins are ubiquitously expressed, meaning that 
there may still be some expression but not to a level detectable by in situ 
hybridisation. However such low levels of expression indicate that they are unlikely 
to have active roles in OPC migration at this time point. 
Yeast two hybrid experiments and subsequent validation has identified 
approximately 600 interacting partners of Disc1 (Camargo et al 2007), and to go 
through these systematically to look at whether there is expression in OPCs would 
have been inefficient. Investigating the localisation of the Disc1 protein in OPCs, at 
all stages of their development would provide a more defined list of candidate 
proteins to investigate further based on their sub-cellular localisation. Proteins with 
a similar localisation to Disc1 would be more likely to interact and form complexes 
and thus contribute to OPC migration. As discussed previously (Section 1.3), the 
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localisation of DISC1 has been debated for several years, with different antibodies 
showing DISC1 expression in a variety of cellular locations (Figure 1-1) and the 
majority of this data was obtained with neuronal cells. Localisation information is 
lacking for DISC1 in OPCs in vivo and so investigating the cellular location of Disc1 
during OPC development in the zebrafish could provide novel mechanistic 
information into Disc1 biology. 
5.3 Overexpression studies of Disc1 to decipher cellular 
localisation 
There are several methods available that can be used in the zebrafish to decipher 
the subcellular localisation of a protein. Overexpression studies using constructs 
whereby the gene of interest, in this case disc1, is fluorescently tagged and injected 
either as a linearized DNA construct or as capped mRNA into 1 cell stage embryos is 
a popular technique that can give a swift indication of protein localisation within 
cells in vivo. Embryos were injected with capped disc1 mRNA or linearized heat 
shock-inducible disc1 expression constructs to analyse the localisation of 
overexpressed Disc1. 
 Expression of Disc1-GFP fusion proteins via mRNA 
injection 
To visualise Disc1 mRNA, the protein was fluorescently tagged at the N- and C-
terminal ends with GFP contained in PCS2+ (Figure 5-2). Embryos were injected at 
the one cell stage and after 6 hours uniform fluorescence was observed throughout 
the injected embryo. However by 24 hpf fluorescence was no longer visible, 
indicating that both the injected mRNA and the translated protein had been 
degraded. Similarly when the protein was tagged at the N-terminal end with GFP, 
loss of fluorescence again occurred before 24 hpf. This made mRNA injections 
unsuitable for our purposes since the localisation of Disc1 could not be investigated 
at later stages of development (2 dpf) during OPC migration. 
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Figure 5-2: Vector maps of C-terminal and N-terminal GFP tagged disc1 
The disc1 sequence was inserted into the PCS2+ GFP vector backbone using the restriction 
sites EcoR1 and XbaI for the C-terminal GFP vector (A), and BglII and XbaI for the N-terminal 
GFP vector (B). Both vectors were linearized with Not1 and SP6 polymerase was used to 
generate mRNA through in vitro transcription  
 
 Expression of Disc1-mCherry fusion proteins using 
linearized heat-shocked inducible DNA expression 
constructs  
As an alternative to mRNA injection, a disc1-mCherry DNA expression construct 
containing a Heat shock (HSP70) promoter was generated from a heat shock 
mCherry plasmid in the vector backbone pBSK12 (unpublished Semil Choksi) to 
allow for temporal control of protein expression (Figure 5-3). The zebrafish Disc1 
gene was inserted into the plasmid using restriction sites EcoRV and BglII and the 
plasmid was linearized for injection using I-SceI sites. 
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Figure 5-3: Vector map of HSP70: disc1-mCherry  
The disc1 sequence was inserted into the pBSK12 backbone using the restriction sites 
EcoRV and BglII. The vector was linearized using Isce-I meganuclease just prior to injection. 
 
One cell stage tg(olig2:gfp) embryos were injected with linearised HSP70-disc1-
mCherry DNA and allowed to develop until 30 hpf. Embryos were then heat 
shocked in a 37°C water bath which induced expression from the HSP70 promoter 
in response to heat stress. After 2-4 hours, cells containing the DNA construct 
expressed Disc1-mCherry protein. Since DNA is more stable than mRNA, embryos 
could be injected at fertilisation but then heat shocked at later developmental 
stages, thereby increasing the chances of observing expression in migrating OPCs. 
The expression of mCherry however was mosaic, which reduced the chance of the 
construct being present in OPCs. Unfortunately this was the case; no Disc1-mCherry 
was detected in OPCs in 20 embryos analysed. However the fluorescence observed 
was stronger than that during the mRNA expression studies so its localisation was 
still analysed in other cell types of the embryo. It was reasoned that Shh signalling 
could be transduced by OPC primary cilia prior to or during migration and there is 
some evidence to suggest that Disc1 localises to the base of primary cilia in NIH-3T3 
fibroblasts (Marley & von Zastrow 2010) (Section 1.3.4). Therefore acetylated 
tubulin was co-stained with mCherry to investigate whether overexpressed Disc1 
localised to primary cilia in the zebrafish. Disc1-mCherry showed diffuse 
cytoplasmic expression with no clearly defined subcellular localisation, there is also 
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some expression in the nucleus. No expression was seen on either primary cilia or 
motile cilia (Figure 5-4). 
 
Figure 5-4: Cytoplasmic localisation of overexpressed Disc1-mCherry 
Wild type embryos were injected with linearized HSP70: disc1-mCherry construct and heat 
shocked at 37°C for 1 hour at 30 hpf to analyze Disc1 protein expression. Disc1 was not 
seen to be expressed on primary (A) or motile cilia (B) but showed a general cytoplasmic 
localization in muscle and pronephric duct cells. Scale bar 5 µM 
 
 Limitations of overexpression 
Overexpression via mRNA injection was unsuccessful in identifying the localisation 
of Disc1 in OPCs. Degradation of both mRNA and protein before 24 hpf was the 
major limiting factor meaning that the protein localisation in migrating OPCs could 
not be investigated. This was perhaps not surprising since the Disc1 protein is 
relatively large and stability could have been compromised. Conversely, the HSP70-
disc1-mCherry construct could be expressed beyond 24 hpf but posed a different 
limitation in that injection of this DNA construct created a mosaic pattern of 
overexpressed Disc1-mCherry, unlike with mRNA injection where the protein was 
uniformly expressed throughout the embryo. This decreased the likelihood of 
successfully targeting of the HSP70-disc1-mCherry construct into OPCs. Positive 
embryos for Disc1-mCherry were raised to adulthood in an attempt to establish a 
stable line to analyse localisation and also to investigate the consequences of 
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overexpression of disc1 on migrating OPCs. Unfortunately during screening no 
mCherry positive embryos were identified after heat shock although when 
genotyped the disc1-mCherry construct could be identified through PCR. 
Another limitation to this type of analysis is that it is based on over-expression. The 
localisation of over-expressed Disc1 may not necessarily truly mimic that of 
endogenous Disc1. Pumping a cell full of protein could ultimately lead to it being 
expressed in cellular locations not representative of the normal endogenous 
localisation. Specifically detecting and labelling only endogenous protein however 
would eliminate these issues and provide reliable localisation information during all 
stages of development. 
5.4 Development of zebrafish antibodies to label endogenous 
Disc1 
The aim shifted to focus on endogenous Disc1 protein through antibody 
development since overexpression studies were inconclusive and potentially may 
not be reliable. Commercial antibodies that are cross-reactive with the zebrafish 
protein are limited compared to those available for use in mammalian systems, 
making it unlikely that existing commercial anti-DISC1 antibodies would be useful in 
the zebrafish. Instead it was decided that specifically raising antibodies against 
zebrafish Disc1 would improve the chances of the antibodies working effectively. 
Polyclonal antibodies are inexpensive to produce and less time consuming 
compared to the generation of monoclonal antibodies. Polyclonal antibodies 
recognise several epitopes on a single antigen which can provide higher affinity 
since the protein of interest will bind more than one antibody molecule. These 
antibodies are also more tolerant to antigen changes (for example in the case of 
polymorphisms) however they vary from batch to batch and can also produce a lot 
of non-specific antibodies. Previous attempts had been made to make polyclonal 
antibodies but were unsuccessful in specifically labelling endogenous Disc1 protein 
and therefore monoclonal antibody production was attempted as an alternative. 
Monoclonal antibodies are different in that they have high specificity as they only 
detect one epitope on the antigen and therefore have less background during the 
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staining process, however they are more expensive and time consuming to 
produce. Six monoclonal antibodies were raised against zebrafish Disc1 by Abmart 
against the synthetic peptide EDNLPVQSRD corresponding to residues 119-128 of 
Disc1. The antibodies were provided at high titre but with no guarantee regarding 
binding affinity or specificity. Provided these antibodies were successful in labelling 
endogenous Disc1 through immunofluorescence staining, then the localisation of 
Disc1 protein could be investigated in OPCs throughout their development, but also 
in the lower jaw cartilages, otic vesicle and presumptive radial glia cells. 
 Immunofluorescence staining with Abmart anti-Disc1 
monoclonal antibodies 
Of the six antibodies raised against zebrafish Disc1 only 2D24 displayed any affinity 
for detecting Disc1. Western blot analysis detected 3 proteins of approximately 
100-160 kDa compared to a predicted Mr for Disc1 of 112 kDa (NI Alsomali, 
unpublished). It should be noted that Disc1 contains multiple coiled-coil domains so 
it might be expected to run with an apparent molecular mass greater than 
predicted. When used for immunofluorescence staining, the antibody (1:500 
dilution) did not detect any endogenous expression in the cell types identified by in 
situ hybridisation analysis of disc1 mRNA; in fact no staining throughout the entire 
embryo was detected when a standard immunofluorescence protocol was used. To 
determine whether the antibody was able to detect non-physiological levels of the 
Disc1 protein, embryos were injected with the HSP70-disc1-mCherry construct then 
heat shocked for 30 minutes at 24 hpf and then fixed in 4% PFA after mCherry 
fluorescence was observed. Wholemount embryos were co-stained with anti-
mCherry and the 2D24 antibody (1:200 dilution). Co-localisation of 2D24 and anti-
mCherry staining would suggest that the 2D24 antibody was capable of detecting 
zebrafish Disc1 and this was indeed found to be the case (Figure 5-5). Therefore the 
potential of this antibody to detect endogenous Disc1 was pursued using higher 
concentrations of the antibody and implementing changes to the protocol and 
fixation methods that would differ from the standard immunofluorescence 
protocol. 
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Antibody name Concentration (mg/ml) Specific detection 
2D24 36.5 overexpressed HSP70-disc1-
mCherry detection 
2I13 15.6 Unspecific 
6D7 19.8 Unspecific 
6G10 26.4 Unspecific 
7A10 18.0 Unspecific 
7F14 20.8 Unspecific 
Table 16: zebrafish disc1 antibodies specificity analysis 
 
 
Figure 5-5: Antibody Disc1 2D24 can successfully detect overexpressed Disc1 protein in 
injected embryos 
Embryos were injected with HSP70-disc1-mCherry DNA and heatshocked at 26 hpf for 30 
minutes which induced mosaic expression of Disc1-mCherry protein (A). 
Immunofluorescence staining with the 2D24 anti-Disc1 (B) resulted in detection of 
overexpressed Disc1-mCherry protein that can be clearly seen in the merged image (C). 
Images are from whole mount embryos imaged laterally. Scale bar 150uM 
 
Higher concentrations of 2D24 were tested (1:100, 1:50 and 1:10), however no 
endogenous protein expression was detected even using such high concentrations. 
This suggested that although 2D24 is able to detect high levels of the Disc1 protein 
it does not bind with sufficient affinity to detect low levels of the endogenous 
protein (Table 16). Detection of disc1 mRNA with in situ hybridisation required long 
incubation times during the staining process compared with other riboprobes 
applied at the same concentrations, suggesting that Disc1 is expressed at low levels. 
One interpretation of these results is that Disc1 is enriched in OPCs and other areas 
detected using in situ hybridisation, but the expression of the protein is at a low 
level that cannot be readily detected in immunofluorescence. 
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5.5 Utilizing homologous recombination to incorporate a 
fluorescent tag into the endogenous disc1 gene 
 Precise genome editing 
Developing a tool to create fluorescently tagged endogenous Disc1 protein is now a 
possibility since genes can be precisely edited through new and highly efficient 
genome editing methods. These reverse genetic strategies allow a gene of interest 
to be targeted in a chosen region and edited through the induction of double strand 
breaks (DSBs). These DSBs induce the DNA repair machinery which results in non-
homologous end joining (NHEJ) to repair the break in the DNA. This NHEJ creates 
small deletions and insertions (INDELS), which dependent on the number of base 
pairs lost or gained can result in frame shift mutations. As well as using these tools 
to create stable mutant lines, the addition of donor DNA into the system can also 
lead to insertion of a large fragment of DNA into the desired region via homologous 
recombination. The insertion of donor plasmid DNA encoding a fluorescent protein 
can tag the gene of interest leading to an endogenously expressed fluorescently-
tagged fusion protein allowing for visualisation of the subcellular localisations of a 
protein at physiological levels during development. For homologous recombination 
to occur, the donor DNA plasmid is designed in such a way that homology arms 
matching the region of the targeting gene are incorporated flanking either side of 
the fluorescent. These homology arms on either side of the fluorescent protein 
sequence act as a template for the DNA repair machinery so that it can incorporate 
the fluorescent protein sequence into the endogenous gene, resulting in a perfectly 
edited genome containing a fusion protein (Grunwald 2013). 
Genome Editing system Abbreviation Limitation 
Zinc finger nucleases ZFN High cost of production 
Low rate of mutagenesis 
Transcription activator-
like effector nucleases 
TALENs Highly repetitive which 
can cause difficulty in the 
assembly of plasmids 
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Clustered regularly 
interspaced short 
palindromic repeats 
CRISPR/Cas9 Requires PAM sequence 
(NGG) 
Table 17: Precise genome editing techniques in the zebrafish 
 
Earlier methods of targeted genome editing in the zebrafish were not widely 
utilized due to a high cost of production and a relatively low mutation rate; mainly 
referring to zinc finger nucleases (ZFN) (Chen et al 2013b). However recent 
developments in genome editing have made the process simpler, more cost 
effective and highly efficient. Methods such as TALENs (Transcription activator-like 
effector nucleases) and the CRISPR/Cas9 (Clustered regularly interspaced short 
palindromic repeats) system have revolutionized genome editing in the zebrafish, 
both in producing stable mutant lines and endogenous fusion proteins through site 
specific mutagenesis (Bedell et al 2012, Chang et al 2013, Huang et al 2011, Hwang 
et al 2013). In order to try and address the localisation of endogenous Disc1, both 
the TALEN and CRISPR/Cas9 systems were investigated to determine the possibility 
of tagging endogenous disc1 with mCherry at the 3’ end of the gene. The 
CRISPR/Cas9 system was considered first since the plasmids are easier to design. 
However the guide RNA (gRNA, which is responsible for targeting the gene of 
interest and guiding the CAS9 to induce DSBs) requires a protospacer associated 
motif (PAM) sequence (NGG, any nucleotide followed by nucleotides GG) on the 3’ 
end of the target sequence, and no PAM sequence was situated at the end of the 
disc1 gene. Therefore the TALEN system which does not have the same sequence 
restrictions, was selected for disc1 genome editing (Blackburn et al 2013). 
TALENs were designed to create a double strand break at the stop codon of disc1 
(Figure 5-6). Linearized donor DNA was also introduced should be incorporated into 
DSBs to generate a C-terminal fusion protein termed disc1-mCherry-pA. The two 
TALEN arms and the donor DNA were synthesised by ZGENEBIO, Taiwan.  
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Figure 5-6: TALEN arms targeting sequence 
The left and right TALEN arms were generated to recognize specific sequences on either 
side of the target site (spacer region) containing the stop codon of disc1 (as shown in red 
box).  
 
 Function of Transcription activator-like effector 
nucleases  
Each TALEN arm is composed of a TAL effector DNA binding domain fused to a DNA 
cleavage domain. The TAL effector DNA binding domain acts as the target site to 
the gene of interest and is comprised of several TALE repeats which are organised 
into TALE effector arrays, and each repeat recognises a specific nucleotide. Within 
these highly conserved repeats there are two amino acids referred to as repeat 
variable di-residues (RVDs) which provide specificity to the target nucleotide 
sequence (Bogdanove & Voytas 2011). The DNA cleavage domain comprises of a 
Fok1 endonuclease situated on each TALEN arm and initiates DSBs in the spacer 
region between the two TALEN targets sites (encoded by the left and right arms) 
which in this case contained the TGA stop codon of disc1. The TALEN arms are 
incorporated into plasmids which are linearized and transcribed into capped mRNA, 
then both TALEN arms are co-injected into 1 cell stage zebrafish embryos. Genomic 
DNA is extracted from injected embryos and screened for double stand breaks in 
the target region. The function of TALENs is summarised in the schematic below 
(Figure 5-7).  
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Figure 5-7: Cartoon illustrating the use of TALENs for gene targeting 
TALENs (Transcription activator-like effector nucleases) are made up of 2 arms targeting 
specific regions in the gene of interest with a spacer sequence between them. Each arm 
consists of a DNA binding domain fused to a DNA cleavage domain. TALEN mRNA arms are 
co-injected to induce double strand breaks in the targeted region which subsequently 
induce non-homologous end joining (NHEJ) by the DNA repair machinery. NHEJ is error 
prone and results in small deletions and insertions causing mutations in the gene of 
interest. 
 Identifying INDELs in zebrafish embryos 
 Prior to attempting knock-in of the donor DNA via TALEN-induced double strand 
breaks, it was first important to ensure that the TALENs were capable in inducing 
double strand breaks in the target region with reasonable efficiency. Wild type AB 
strain embryos were injected with left and right TALEN-encoding mRNA at varying 
volumes of 150 ng/µl of each arm to determine toxicity levels; a 50% survival rate 
was desired for efficient mutagenesis and embryos that survived were genotyped 
for double strand breaks. After injection, genomic DNA was extracted from injected 
embryos at 2 dpf in pooled batches of 30 embryos per group. A batch of un-injected 
embryos was used as a control group. A 450 bp region surrounding the target site 
was amplified using PCR and purified. The amplified DNA fragments underwent T7 
endonuclease I analysis to assay for the presence of DNA mismatches which is 
indicative of double strand breaks and non-homologous end joining. The T7 
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endonuclease I functions by recognising imperfectly matched DNA and cleaving that 
mismatched DNA. The DNA was then electrophoresed in a 3% agarose/TBE gel to 
screen for any fragments smaller than the 450 bp wild-type product. Embryos 
injected with 0.5 nl of 150 ng/µl mRNA of each TALEN arm showed two bands 
below the amplified 450 bp product which suggested that the TALENs had 
successfully induced DSBs in disc1 (Figure 5-8). The injections of greater volumes 
did not result in lower fragments and therefore did not appear to induce DSBs and 
it could be hypothesised that this level of mRNA caused too much toxicity so 
embryos that had DSBs would not survive.  
 
Figure 5-8: T7 endonuclease I analysis in TALEN injected embryos identified DNA 
mismatches  
Embryos injected with different volumes of TALENs were analyzed for INDELs using the T7 
endonuclease I which recognizes and cleaves mismatched DNA indicative of NHEJ. Each 
group had a negative control performed with no T7 endonuclease I in the reaction. 
Embryos injected with 0.5nl of 150ng/µl TALEN mRNA showed digested products below the 
wild type product (indicated in lane 4 with *) which indicated that the TALENs had induced 
DSBS in the region of disc1 amplified from pooled genomic DNA. 
 
Following T7 endonuclease I analysis, the PCR fragments positive for DNA 
mismatches were cloned into the pCR™2.1-TOPO® vector in order to confirm the 
presence for INDELs. Individual DNA fragments had to be cloned since the DNA was 
amplified from pooled embryos, thereby ensuring that the sequencing was clean 
and represented single alleles. Sequencing results were aligned with the wild type 
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zebrafish disc1 sequence using the DNA analysis software Lasergene (Seqman 
program), and the results showed that the TALENs induced DSBs in approximately 
10% of injected embryos in the spacer target region (Figure 5-9). 
 
Figure 5-9: disc1 sequencing results from individual TALEN injected embryos 
A 450 bp region of disc1 was sequenced in genomic DNA extracted from TALEN injected 
embryos and aligned against wild type disc1 to determine the nature of INDELs induced. 
Ten percent of embryos had DSBs induced by injection of the TALEN mRNAs which resulted 
in deletions in the target region of disc1. 
 
After it was confirmed that the TALENs were efficient in causing specific DSBs, 
knock-in of the donor DNA was explored. 
 Homologous recombination 
Knock-in of the donor DNA involved co-injecting the TALEN mRNAs with the 
linearized donor DNA (40 ng/µl). At this point it was observed that co-injection 
caused a much higher rate of toxicity therefore higher numbers of embryos had to 
be injected. After induction of DSBs (Figure 5-10A), the homology arms in the donor 
DNA should act as a template to the DNA repair machinery resulting in a 
homologous recombination event (Figure 5-10B) and insertion of the mCherry 
fluorescent tag into the 3’ end of disc1 (Figure 5-10C).  
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Figure 5-10: Cartoon of genome editing through homologous recombination using donor 
DNA as a template in the zebrafish disc1 gene 
DSBs are induced in the target region of the disc1 gene by the TALEN pair (A). When donor 
DNA containing homology arms encoding the disc1 target region is introduced it acts as a 
template for the DNA repair machinery (B). Insertion of this template will result in 
incorporation of a DNA-encoding fluorescent tag into the 3’end of the disc1 gene (C).  
 
 
This should theoretically leave a perfectly edited genome containing the mCherry-
pA sequence (Figure 5-11). The mCherry sequence was selected since the end goal 
was to cross this line with the tg(olig2:gfp) line in the future to study directly the 
localisation of Disc1-mCherry in GFP positive cells.  
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Figure 5-11: The expected edited disc1-mCherry fusion after a homologous recombination 
event. 
The homologous recombination event is expected to result in a disc1-mcherry fusion via a 
12bp linker without affecting the reading frame of the endogenous gene. 
 
 Identifying homologous recombination 
To screen for homologous recombination events, primers had to be designed that 
would not amplify residual donor DNA that had not undergone homologous 
recombination. Three Primer sets spanning different regions were designed to 
identify a successful knock-in event (Figure 5-12). Primer set 1 was designed 
whereby the forward (FWD) primer sat 5’ to the left homology arm and the reverse 
(RVS) primer sat 3’ to the right homology arm. If there was a successful homologous 
recombination event then a 3 kb fragment would be amplified containing the disc1 
gene and the mcherry/pA sequence; however if no event occurred then a wild-type 
product of 2 kb would be amplified instead, which served as a positive control. The 
wild type alleles were consistently amplified but no 3 kb product was ever amplified 
in injected embryos. This could have been due to the fact that amplifying a large 
product from genomic DNA can be inefficient due to the complexity of the template 
and potential shearing of the DNA during the extraction process. An alternative 
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method was to design one primer situated in the donor mCherry sequence with the 
other primer sitting 5’ to the left homology arm or 3’ to the right homology arm 
(Figure 5-12 primer sets 2 and 3 respectively). This would amplify a 1.2 -1.4 kb 
product only in the case of a successful HR event. Although this method has the 
advantage of amplifying a smaller product, there is no positive control to ensure 
that the primers were working.  
A variety of different primers were used to screen however none have showed 
consistent and reliable screening of positive homologous recombination events, 
potential founder fish will continue to be screened for a positive insert although 
none had been identified before this thesis submission. Although the TALENs cut at 
10%, the success rate of a knock in is 0.3% which means that a higher number of 
potential founders require screening in the future. 
 
Figure 5-12: Primer pairs used to screen for homologous recombination events in the 
disc1 gene 
Three different primers sets were designed to screen for HR events using DNA extracted 
from injected embryos. P1 set would result in a 3 kb product if there was a positive 
insertion of the donor DNA or a wild-type 2 kb product if there was no insertion event. P2 
and 3 consists of one primer in the mCherry donor sequence and the other primer outside 
of the homology arm sequences so only an HR event would result in an amplified product. 
 
5.6 Conclusion 
The localisation of zebrafish Disc1 has proved elusive, several attempts to identify 
the sub-cellular localisation of Disc1 have been unsuccessful. Over-expression 
assays through the injection of fluorescently tagged Disc1 constructs suggested 
cytoplasmic expression with no defined localisation. Early degradation and mosaic 
expression patterns restricted the investigation of Disc1 localisation in migrating 
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OPCs. Although over-expression studies are popular for localisation studies as 
discussed previously they do not address the endogenous protein and therefore 
antibodies were developed to specifically detect endogenous Disc1. Although 2D24 
anti-Disc1 was capable at detecting over-expressed Disc1, it did not show any 
endogenous detection of the protein. Finally as an alternative method, 
endogenously tagging the gene with mCherry was attempted using precise genome 
editing techniques to create a useful tool for the Schizophrenia and DISC1 
community. 
The TALENs were shown to work efficiently, inducing DSBs in the target sequence of 
disc1. Screening for homologous recombination after co-injection with the donor 
DNA has proved more problematic than expected. Several primer sets were 
designed to identify insertion events however none successfully gave the expected 
fragment size. This could be because the primers were designed to amplify non-
coding regions, which are more prone to sequence variations. Sequencing the 3’ 
end of the disc1 gene of adult wild-type strains in the zebrafish facility in Singapore 
showed several SNPs in the coding and non-coding regions which resulted in 
sequence variations between the embryos and the homology arms of the donor 
DNA. This could have decreased the rate at which the donor DNA was incorporated 
into the DSB due to homologous recombination requiring the template to match 
the genomic sequence. However zebrafish were selected that had only highly 
similar sequences after showing the higher number of SNPs. The low rate of germ 
line transmission during precise genome editing particularly in knock in studies has 
made screening for HR directed insertions challenging. A very recent study has 
attempted to improve the screening and efficiency of germ line transmission of 
knock ins which could be utilised in the future during the screening process (Dong 
et al 2014). In the event of the C-terminal tagging of the disc1 gene is unsuccessful 
then an attempt to tag the N-terminal end could be considered and tested. The N-
terminal end of the protein is less well conserved and so creating the tag at this side 
of the protein may have less impact on its function. The C-terminal tag was 
originally attempted due to the HSP70: disc1-mcherry showing stability when 
injected, and the 2D24 anti-Disc1 antibody was able identify the protein suggesting 
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it did not impact on protein folding and the majority of tagged Disc1 constructs had 
a C-terminal fluorescent tag. 
As an alternative method of screening, instead of waiting for embryos to be raised 
to adulthood and using a fin clip sample to genotype, embryos could be grown to 2 
dpf only and a small larval fin clip taken to genotype. This would mean that only 
positive embryos are grown to adulthood and analysed which would save time, 
space and cost and this method will be utilised in the future. 
Although currently there is no conclusive evidence as to the localisation of Disc1, 
this tool is still being developed to endogenously tag the disc1 gene with mCherry 
and consequently eliminate the need to rely on overexpression studies or 
antibodies to detect the protein. To improve the screening assay, embryos at 2 dpf 
could be fin-clipped directly and screened for homologous recombination events 
and only those that had an insertion are raised to adulthood. This stable line would 
not only provide reliable information regarding the true localisation of Disc1 in a 
variety of cell types but the tool can be used in chemical manipulation to 
investigate localisation variations to be discussed in further detail in the discussion. 
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 A preliminary in vivo drug 
screen to identify compounds 
modulating OPC development 
 Conventional drug screens currently use biochemical or in vitro cell culture 
systems, and although these are high throughout, many drugs identified 
subsequently fail validation or clinical screening when taken into in vivo systems. 
This is most likely because early on, one cannot assess the effects of a drug on an 
entire tissue or animal. To overcome this major issue, the development of assays in 
which compounds can be initially screened in an in vivo vertebrate system, yet still 
be high throughput, would potentially improve the hit rate of taking successful 
drugs to the clinic. The zebrafish, as a small vertebrate and well established 
research tool, is being increasingly appreciated and utilized in medium to high-
throughput in vivo drug screens (Baxendale et al 2012, Bruni et al 2014, Buckley et 
al 2010). Their small size, rapid external development, and genetic similarity to 
humans make them an ideal candidate in which to screen libraries of compounds 
and observe drug effects on an entire organism throughout early development. 
Furthermore, compound libraries can be simply applied to the medium in which the 
embryos are submerged and removed after the desired treatment time. Finally 
embryos have a high tolerance for DMSO, a solvent used to dissolve a large 
majority of compounds. Thus ease of drug administration is therefore another 
advantage to using zebrafish embryos in medium to high-throughput drug screens 
to identify new therapeutic targets and treatments for a variety of diseases and 
developmental disorders. Drug screens can be designed to target a variety of 
systems and cells in the zebrafish including different cell types of the brain. For 
example a screen in 2010 utilized the zebrafish to screen for pro-myelinating drugs 
in attempt to identify new compounds for multiple sclerosis treatment (Buckley et 
al 2010).  Another screen using zebrafish investigated therapeutic targets for 
epilepsy screen, making the zebrafish an attractive model to investigate drugs that 
modify a variety of brain diseases (Baxendale et al 2012). 
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6.1 A drug screen to identify novel compounds and signalling 
pathways involved in OPC migration and proliferation 
Another way to understand the signalling pathways governing OPC migration and 
more specifically which signalling pathways are relevant to disc1 in OPC 
development was to design a medium throughput drug screen using the zebrafish. 
A drug screening assay using whole mount in situ hybridisation for olig2 expression 
as a read out for OPC development was developed to identify novel compounds 
involved in OPC migration in the hindbrain of the zebrafish embryo. The screen was 
designed to focus on OPC migration after the initial specification of the cell type 
had occurred. Drugs were therefore applied after the initial period of specification 
and removed during or after the initial migration events but prior to differentiation, 
after which embryos were fixed and analysed. The reasons for performing this drug 
screen were two-fold. Firstly, it should allow for the identification of novel signalling 
pathways involved in OPC migration through analysis of olig2 expression patterns in 
compound-treated embryos. In particular, embryos were analysed for restricted 
migration, excessive migration and migration pattern differences. Although several 
signalling pathways have been implicated in OPC migration in mouse and human 
systems, this process is still not fully understood. In the zebrafish hindbrain, how 
OPCs populate the hindbrain is not completely characterised, although work 
towards this thesis after the drug screen was performed, has highlighted the 
importance of Shh signalling in the migration and proliferation of this population of 
OPCs. The identification of additional signalling pathways would contribute the 
characterisation of OPC migration in the zebrafish hindbrain, and potentially in 
other systems. Secondly since disc1, is also implicated in hindbrain OPC 
development in the zebrafish, it would be interesting to investigate whether any of 
the signalling pathways identified through chemical manipulation, work with or are 
modulated by disc1 during development. 
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6.2 Primary drug screening assay development 
 Selection of the compound library 
The spectrum library (Microsource delivery systems) was selected to screen for OPC 
migration deficiencies in the zebrafish. This library contained a collection of 2000 
bioactive small molecules. The library included FDA approved molecules (60%), 
naturally occurring products whose biological functions are not known (25%), and 
other bioactive compounds (15%). The library was provided in a 25X 96 well plate 
format so that a high number of compounds can be screened simultaneously. This 
library gave the opportunity to screen a large variety of different compounds and 
therefore many potential target signalling pathways in a medium-through put in 
vivo screen.  
 Selection of the appropriate controls 
It was important to include different controls with which to compare the olig2 
expression patterns of spectrum library compound-treated embryos. DMSO only-
treated embryos served to provide a wild type olig2 expression pattern reference; 
these embryos were treated with DMSO at the same time point as the compound-
treated embryos and acted as a negative control. The FB148.5 mutant (obtained 
from an ENU screen in the Ingham group (Wolff et al 2004)) shows a similar 
phenotype to disc1 morphant embryos in that OPCs remain restricted to their birth 
place in r5/6, and therefore acted as positive control for migration deficiency. 
Chemical inhibition of Nrg-1 signalling via ErbB signaling, a signalling pathway with 
an established role in OPC migration, was also used as a positive control. ErbB 
inhibition results in a similar phenotype to that observed in nrg-1 and disc1 
morphant embryos (Wood et al 2009), again where OPCs remain restricted to the 
midline of the hindbrain. Two different compounds were used to block Nrg-1-ErbB 
signalling and these compounds were also used to investigate the most appropriate 
time to expose embryos to the spectrum library compounds in order to induce 
readily detected migration defects (Table 18).  
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Positive control 
Compound 
Mode of action Test Concentration Compound 
supplier and 
product code 
EGFR/ErbB-2/ErbB-4 
inhibitor I 
Inhibits Nrg-1-
ErbB signalling  
20 µM 324840-1MG 
Calbiochem 
EGFR/ErbB-2/ErbB-4 
inhibitor II 
Inhibits Nrg-1-
ErbB signalling 
20 µM 324842-5MG 
Calbiochem 
Table 18: Positive control compound information 
 
Embryos were exposed to 20 µM of each inhibitor drug alongside DMSO-treated 
embryos as a control group at a range of time points from 26-32 hpf prior to the 
main phase of OPC migration in order to determine the best time at which to apply 
the spectrum library compounds to screen for effects on migration. Since it was 
known that these inhibitors cause an apparent migratory defect they were ideal to 
investigate at which time point to apply the spectrum compounds. The time point 
that showed the greatest restriction of OPCs without affecting the overall 
morphology of the embryos was selected and utilised for the entire drug screen. It 
was important to establish the optimal time point at which to treat the embryos, 
since drugs need to be absorbed and then elicit their function on their target 
signalling pathways and may require a prolonged period of exposure to give an 
effect. Four time points were tested after the initial specification of olig2-positive 
cells have occurred (26, 28, 30 and 32 hpf). The time of exposure that showed the 
greatest effect on OPC migration was from 28 hpf so embryos were submerged in 
drug from this time point throughout the initial screen to give prolonged time for 
the compounds to take effect (Figure 6-1). Any hit compounds that were identified 
would then be tested at different time points in future investigations to determine 
the stage of OPC development it is having its effect on. 
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Figure 6-1: Inhibition of Nrg-1 signalling through chemical manipulation at 28 hpf resulted 
in restricted migration of hindbrain olig2-positive cells. 
EGFR/ErbB-1/ErbB-4 inhibitor I and II was applied at four time points (26, 28, 30 and 32 
hpf) and fixed at 50 hpf during active migration to determine which time point to expose 
embryos to the spectrum library compound. The time point which showed the strongest 
effect on OPC migration was at 28 hpf and embryos were exposed at 28 hpf during the drug 
screen. (20 embryos were exposed to compounds per treatment group) scale bar 100uM. 
 
The objective of this compound screen was not only to screen for compounds that 
caused a deficiency in migration but also to identify compounds that caused 
accelerated migration or an altered migration pattern, for example OPCs migrating 
out of their normal ventral domain into dorsal areas of the hindbrain, but there was 
not a positive control available at the time of the screen. 
 Compound plate and embryo preparation 
Each compound plate had the same set up, with controls in rows 1 and 12 and the 
spectrum library compounds to be screened in rows 2 through to 11. Spectrum 
compounds were screened at a test concentration of 25 µM. Three Nacre strain 
embryos were placed in each well and were submerged in medium containing the 
compounds from 28 hpf. The plates were then incubated at 28°C overnight. 
Embryos were removed from the compounds at 50 hpf and fixed in 4% PFA 
overnight. Embryos were fixed at 50 hpf during the active phase of migration to 
detect early migration defects such as in the initiation of migration. Embryos were 
then stored in methanol and the following week were processed for in situ 
hybridisation staining. In situ hybridisation using an olig2 anti-sense riboprobe was 
performed using an automated in situ hybridisation Biolane robot and the stained 
embryos were analysed under a light microscope for expression pattern 
differences. A flow chart of the preliminary drug screen is summarised below 
(Figure 6-2). Each plate of compounds was screened once but was visually analysed 
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twice on two different days and the positive hits were compared. Those hits that 
had been selected as positive on both days were considered a primary positive hit 
and were taken forward to validation screening.  
 
 
Figure 6-2: Flow chart of preliminary drug screen 
The drug screen was split into 3 parts consisting of embryo preparation (red panel), drug 
exposure (green panel) and analysis of olig2 expression (purple panel). Embryos were 
placed at 3 per well after pronase treatment after which they were exposed to a test 
concentration of 25 µM at 28 hpf. Embryos were left to develop and fixed at 50 hpf 
overnight in 4% PFA and were stored in MeOH until OPC analysis using an olig2 in situ 
hybridization. Embryos were screened visually for olig2 expression abnormalities and 
positive hits recorded and taken forward for validation screening. 
 
 Preliminary screen for positive compound hits 
Of the 2000 compounds initially screen, 174 compounds were carried forward for 
primary validation. These compounds were picked and consolidated into 2 new 96 
well plates which were screened and compared for consistency. The validation 
screen was performed twice (validation screen 1 and validation screen 2). The first 
validation screen identified 47 hits from the 174 primary compounds. The second 
validation screen, in which the whole process was repeated, identified 65 hits from 
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the original 174 primary hits. The validation screening process was carried out using 
the same conditions as with the primary screen. The results were consolidated 
Table 19, which shows basic information for the 174 compounds originally 
identified as positive hits in the primary screen. The ‘validation screen’ column 
shows whether these primary hits were also identified as positive in validation 
screen 1, validation screen 2 or in both screens (1 and 2). Those that were not again 
identified as positive were labelled as false. The final set of hits has been marked in 
blue for ease of reference (Table 19). 
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Compound name Known actions Formulae Source 
001 A5 1 and 2 Mechlorethamine Anti-neoplastic, 
alkylating agent 
C5H11CI2N Synthetic 
B3 false Methacholine 
chloride 
Cholinergic, diagnostic 
acid 
C8H18CINO2 Synthetic 
D4 false Nitrofurantoin Antibacterial C8H6N4O5 Synthetic 
E3 false Novabiocin 
Sodium 
Anti 
bacterial 
C31H35N2NaO1
1` 
Streptomyces 
niveus and S 
griseus 
E5 false Nystatin Anti-fungal, binds to 
membrane sterols 
C47H75NO17 Streptomyces 
noursei 
F11 2 Phenylbutazone Anti-inflammatory C19H20N2O2 Synthetic 
G6 1 and 2 Fenbendazole Anthelmintic C15H13N3O2S Synthetic 
G8 2 Mefenamic acid Anti-inflammatory, 
analgesic 
C15H15NO2 Synthetic 
H7 false Memantine 
Hydrochloride 
Muscle relaxant 
(skeletal) 
C12H22CIN Synthetic 
002 A3 false Pirenzepine 
hydrochloride 
Antiulcer C19H23C12N5O
2 
Synthetic 
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A10 1 and 2 Sulconazole 
nitrate 
antifungal C18H16Cl3N3O
3S 
Synthetic 
B2 false 'SULPIRIDE dopamine receptor 
antagonist, antipsychotic 
C15H23N3O4
S 
 
Synthetic 
D5 false 'FOLIC ACID hematopoietic vitamin C19H19N7O6 liver, kidney, 
green plants and 
fungi 
E7 2 'CEFMETAZOLE 
SODIUM 
antibacterial C15H16N7NaO5
S3 
Semi-synthetic 
G8 2 VINCRISTINE 
SULFATE 
antineoplastic C46H58N4O1
4S 
'Vinca rosea; 
37231, NSC-
67574 
G11 2 DEBRISOQUIN 
SULFATE 
anti-hypertensive C10H15N3O4
S 
synthetic; RO-5-
3307/1 
H4 1 PENTETIC ACID chelating agent, 
diagnostic aid 
C14H23N3O10 synthetic; DTPA 
H9 1 and 2 'CEFPROZIL antibacterial C18H19N3O5S 'semisynthetic; 
BMY-28100-03-
800 
003 A6 false 'SCOPOLAMINE 
HYDROBROMIDE 
anticholinergic, 
treatment of motion 
sickness 
C17H22BrNO4 'Scopolia, Datura, 
Atropa spp 
A7 false THEOPHYLLINE bronchodilator C7H8N4O2 Camelia, thea, 
Paullinia cupana 
B8 false 'PROPAFENONE 
HYDROCHLORIDE 
antiarrhythmic C21H28ClNO3 Synthetic 
B9 2 FLUCONAZOLE Anti-fungal C13H12F2N6O Synthetic 
B10 1 and 2 LOVASTATIN antihyperlipidemic, 
HMGCoA reductase 
inhibitor 
C24H36O5 'Aspergillus spp; 
mevinolin 
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D5 false 'HYDROQUINONE antioxidant C6H6O2 synthetic 
E9 1 CANRENONE aldosterone antagonist; 
antifibrogenic 
C22H28O3 Synthetic 
E11 1 'CLIOQUINOL antiseptic, antiamebic C9H5ClINO Synthetic 
F7 false 'TRAMADOL 
HYDROCHLORIDE 
analgesic C16H26ClNO2 synthetic; U-
26225A, CG-315E 
G2 false 'LEVALBUTEROL 
HYDROCHLORIDE 
bronchodilator, tocolytic C13H22ClNO3 synthetic 
 G5 2 'TOPOTECAN 
HYDROCHLORIDE 
antineoplastic; 
topoisomerase I inhibitor 
C23H24ClN3O5 Semi-synthetic 
 G11 false PODOFILOX antineoplastic, inhibits 
microtubule assembly, 
and human DNA 
topoisomerase II; 
antimitotic agent 
C22H22O8 'Podophylum 
peltatum; 
podophylotoxin 
 H5 false SPARTEINE 
SULFATE 
oxytoxic C15H28N2O4S 'Lupinus spp and 
other 
Leguminosae 
004 B2 1 and 2 IVERMECTIN antiparasitic C48H74O14 'semisynthetic 
D4 1 and 2 'AMPHOTERICIN 
B 
Antifungal C47H73NO17 'Streptomycetes 
nodosus 
005 B2 false 'CLEMASTINE antihistaminic C25H30ClNO5 synthetic 
B9 1 and 2 CLOXYQUIN antibacterial, antifungal C9H6ClNO Synthetic 
E8 1 DICUMAROL anticoagulant C19H12O6 Synthetic 
006 C11 false HALAZONE antiinfectant C7H5Cl2NO4S synthetic 
E9 1 IBUPROFEN Antiinflammatory C13H18O2 synthetic 
D8 false HOMATROPINE 
METHYLBROMIDE 
anticholinergic 
(opthalmic) 
C17H24BrNO3 Semi-synthetic 
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F3 1 and 2 INDOPROFEN analgesic, 
antiinflammatory 
C17H15NO3 Synthetic 
007 A2 2 'OXYQUINOLINE 
HEMISULFATE 
antiinfectant C9H9NO5S Synthetic 
B3 1 'PIROXICAM antiinflammatory C15H13N3O4S Synthetic 
B9 2 PREDNISONE glucocorticoid C21H26O5 Semi-synthetic 
F3 false 'SULFABENZAMID
E 
antibacterial C13H12N2O3S Synthetic 
008 A7 false Trifluoperazine Anti-psychotic C21H26CI2F3N3
S 
Synthetic 
A10 false Trimethoprim Antibacterial C14H18N4O3 Synthetic 
B2 false Tripelennamine 
citrate 
Anti-histaminic C22H29N3O7 Synthetic 
C6 false Merbromin Antibacterial C20H8Br2HgNa
2O6 
Synthetic 
C9 1 Sulfanilamide Anti-bacterial C6H8N202S Synthetic 
D2 1 Theobromine Diuretic, bronchodilator, 
cardiotonic 
C7H8N4O2 Camelia, 
theobroma, Cola 
spp 
D4 2 Aconitine Anesthetic (gastric), anti-
pyretic, and cardiotonic 
C34H47NO11 Aconitum spp 
F3 false Iodipamide Radioopaque agent C12H11I3N2O4 Synthetic; L-
isomer. spectrum 
F9 false Bekanamycin 
sulphate 
Antibacterial C18H39N5O14S Semi-Synthetic, 
Streptomyces 
kanamyceticus, 
NK-1006 
F10 false Budesonide Anti-inflammatory C25H34O6 Semi-synthetic 
G3 2 Chenodiol Anti-cholithogenic, anti-
lipemic 
C24H40O4 Human bile 
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G9 1 Piperine Analeptic, antibacterial C17H19NO3 Black pepper 
H2 false Flumequine Antibacterial C14H12FNO3 Synthetic 
H4 1 and 2 Fluphenazine 
hydrochloride 
H1 anti-histamine C22H28CI2F3N3
OS 
Synthetic 
H8 false Etodolac Anti-inflammatory C17H21NO33 Synthetic 
009 A5 false Nicergoline Vasodilator C24H26BrN3O3 Synthetic 
A7 false Erythromycin 
estolate 
Antibacterial C52H97NO18S Synthetic 
B3 1 and 2 Tretinon Kerotolytic, carboxylic 
acid form of vitamin A 
C20H28O2 Semi-synthetic 
B6 false Cefsulodin 
sodium 
Antibacterial C22H19N4NaO8
S2 
Semi-synthetic 
C6 1 and 2 Cycloheximide Protein synthesis 
inhibitor 
C15H23NO4 Synthetic 
C11 1 Anisindione Anti-coagulant C16H12O3 Synthetic 
D7 1 Abamectin Anti-parisitic C48H72O14 Streptomyces 
avermitilis 
E4 1 Nicotinyl alcohol 
tartrate 
Vasodilator C10H13NO7 Synthetic 
E5 2 Floxuridine Anti-neoplastic, anti-
metabolite 
C9H11FN2O5 Synthetic 
E11 1 Amifostine Radioprotectant C5H15N2O3PS Synthetic 
F9 false Ceftriaxone 
sodium trihydrate 
Antibacterial C18H22N8Na2O
10S3 
Semi-synthetic 
G7 1 and 2 Chloroxine Chelating agent C9H5CI2NO Synthetic 
H8 1 Paromomycin 
sulfate 
Antibacterial, antiamebic C23H47N5O18S Streptomyces 
rimosis 
paramonycinus 
010 C4 false OXETHAZAINE anesthetic (local) C28H41N3O3 Synthetic 
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H5 false PAROXETINE 
HYDROCHLORIDE 
antidepressant C19H21ClFNO3 Synthetic 
011 A9 2 TRIMETOZINE sedative, neurosedative C14H19NO5 Synthetic 
C2 2 'ORLISTAT reversible lipase 
inhibitor, antiobesity 
C29H53NO5 Synthetic 
C10 1 and 2 FLUNIXIN 
MEGLUMINE 
analgesic, 
antiinflammatory 
C21H28F3N3O7 'synthetic; SCH-
14714 
E2 1 and 2 'EZETIMIBE sterol absorption 
inhibitor 
C24H21F2NO3 Synthetic 
H2 false KETANSERIN 
TARTRATE 
5HT2/5HT1C seritonin 
antagonist 
C22H22FN3O3 Synthetic 
012 A7 2 ETHOXZOLAMIDE carbonic anhydrase 
inhibitor, antiulcer, 
antiglaucoma 
C9H10N2O3S2 Sythetic 
B3 false LEVOCARNITINE cofactor for fatty acid 
metabolism, replenisher 
in arterial disease 
C7H15NO3 Semi-synthetic 
C5 false TRICLOSAN Anti-infective C12H7Cl3O2 synthetic; CH-
3565 
D8 false DEXCHLORPHENI
RAMINE 
MALEATE 
antihistamine C20H23ClN2O4 synthetic 
E2 1 NORGESTIMATE progestin C23H31NO3 Semi-synthetic 
H7 2 'PREGNENOLONE 
SUCCINATE 
glucocortcoid, 
antiinflammatory 
C25H36O5 Semi-synthetic 
013 B2 1 Glycopyrolate  Anti-cholinergic C19H28BrNO3 Synthetic 
D7 2 Ethynodiol 
diacetate 
Progestin C24H32O4 Semi-synthetic 
F11 2 Nizatidine Anti-ulcer, H2 antagonist C12H21N5O2S2 Synthetic 
H6 false Aniracetam Cognitive enhancer C12N13NO3 Synthetic 
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016 A2 false Chiniofon Anti-protozoal, 
amebicide 
C9H5INNaO4S Synthetic 
A3 false Piribedil 
hydrochloride 
Dopamine agonist C16H18N4O2 Synthetic 
B5 false Barbital Sedative C8H12N2O3 Synthetic 
B6 false Oxedrine Anti-obesity C9H13NO2 Citrus aurantium 
C4 false Xylocarpus A N/A C31H38O11 Meliaceae spp 
D4 1 Euphol acetate N/A C32H52O2 Euphorbia spp 
D6 false Tartaric acid Pharmaceutical aid C4H6O6 Common plant 
constituent 
E2 2 Piromidic acid Antibacterial C14H16N4O3 Synthetic 
E7 false Chloropyramine 
hydrochloride 
Anti-histamine C16H21CI2N3 Synthetic 
E11 false Strophanthidinic 
acid lactone 
acetate 
N/A C25H32O7 Semi-synthetic 
G6 1 and 2 Avocadyne 
acetate 
Anti-fungal C19H34O4 Persea spp 
G8 false Diacerin Anti-inflammatory C19H12O8 Synthetic 
G11 false Mepiroxol Anti-hyperlipemic C6H7NO2 Synthetic 
H6 false Carzenide Diuretic, carbonic 
anhydrase inhibitor 
C7H7NO4S Synthetic 
H9 1 and 2 Chaulmoogric 
acid 
Antibacterial C18H32O2 Hydnocarpus and 
oncola spp 
H11 false 2,6-
Dimethoxyquinon
e 
Anti-bacterial, induces 
dermatitis, mutagen 
C8H8O4 picrasmus 
017 A2 false 'DECAHYDROGA
MBOGIC ACID 
N/A C38H54O8 derivative 
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A4 false BISANHYDRORUTI
LANTINONE 
'antibacterial C22H16O7 Streptomyces 
spp; also 
rutilantinone 
A6 false LANOSTEROL 
ACETATE 
N/A C32H52O2 derivative of 
lanosterol 
A9 false 'GALLIC ACID antineoplastic, 
astringent, antibacterial 
C7H6O5 'insect galls 
A11 false GLUTATHIONE 'antioxidant C10H17N3O6S 'plant and animal 
tissue 
B4 false CARAPIN N/A C27H32O7 'Carapa and 
Cedrela species; 
mp 180-185 
B10 false ALLOPREGNANOL
ONE 
N/A C21H34O2 semisynthetic 
C4 false '1,7-
DIDEACETOXY-
1,7-DIOXO-3-
DEACETYLKHIVOR
IN 
N/A C26H32O7 'Meliaceae spp 
C9 false MEXICANOLIDE N/A C27H32O7 'Meliaceae spp 
D3 1 '8beta-
HYDROXYCARAPI
N, 3,8-
HEMIACETAL 
N/A C27H32O8 derivative 
E2 false '3-DEOXO-3beta-
ACETOXYDEOXYDI
HYDROGEDUNIN 
N/A C30H40O7 
 
Meliaceae spp 
 
E7 2 3beta-
HYDROXYISOALLO
SPIROST-9(11)-
ENE 
N/A C27H42O3 semisynthetic 
F6 2 'DEOXYKHIVORIN N/A C32H42O9 'Meliaceae spp 
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F8 1 and 2 DEACETOXY-7-
OXOGEDUNIN 
Anti-HIV activity C26H30O6 'Meliaceae spp 
G9 false BOVINOCIDIN (3-
nitropropionic 
acid) 
'antineoplastic C3H5NO4 'Aspergillus, 
Streptomyces spp 
& other 
microorganisms 
G10 1 and 2 CHRYSIN diuretic C15H10O4 'Ulnus 
sieboldiana, 
Flourensia 
resinosa, 
Oroxylum 
indicum, Pinus 
and Scutellaria 
spp. 
H3 2 7,4'-
DIHYDROXYFLAV
ONE 
'antioxidant C15H10O4 'Pterocarpus 
marsupium 
H11 false HECOGENIN antiinflammatory C27H42O4 Agave and Yucca 
spp 
018 B3 false CARNOSINE N/A C9H14N4O3 Mammalian 
Skeletal muscle 
C2 2 LAPACHOL Anti-neoplastic, anti-
fungal 
C15H14O3 Heartwood of 
bignoniaceae 
H5 2 GANGALEOIDIN N/A C18H14CI2O7 Lecanora 
gangaleoides 
019 B3 2 IRIGENIN, 7-
BENZYL ETHER 
N/A C25H22O8 Derivative of 
irigenin from iris 
spp 
B11 false VIOLASTYRENE N/A C17H18O3 Dalbergia 
miscolobium 
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D3 false Pachyrrhizin Insecticide  C19H12O6 Pachyrrhizus 
erosus mp 206-
207 
E4 1 SPHONDIN N/A C12H8O4 Heracleum 
maximum root; 
mp 191-192 C 
F3 1 and 2 'EPI(13)TORULOS
OL 
Anti-fungal C20H34O2 Cryptomeria 
japonica and Larix 
sibirica 
F5 1 and 2 LARIXOL N/A C20H34O2 Larix sibiricia 
F6 1 and 2 LARIXOL ACETATE N/A C22H36O3 Larix europaea 
G6 1 and 2 DEHYDROABIETA
MIDE 
Anti-viral activity C20H29NO derivative 
H2 2 HYMECROMONE 
METHYL ETHER 
N/A C11H10O3 'Dalbergia 
volubilis, 
Eupatorium 
pauciflorum 
020 A3 2 ACACETIN antiinflammatory, 
spasmolytic agent, 
antioxidant 
C16H12O5 Robinia 
pseudoacacia 
A11 false EPICATECHIN 
MONOGALLATE 
N/A C22H18O10 tea pigment 
B4 false RHODINYL 
ACETATE 
N/A C12H22O2 common 
constituent of 
plant essential 
oils 
B11 false PHYTOL N/A C19H38O nettles 
C5 false HESPERIDIN 'capillary protectant C28H34O15 Citrus spp. 
C8 false QUASSIN insecticide, antiamoebic C22H28O6 Quassia amara, 
Picrasma excelsa 
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and Ailanthus 
glandulosa 
C9 2 APIIN N/A C26H28O14 parsley seed; 
flowers of 
Anthemis nobilis. 
80% + other 
glycosides 
D8 2 MEVASTATIN antihyperlipidemic, 
HMGCoA reductase 
inhibitor 
C23H34O5 Penicillium 
brevicompactum; 
Compactin 
E7 2 PIPERONYLIC 
ACID 
N/A C8H6O4 Piper longum, 
Cinnamumum spp 
E8 false PHENACYLAMINE 
HYDROCHLORIDE 
N/A C8H10ClNO 'Castanopsis 
cuspidata, Vitis 
spp 
E9 false CYCLOVERATRYLE
NE 
N/A C27H30O6 Halopythus spp 
F3 2 DERRUSTONE N/A C18H14O6 Derris robusta 
F9 1 LEOIDIN N/A C18H14Cl2O7 lichen metabolite 
G11 false 4-
METHYLESCULETI
N 
N/A C10H8O4 analog of 
esculetin 
H3 false 4-
METHYLDAPHNET
IN 
N/A C10H8O4 analog of 
daphnetin 
021 A2 false BICUCULLINE (+) GABAa antagonist C20H17NO6 Dicentra 
cucullaria, 
Corydalis spp 
C6 false GITOXIN cardiotonic C41H64O14 Digitalis spp. 
G5 false TRIPTOPHENOLID
E 
N/A C20H24O3 'Tripterygium 
wilfordii 
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G7 false alpha-
MANGOSTIN 
N/A C24H26O6 Garcinia 
mangostana, 
Hydnocarpus 
octandra, H 
venenata 
G11 2 SALSOLIDINE 'antihypertensive C12H17NO2 Salsola Richteri 
22 C7 2 DEMETHYLNOBIL
ETIN 
N/A C20H20O8 Citrus, Sideritis, 
Heteropappus 
and Thymus spp; 
Mentha piperita, 
Amaracus 
pampanini 
G11 1 and 2 HEXAMETHYLQUE
RCETAGETIN 
N/A C21H22O8 Citrus spp 
H3 2 RHIZOCARPIC 
ACID 
N/A C28H23NO6 Rhizocarpon spp, 
Calicium 
hyperelium; mp 
178 C 
23 D10 false 12a-HYDROXY-5-
DEOXYDEHYDRO
MUNDUSERONE 
N/A C19H18O6 derivative 
H6 false FARNESOL N/A C15H26O major component 
in oil of Hibiscus 
abelmoschus 
H11 2 PERILLIC ACID (-) inhibits posttranslational 
cys isoprenylation, 
blocks G-protein 
C10H14O2 Salvia dorisiana 
24 A3 2 ISOROTENONE N/A C23H22O6 semisynthetic 
B6 fasle APIGENIN 
DIMETHYL ETHER 
N/A C17H14O5 common plant 
metabolite 
C5 2 3-HYDROXY-4-
(SUCCIN-2-YL)-
N/A C19H28O4 'derivative of 
caryophyllene 
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CARYOLANE 
delta-LACTONE 
E2 2 ESTRADIOL 
METHYL ETHER 
estrogen C19H26O2 semisynthetic 
E6 1 and 2 4-
NAPHTHALIMIDO
BUTYRIC ACID 
aldose reductase 
inhibitor 
C16H13NO4 synthetic 
E8 false N- (9-
FLUORENYLMETH
OXYCARBONYL)-L-
LEUCINE 
antiinflammatory C21H23NO4 synthetic; NPC-
15199 
E10 1 and 2 5-
FLUOROINDOLE-
2-CARBOXYLIC 
ACID 
'NMDA receptor 
antagonist (gly) 
C9H6FNO2 synthetic 
F8 1 and 2 'PHENETHYL 
CAFFEATE (CAPE) 
'antineoplastic, 
antiinflammatory, 
immunomodulator, 
NFkB blocker 
C17H16O4 synthetic 
G6 1 EXALAMIDE antifungal C13H19NO2  synthetic 
25 A3 1 and 2 ARTENIMOL antimalarial, 
antiinflammatory 
C15H24O5 semisynthetic; 
dihydroartemisini
n 
4C false VALINOMYCIN antibiotic; LD50 (rat, po) 
4 mg/kg 
C54H90N6O18 Streptomyces spp 
10G false FLOPROPIONE antispasmodic C9H10O4 synthetic 
Table 19: Details of the 174 positive drug hits identified from the primary drug screen. 
There were 174 compounds observed as exerting an effect on OPC development, those 174 
compounds were screened again twice in validation screening. Those compounds that were 
selected a positive again in both validation screen I and II were marked in blue to give 28 
final primary hits. 
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The two sets of hits identified in the validation screens were compared to give a 
final list of 28 compounds (Table 20) that were positive in all three assays 
performed (1.4%).  
Screen level Number of compounds 
screened 
Positive hits identified 
Primary screen 2000 174 (8.7%) 
Validation screen I 174 47  
Validation screen II 174 64 
Comparison of Validation 
screens  
111  28 (1.4%) 
Table 20: Compounds numbers taken forward through the screening process 
  
These final 28 hits were consolidated into a table where their effect on olig2 
expression was described (Table 21). The majority of compounds gave a restricted 
expression phenotype where olig2-positive cells remained either along the 
anterior-posterior axis without any lateral migration (Figure 6-3E and F) or the cells 
were completely restricted to their initial birthplace in rhombomeres 5/6 (Figure 
6-3C). Some compounds, such as Choroxine, resulted in olig2 expression being 
completely lost. This could mean that although olig2 expression was presumably 
normal before compound treatment olig2 expression was completely blocked and 
existing mRNA degraded, alternatively the early OPCs expressing olig2 were 
destroyed by this compound leading to the loss of olig2 expression observed (Figure 
6-3D). Interestingly a handful of compounds gave a phenotype in which a long thick 
strip of olig2 expression was observed along the midline (Figure 6-3B) where 
individual OPCs were not clearly visible including compound Tretinon. An 
explanation for this expression pattern could be that proliferation continues as 
normal after compound treatment but no lateral migration occurs resulting in an 
accumulation of olig2 expressing cells.  
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Plate Hit 
well 
Compound Function olig2 expression 
phenotype 
001 A05 MECHLORETHAMINE antineoplastic, alkylating 
agent 
Restricted to R5/6/7 
001 G06 FENBENDAZOLE anthelmintic  One patch of olig2 
positive cells in the 
hindbrain r5? 
002 A10 SULCONAZOLE 
NITRATE 
antifungal Restricted to R5/6, 
spinal cord expression 
decreased 
002 H09 CEFPROZIL antibacterial Pattern of migration 
is patchy, cerebellar 
neurons lost 
003 B10 LOVASTATIN antihyperlipidemic, 
HMGCoA reductase 
inhibitor 
Restricted to r5/6 
004 B02 IVERMECTIN antiparasitic Patchy midline 
expression 
004 D04 AMPHOTERICIN B antifungal Increased olig2 
expression but 
pattern normal 
005 B09 CLOXYQUIN antibacterial, antifungal Decreased lateral 
migration but 
migration along A/P 
axis 
006 F03 INDOPROFEN analgesic, 
antiinflammatory 
Decreased lateral 
migration 
008 H04 FLUPHENAZINE 
HYDROCHLORIDE 
H1 antihistamine Decreased lateral 
migration,  
009 B03 TRETINON keratolytic Continuous thick strip 
of olig2 expression, 
hard to see individual 
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cells, large dip in strip 
of expression  
009 C06 CYCLOHEXIMIDE protein synthesis 
inhibitor 
Restricted expression 
to r5 and 6 
009 G07 CHLOROXINE chelating agent Olig2 expression is 
lost throughout the 
entire embryo 
011 C10 FLUNIXIN 
MEGLUMINE 
analgesic, 
antiinflammatory 
Restricted expression 
to r5 and 6 
011 E02 EZETIMIBE sterol absorption 
inhibitor 
 
016 G06 AVOCADYNE 
ACETATE 
antifungal Strip of expression no 
ventral migration 
016 H09 CHAULMOOGRIC 
ACID 
antibacterial 
(mycobacteria) 
Restricted expression 
to r5 and 6 
017 F08 DEACETOXY-7-
OXOGEDUNIN 
 Anti-HIV activity Lateral migration 
decreased, very 
similar to NRg-1 
treatments 
017 G10 CHRYSIN diuretic Restricted expression 
to r5 and 6 
019 F03 EPI(13)TORULOSOL 
anti-fungal 
 
Restricted expression 
to midline or r5 and 6 
019 F05 LARIXOL  unknown Patches of olig2 along 
midline but no 
ventral/lateral 
migration 
019 F06 LARIXOL ACETATE  unknown Patches of olig2 along 
midline but no 
ventral/lateral 
migration 
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019 G06 DEHYDROABIETAMID
E 
 Antiviral activity against 
JC polyomavirus 
M1/SVEdelta 
No ventral expression 
but A/P midline is 
okay 
022 G11 HEXAMETHYLQUERC
ETAGETIN 
 
flavnoid Overall olig2 
expression decreased 
024 E06 4-
NAPHTHALIMIDOBU
TYRIC ACID 
 
aldose reductase inhibitor Overall olig2 
expression decreased 
024 E10 5-FLUOROINDOLE-2-
CARBOXYLIC ACID 
 
NMDA receptor antagonist 
(gly)  
Thick olig2 eye 
expression, but brain 
and spinal cord 
expression lost 
024 F08 PHENETHYL 
CAFFEATE (CAPE) 
 
antineoplastic, 
antiinflammatory, 
immunomodulator, NFkB 
blocker 
Restricted to r5 and 6 
025 A03 ARTENIMOL 
 
antimalarial, 
antiinflammatory 
 
Patchy expression in 
the rhombomeres (4-
7) and lost expression 
in the spinal 
Table 21: Observed olig2 expression in the hindbrain of embryos treated with final hit 
compounds 
 
 Grouping of Compounds 
Compounds were grouped according to their biological activity to identify 
similarities and compounds targeting similar signalling pathways. Compounds could 
be grouped into: A) anti-fungal, B) anti-bacterial, C) anti-inflammatory, D) unknown 
function, E) anti-parasitic, F) Anti-Neoplastic, G) cholesterol reduction compounds 
and group H) others (single compounds that did not fall into a group). Literature 
searches that did not bring up any biological function information were grouped 
into unknown function (Table 22). 
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Group A  
Anti-fungal 
Group B 
Anti-bacterial 
Group C 
Anti-
inflammatory 
Group D 
Unknown function 
SULCONAZOLE 
NITRATE 
CEFPROZIL INDOPROFEN DEACETOXY-7-OXOGEDUNIN 
AMPHOTERICIN 
B 
CHAULMOOGRIC 
ACID 
FLUNIXIN 
MEGLUMINE 
LARIXOL 
CLOXYQUIN CLOXYQUIN PHENETHYL 
CAFFEATE 
(CAPE) 
LARIXOL ACETATE 
AVOCADYNE 
ACETATE 
CHLOROXINE  DEHYDROABIETAMIDE 
   HEXAMETHYLQUERCETAGETI
N 
Group E 
Anti-parasitic 
Group F 
Anti-neoplastic 
Group G 
Cholesterol 
reduction 
Group H 
Other 
FENBENDAZOLE MECHLORETHAM
INE 
LOVASTATIN NMDA receptor antagonist 
5-FLUOROINDOLE-2-
CARBOXYLIC ACID 
IVERMECTIN PHENETHYL 
CAFFEATE (CAPE) 
EZETIMIBE H1 antihistamine 
FLUPHENAZINE 
HYDROCHLORIDE 
   Keratolytic 
TRETINON 
   protein synthesis inhibitor 
CYCLOHEXIMIDE 
   Diuretic 
CHRYSIN 
   aldose reductase inhibitor 
4-NAPHTHALIMIDOBUTYRIC 
ACID 
Table 22: Compounds were grouped according to biological activity to identify 
compounds potentially working in similar pathways 
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 Secondary validation of 28 initial hits 
Several primary hits were identified in the initial drug screen and for these to be 
taken forward into future screening a number of validation studies would need to 
be performed to maximise their success rate in later clinical studies. These 28 final 
hits have not yet been subjected to further validation and it is likely that thorough 
validation analysing dose responses and toxicity will reduce the final hit number 
further, thereby leaving a smaller group of compounds that warrant further 
investigation. Initially one would aim to firstly provide extensive replicates to 
ensure that each drug consistently gives the same phenotype, these primary hits 
have undergone 3 replicates prior to secondary validation which does suggest 
phenotype reliability. Secondly, an important issue to consider is that of toxicity, a 
common occurrence in drug screening. Screening for toxicity would involve 
examining embryos for any overall morphological abnormalities such as delayed 
development, malformed head and brain, curved body axis and cardiac oedema. In 
some hits there does seem to be a some developmental delay at 50 hpf however 
this needs more analysis over a longer developmental time period. Since results for 
only a single test concentration has been achieved thus far dose response curve 
experiments will help to determine concentrations that cause a migration 
phenotype without effecting general development. In some cases there will not be 
a concentration that doesn’t cause developmental abnormalities in embryos and 
these would be removed prior to further validation. Similarly, comparing the 
behaviour and motility of treated and control embryos will also be an important 
consideration. Alteration of the behaviour or motility of the developing larvae 
would also deem the compound as potentially toxic and this can be further 
analysed with dose response curves. It might be expected that detailed toxicity 
assays would again reduce the compound hit rate. For those compounds that prove 
to be consistent in phenotype and also have no overt toxicity, it would next be 
appropriate for treated embryos to be analysed for cell death. If compounds are 
shown to be reducing olig2 expression due to death of the cell type they again 
would be not be appropriate for further investigation. Dose response curves are 
also critical for validation screening to determine at which point during OPC 
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migration are the compounds exerting their effect. With a final set of characterised 
compounds, a thorough literature investigation to identify potential target 
signalling pathways and any structural similarity could be performed. The few 
compounds remaining would then have further structural analysis performed to 
look for any structural similarity between them or with other drugs that may have a 
similar function. Screening a small panel of structurally similar compounds would 
increase the likely hood of understanding mechanistically how they function in 
disrupting or altering OPC development. 
Any compounds that persist through validation screening could be used for disc1 
expression analysis in OPCs in future studies. Investigating whether any of these 
compounds identified as a positive hit for migratory defects could be further 
analysed for disc1 expression changes. Understanding the signalling pathways that 
regulate disc1 could potentially improve psychiatric treatment in the future. 
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 Discussion 
Oligodendrocytes are the myelinating cells of the CNS and primarily function to 
allow efficient axonal signal transduction through wrapping of neuronal axons with 
myelin sheaths. Myelination abnormalities have been reported in several brain 
disorders, including mental illnesses. In schizophrenia, hypothesised to be partly a 
disorder of neurodevelopment, it is reasonable to suggest that the myelination 
irregularities reported could be due to early dysfunction in oligodendrocyte 
development (Weinberger 1987) (Peters & Karlsgodt 2014). Schizophrenia is highly 
heritable and many genes have been postulated to confer risk to schizophrenia, 
although no causal gene has been identified. It should be noted that several 
environmental factors are associated with the disease, so although gene mutations 
do confer risk, studies based on genetics alone will not paint a complete picture of 
the disease. However, genetic studies have and will provide further valuable 
insights into the biological pathways affected, thereby identifying potential targets 
for future therapeutic development. Several genes reported to confer risk are 
expressed in the brain and converge on similar biological pathways, implicating 
neuronal signalling, synapses, neuronal migration and white matter abnormalities 
in disease pathology. The most recent GWAS did not implicate oligodendrocyte 
related genes in schizophrenia so it is important to acknowledge that 
oligodendrocyte dysfunction in the disease could be a secondary result of neuronal 
defects (Schizophrenia Working Group of the Psychiatric Genomics 2014). 
Neuronal-glial interactions are important during development so this is a plausible 
hypothesis. Nonetheless there is wide biological evidence to suggest that white 
matter abnormalities and oligodendrocyte related genes are involved in 
schizophrenia pathology. This thesis is based on a previous study which identified a 
potential role between DISC1, a novel protein with known roles in 
neurodevelopment and a schizophrenia risk factor gene, and oligodendrocyte 
migration (Wood et al 2009). At the time of publication, it was one of the first 
studies to implicate DISC1 in oligodendrocyte development. The majority of studies 
have concentrated on DISC1 in neuronal development, particularly in migration. In 
the zebrafish embryo upon knockdown of disc1, OPCs in the hindbrain failed to 
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proliferate and migrate away from their birthplace and the authors suggested that 
it could have important roles in OPC migration (Wood et al 2009). How disc1 
contributed to migration and what external signalling factors initiate and are 
responsible for turning on disc1 expression in zebrafish OPCs was not known and 
this project aimed to follow up on these unresolved questions. Other groups have 
since made similar observations and DISC1 function in brain development is now 
suggested to be more diverse than originally thought, and there is increasing 
evidence for roles in neuronal, oligodendrocyte and neural crest development 
(Drerup et al 2009, Hattori et al 2014, Schurov et al 2004, Shimizu et al 2014). In a 
CNS cell type exon array, disc1 was found to be most highly expressed in OPCs 
further encouraging investigation of DISC1 in OPC development (Cahoy et al 2008). 
Understanding fully the function of these risk factor genes in all aspects of 
neurodevelopment, both in neuronal and non-neuronal cell types, is therefore 
important for understanding brain development and improving knowledge of brain 
diseases. This thesis provides evidence to suggest that DISC1 acts downstream of 
the Hh signalling pathway in hindbrain OPC development in the zebrafish embryo. 
7.1 Hh signaling acts as a ventral external chemoattractant 
for OPC migration 
After observing that OPCs consistently extend their initial processes in a ventral 
direction and predominantly occupy the ventral portion of the hindbrain, the 
ventral external cue responsible for this downward movement was investigated. 
Candidate signaling pathways with known ventral locations were compared and the 
Sonic Hedgehog signaling pathway was selected for further analysis. The Shh 
signaling pathway is vital for dorso-ventral patterning of the neural tube and is 
ventrally located in the notochord and floor plate, including turning on expression 
of olig2. It has also been linked to having roles in migration of optic nerve OPCs and 
therefore was a suitable and feasible candidate. It was shown that disruption of Hh 
signaling through cyclopamine treatment resulted in a greatly reduced population 
of OPCs occupying the hindbrain, indicative of defective OPC migration. However 
there was also an apparent defect in proliferation of OPCs. This could mean that a 
proliferation defect is the primary result of Hh signaling abnormalities, which 
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subsequently results in secondary migration defects.  However, introducing a dorsal 
source of mouse N-terminal Shh protein caused OPCs to extend processes in the 
opposite direction to their normal ventral path, indicating that Hh could act as a cue 
for migrating OPCs. In ptch1; ptch2 double mutants, olig2 expression was increased 
and OPCs were observed in dorsal domains of the hindbrain, suggesting abnormal 
migration out of normally restricted domains. The expression pattern of olig2 in 
these mutants could be a result of excessive migration out of the ventral domain, 
but it was also interpreted that the progenitor domain increased which lead to the 
subsequent expression in dorsal domains. However when examining these mutants 
at an earlier time point prior to migration, although there was increased olig2 
expression in r5/6 there was not expression in the dorsal domain. It could also be a 
result that the increased number of olig2 positive cells in the progenitor domain 
meant that cells had to move further apart through contact inhibition leading to 
movement into dorsal domains. These data demonstrate an essential role for Hh in 
OPC development after the initial specification of clusters of OPCs in r5/6, both in 
terms of migration and proliferation, perhaps through primary cilia which are 
present on OPCs. This data however does not confirm that Shh signaling is the only 
pathway responsible for causing ventral migration, other recent studies have shown 
that other Hh signal proteins, including indian hedgehog B which was identified to 
have roles in OPC development in the zebrafish (Chung et al 2013). There have been 
other studies which have supported a role for Shh signalling in cellular migration in 
the brain including in vitro and in vivo chick studies of the optic nerve (Merchan et 
al 2007). A more recent in vitro study has characterized megalin, a multi-ligand 
receptor, in relation to Shh OPC migration and proliferation. It was shown to be 
expressed by astrocytes, to internalize Shh and provide Shh signalling to OPCs of the 
optic nerve (Ortega et al 2012). There have also been other studies identifying a role 
for Shh signaling in the migration of other cell types including cancer cell invasion. 
For example one recent study showed that Shh signaling promoted cell migration in 
liver cancer (Chen et al 2013a), thus supporting our hypothesis that Shh has 
additional migratory roles in OPC development. Further work is required to attempt 
to understand whether Hh signaling has a specific migration roles in OPC 
development of the hindbrain, and these phenotypes are not a result of altered 
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specification and proliferation. Cell culturing of hindbrain OPCs in migration assays 
and altering Hh signaling could help to determine whether there are specific 
migration cues.  
7.2  disc1 is a downstream target of Hh signaling in OPCs 
After the identification of a signaling pathway acting as a ventral chemoattractant to 
initiate process extension and drive ventral migration, the next objective was to 
determine whether disc1 was a downstream target of this pathway. Since disc1 is a 
cytoskeletal protein and interacts with other cytoskeletal/centrosomal proteins, it is 
plausible that it contributes to OPC migration by causing the physical movement of 
cells in response to Hh signaling. Much research has investigated what pathways are 
regulated by the DISC1 protein, however there is still a lack of research into which 
signaling pathways sit upstream of DISC1, and control its regulation during 
development (Chubb et al 2008). There has been one study however which 
identified FOXP2 targets DISC1, but further analysis of DISC1 regulators is important 
for understanding further its biological function during development and disease 
(Walker et al 2012). Experiments performed in this thesis suggested that disc1 may 
be a downstream target of Hh signaling that is required for OPC migration. This 
thesis has provided evidence that disc1 is expressed in OPCs during their migratory 
phase as well as in presumptive radial glia, neural crest, otic vesicle and lower jaw 
cartilage during zebrafish development. Expression of disc1 in a variety of tissues 
suggests that it has important roles in overall embryo development, however the 
function of disc1 in these tissues was beyond the scope of the project. Hh signalling 
also has roles in the development of some of these tissues including the 
presumptive ear and neural crest (Raft & Groves 2014) (Fu et al 2004). It is 
interesting that disc1 expression is present in tissues that respond to Hh signalling. 
It would be interesting in the future to determine whether disc1 was responsive to 
Shh in the development of these tissues. Interestingly disc1 expression was lost in 
the midline of the hindbrain in iguana ts294e (-/-) mutants and smob641 (-/-) mutant 
embryos, but expression of disc1 appeared to be maintained in other areas 
including the lower jaw and otic vesicle. However the qPCR data showed a 
complete loss of disc1 in smob641 compared to siblings which may be because the 
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expression of the gene did not pass the threshold set by the analysis software but 
there was still some low level expression.  In ptch1;ptch2 double mutants, disc1 
expression was expanded in the midline along with excessive OPC migration and 
increased olig2 expression levels. However this was not confirmed by qPCR when 
compared to a pool of ptch1;ptch2 siblings. This likely due to the ptch1;ptch2 pool 
of siblings containing a collection of single homozygote and heterozygote mixes 
which may have increased disc1 expression and collectively resulted in a higher 
level of expression. When the expression of disc1 was compared between smob641 
siblings and ptch1;ptch2 mutants however there was an increase in expression in 
the double mutants as expected. The in situ hybridisation data suggested that disc1 
is responsive to Hh signalling, and alterations from normal Hh signalling result in 
aberrations in disc1 OPC expression and may therefore affect its function in OPC 
development. When disc1 expression was analysed in cyclopamine treated 
embryos, expression was lost in olig2-expressing OPCs present in the midline. Hh 
external signalling transduced by OPCs could be responsible for initiating expression 
of cytoskeletal proteins, possibly including disc1, that are required for process 
extension towards the ventral signalling source, as well as initiating migration 
through promoting cytoskeletal gene expression and/or recruitment. How OPCs 
respond to this Hh signal is yet to be determined; it is expected that for such a quick 
and dynamic process like migration it could be a non-transcriptional response since 
transcriptional changes through the Gli family will take time. For example, it has 
been shown that during fibroblast migration, Shh stimulates small Rho GTPases and 
this was independent of transcription by Gli proteins (Polizio et al 2011a, Polizio et 
al 2011b) (Jenkins 2009). Canonical and non-canonical Hh signalling could work in 
parallel during OPC migration to cause recruitment of cytoskeletal proteins to 
leading cell edges and over a longer period of time, cause transcriptional changes to 
increase expression of cytoskeletal proteins to facilitate extensive branching during 
later stages of migration. 
7.3 Hedgehog signalling in psychiatric disorders 
Since this thesis suggests the disc1 and Hh signalling are linked during development, 
it could be feasible that Hh is directly implicated in psychiatric disorders.  A 
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literature search showed that Hh signalling has been implicated in mental disorders. 
For example craniofacial dysmorphology is a feature of schizophrenia, and is 
evidence of a developmental origin based disorder (Lane et al 1997). Neural crest 
gives rise to many craniofacial features, and Hh signalling has known roles in neural 
crest development (Mishina & Snider 2014). Furthermore, disc1 has also been 
implicated in neural crest development in the zebrafish (Drerup et al 2009). 
Therefore it could be that Hh signalling regulates neural crest development through 
DISC1. Many current antipsychotic medications act on dopamine receptors, and it 
has been shown that Shh is essential for the development of midbrain 
dopaminergic neurons (Sillitoe & Vogel 2008). Finally, further evidence for 
involvement of Hh signaling in psychiatric disease has come from analysis of mouse 
models. Male Desert hedgehog (Dhh) knockout mice, but not females, show 
increased anxiety-like and depressive behavior (Umehara et al 2006). This data 
shows the further investigation into Hh signaling regulating disc1, in development 
and in psychiatric diseases could yield some interesting findings. 
7.4 Current model for OPC ventral migration in the zebrafish 
hindbrain 
OPCs require directional information in order to migrate to their axonal destination, 
and this information is provided by external signals to both attract and repel OPCs 
during migration. These external factors are tightly regulated to create a defined 
and detailed migratory map which allows OPCs to communicate with their 
surrounding environment. Perturbation of any of these external factors may cause 
dysregulation in the entire migratory map leading to aberrant migration which 
could result in brain disorders. This current model proposes that in the zebrafish 
hindbrain, OPCs require Hh signalling to act as a ventral chemoattractant to direct 
cells downwards towards the primary source  of the signal located in the notochord 
and ventral floor plate (Figure 7-1A). Although we have not determined which Hh 
ligand is responsible, we hypothesize that it is Shh given the already known roles for 
Shh in OPC development and nervous system development. 
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Figure 7-1 Model for OPC migration in the zebrafish hindbrain 
Prior to migration, OPCs transduce a ventral chemoattractant signal proposed to be Shh 
which provides initiation and positional information through primary cilia (A). OPCs 
transduce this Shh signal and up-regulate the relevant cytoskeletal proteins required for 
migration (B). OPCs extend processes in a ventral direction and migrate downwards to 
eventually populate the ventral hindbrain (C). Cartoon shows a transverse section of the 
hindbrain. Dorsal top and ventral bottom. 
 
OPCs transduce the Shh signal through primary cilia prior to migration, then signal 
transduction leads to cytoskeletal protein recruitment and ventral process 
extension (Figure 7-1B). Such downstream cytoskeletal proteins could include 
Disc1, a scaffold protein, which is expressed in OPCs during their migratory period 
(Figure 7-1C). Furthermore, it was suggested from the bead assays (section 3.6) that 
Shh acts as a directional cue to migrating OPCs, ensuring that cells extend processes 
towards the ventral signalling source as well initiating migration through promoting 
cytoskeletal gene expression.  
Mechanistic information into how Disc1 might contribute to OPC migration in the 
zebrafish is an interesting question and has the potential to link schizophrenia 
oligodendrocyte abnormalities to schizophrenia risk factor genes. However it has to 
be appreciated that the most recent GWAS study into schizophrenia did not identify 
DISC1 or any oligodendrocyte genes (Schizophrenia Working Group of the 
Psychiatric Genomics 2014). To investigate the molecular mechanisms involved, the 
localisation of the protein in OPCs was explored. Understanding its localisation is 
important to provide insights into where the protein is recruited during 
development, for example was it being trafficked to primary cilia, the leading edge 
of the cell or the centrosome (Marley & von Zastrow 2010, Morris et al 2003) 
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(Wang & Brandon 2011)? It was expected that Disc1 would be seen to be localised 
to one or more of these regions as previous studies in mouse and cell culture has 
shown some evidence for centrosomal and primary cilia localisation, however this 
has not been convincingly demonstrated in the context of the endogenous protein 
(Morris et al 2003). Similarly the localisation of Disc1 in the zebrafish has not been 
addressed before. Since Disc1 has a wide variety of interacting partners, 
understanding its cellular location in OPCs would present a defined list of potential 
Disc1 interacting partners based on similarities in cellular localisation, which would 
provide important mechanistic clues.  
7.5 Analysis of Disc1 localisation  
Extensive localisation analysis was performed in vivo using a range of techniques. 
Over-expression analysis showed cytoplasmic punctate expression with no defined 
localisation, and this expression pattern was observed in other cells of the embryo 
and not in OPCs. Furthermore it did not address the endogenous protein. In order 
to localise the endogenous protein, antibodies were developed against zebrafish 
Disc1. These antibodies were shown to readily detect over-expressed Disc1. 
Although several attempts were made to detect the endogenous protein using 
these antibodies, no specific staining in the regions that have been shown to 
express detectable levels of disc1 mRNA were observed. Only anti-peptide 
antibodies were attempted, other methods for antibody production are available 
which could be used in the future. As an alternative to antibodies, in vivo precise 
genome editing was attempted to fluorescently label the endogenous Disc1 
protein. TALENs were designed to cause a double strand break around the stop 
codon of disc1 which initiates the DNA repair machinery. Donor DNA containing a 
fluorescent mCherry sequence flanked by disc1 homology arms was co-injected 
with the expectation that it would be incorporated into the genome through 
homologous recombination. Although the TALENs were shown to work efficiently, 
at the time of submission no positive founder fish with an incorporated mCherry 
sequence have been identified, although this is an ongoing project. Developing this 
tool is important, not only will the precise fluorescently-labelled line give valuable 
localisation information in OPCs but the line could also be used to investigate Disc1 
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function in other cell types where it is seen to be developmentally expressed. If C-
terminal fluorescent tagging of Disc1 is unsuccessful, the N-terminal end could be 
tagged.  
7.6 Project limitations and future directions 
At the outset of this project, using morpholino antisense methods to knockdown a 
gene of interest was the most prominent form of reverse genetics. It provided rapid 
and full knockdown of a gene which resulted in morphant embryos that could be 
easily analysed for phenotypic consequences without the need to grow up to 
adulthood. Although some morpholinos were shown to be highly specific to their 
target gene, others caused major off-targets effects (Wright et al 2004). This could 
be alleviated to some extent by co-injection with a p53 morpholino and validation 
through RNA rescue experiments (Robu et al 2007). Morpholinos have fallen from 
favour in the zebrafish community since the introduction of precise genome editing 
methods which have evolved over the last 3-4 years and has become more 
efficient, accessible and inexpensive for the creation of stable mutant lines (Eisen & 
Smith 2008) (Kok et al 2015). However, there have been several reported cases 
where these endonucleases have successfully produce INDELs in a gene without a 
phenotypic consequence and it seems that in some cases, mutagenized fish have 
been able to bypass the induced mutation to still produce a functional protein 
(S.Elworthy, personal communication). Therefore although morpholinos can give 
indications of biological functions provided the proper controls are in place, it is 
now expected that through genome editing, stable mutant lines should be 
generated to confirm morphant phenotypes. There is of course the important 
discussion point of maternal deposits of transcripts during early development. 
These zygotic mutants made from genome editing would still have maternal 
contribution of the transcript of interest, therefore the creation of maternal zygotic 
mutants would be required to phenocopy start site translation blocking 
morpholinos, which deplete all transcripts in the embryo including maternal 
contributions (Vogan 2015). 
Previous work based on disc1 function in OPCs used morpholino antisense 
techniques and although several parameters were in place to ensure specificity 
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including using two different morpholinos which gave the same phenotypes and co-
injection with a p53 morpholino, one intention has been to confirm such 
phenotypes using a stable mutant line. The disc1 mutants obtained from an ENU 
screen (discussed in section 1.5.5), which harboured mutation points in the poorly 
conserved  N-terminal region, were subsequently acquired by our research group to 
determine whether these mutants phenocopied the morphant oligodendrocyte 
abnormalities documented, since these had not been addressed elsewhere (De 
Rienzo et al 2011). When our group received these stable mutant lines, genotyping 
of embryos showing reported brain abnormalities demonstrated that they were not 
exclusively homozygous mutants, but a collection of homozygotes, heterozygotes 
and wild type embryos.  It was concluded that these phenotypes were a result of a 
secondary mutation. Furthermore when these secondary mutations were removed 
through outcrossing, disc1fh291 and disc1fh292 homozygote adult mutants were viable 
and fertile, and lacked the abnormalities described in the original publication (De 
Rienzo et al 2011). The progeny of maternal zygotic mutants were also viable and 
did not display the disc1 morphant phenotypes previously described, there were 
also no lower jaw cartilage abnormalities described by both groups using disc1 
morpholinos. However subsequent work with these adult mutants has shown some 
behavioural abnormalities and endocrine changes suggesting that the mutations in 
disc1 in these lines are exerting a low penetrance effect, but do not create a full 
knockdout of the gene as originally suggested (Eachus et al unpublished). In the 
future, to validate or disprove the morphant phenotypes the CRISPR/cas9 system is 
being employed to create stable disc1 mutant lines harbouring deletions in the 
conserved coiled-coil domains (Lucas et al unpublished). 
Another important future direction to focus on is elucidating the localisation of 
disc1 in OPCs and other cell types in the zebrafish. Creating a successful 
endogenous knock in Disc1-mCherry fusion protein line would not only give 
valuable information regarding Disc1 cellular expression in OPCs but also in protein 
recruitment and interactions. Furthermore it could prove very useful with regard to 
the preliminary drug screen which was performed to identify compounds and 
signalling pathways involved in OPC migration and development (Chapter 6). 
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Compounds which altered the migration of OPCs either through restriction of 
migration, excessive migration or an altered migratory pattern of olig2-positive cells 
was considered a positive hit and taken forward for validation screening. In the 
future, fish containing engineered disc1 with a fluorescent tag could be crossed 
with the tg(olig2:gfp) line and used to investigate whether any of the 28 
compounds identified had any effect on the expression levels or localisation of 
Disc1. If the signalling pathway that the compound exerts its effect through could 
be identified this could give an indication of which signalling pathways utilise Disc1 
as part of their signalling network. These fish could be then used a readout for 
subsequent future drug screening. 
7.7 Final conclusion 
Investigating OPC migration in the zebrafish hindbrain has provided valuable 
information which suggests further roles of Shh signalling after initial specification 
of OPCs in r5/6 of the hindbrain. Evidence has also been provided which suggests 
that disc1 acts downstream of Shh signalling in OPC development. Since migration 
is critical for subsequent OPC differentiation and myelination of target axons, 
understanding which signalling pathways are responsible for initiating and directing 
OPC migration could be used as a therapeutic target in diseases where myelination 
is defective. For example, in schizophrenia where there is a growing body of 
evidence to suggest oligodendrocyte abnormalities, understanding which risk factor 
genes and how they contribute to these abnormalities would improve our 
knowledge of oligodendrocyte development and potentially schizophrenia 
pathophysiology. This thesis has linked an important developmental signalling 
pathway and a schizophrenia risk factor gene in OPC development using the 
zebrafish as a model system. 
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